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ABSTRACT 
Both MVs and exosomes are isolated by similar methodologies such as 
differential centrifugation of cell culture supernatant (S/N), filtration, floating 
on chemical gradients or using antibody labelled magnetic beads. Hence, 
the isolation techniques, commonly in use, provide low levels of purification 
and therefore require improvements and an in-depth analysis of observed 
results. This research has established a protocol for isolation of these 
vesicles and a means to identify them using known markers and their 
respective properties. The isolation techniques used and developed in this 
research include differential centrifugation, sucrose gradient centrifugation, 
and filtration. MVs and exosomes were later identified and distinguished 
according to their relative ability to bind FITC and PE conjugated annexin V, 
anti-LAMP1, anti-CD63 and anti-CD11b antibodies using flow cytometry. 
Protein gels were run with MVs and exosome samples isolated by different 
techniques to identify some distinct proteins in MVs/exosomes that may be 
uniquely present on one or either and hence that could be used as a marker 
to distinguish MVs from exosomes. 
To prevent exosomal contamination of MV preparations, in a further 
improvement of the newly developed reverse filtration technique, gentle 
disruption of exosome aggregates by gentle water sonication was used and 
measurements of plasma MV levels made from a population of healthy 
donors. This found plasma MV levels to range between 0.51 and 2.82 x 105 
MVs/ml. The MVs were characterised as phosphatidylserine-positive and 
≥0.2 µm in diameter. Most of the variables looked at in this study including 
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freezing at -20ºC, gender and subject age did not alter MV absolute counts 
significantly. For the first time the effect of fasting on MV levels has been 
studied. Fasting individuals had a wider spread and appeared to have higher 
MV levels (2.8x105-5.8x105 MVs/ml). This could be defined as the normal 
baseline fasting reference range, which is almost 3-fold higher compared to 
the non-fasting group reference range (0.9-1.5x105) MVs/ml. These results 
suggest that when analysing total MVs, further investigations should use 
fasting subjects, as for quantification of other fasting analytes. 
Prospective markers of (monocyte-derived) MVs, IL-1α, RANTES, G-CSF, 
CCL-1 and IL-17E are proposed for further investigation. MVs were shown 
to inhibit phagocytosis of apoptotic bodies more effectively than exosomes. 
With a view to understanding likely pathways being stimulated during MV 
release, and to also shortlist possible pharmacological reagents capable of 
being used to therapeutically inhibit Y27632, calpeptin and methyl-β 
cyclodextrin were shown to inhibit MV release. MV release from K562 cells 
was inhibited by Y27632 and calpeptin but less effectively by chlorpromazine 
or methyl-β-cyclodextrin, MV release from THP-1 acute monocytic 
leukaemia cells was greater than from peripheral blood monocytes which 
were in turn shown to express more phosphotidylserine than on exosomes.  
With a view to using MVs as drug delivery vehicles, THP-1 MVs were found 
to fuse/hemifuse to K562 erythroleukaemia cells, but not at 4°C or if the MV 
surface was blocked with annexin V. β-Gly (10 µM) (as well as MVs carrying 
β-Gly [β-Gly MVs]) was found to inhibit proliferation at least 3-fold compared 
to untreated control. β-Gly and β-Gly MVs increased the doubling time but 
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neither induced apoptosis of K562 cells (unlike MVs from apoptotic cells). 
Finally, β-Gly increased the percentage of cells in G0/G1 whilst decreasing 
the cells in G2/M and appears to induce erythroid differentiation as seen by 
the increase in the percentage of benzidine-stained cells. 
 
 
Key words: MVs, exosomes, reverse filter, sucrose gradient 
ultracentrifugation, Lifestyle, Cancer Prevention, Epigenetics. 
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1. Introduction 
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1.1 First reports of extracellular vesicles 
Exosomes are released from cells and are of endosomal origin but besides 
these vesicles, cells release membrane-derived vesicles that are released 
by direct budding form the cell surface. Over seventy years ago in the 1940s, 
the first clue that there might be pro-coagulant subcellular entities in plasma 
was proposed, when it was found that platelet-poor plasma (PPP) took 
longer to clot after it had been centrifuged at high g forces (reviewed in Inal 
et al., 2012). Twenty years later in 1967, it was shown for the first time 
showed that activated platelets shed membrane fragments, which he termed 
“Platelet Dust” (Wolf et al., 1967). Wolf and colleagues went on to show that 
the platelet-derived membrane fragments were associated with the 
phospholipid-related procoagulant activity, otherwise now known as platelet 
factor 3 (PF3). 
1.2 Ectosomes, microparticles, plasma membrane derived 
microvesicles, otherwise known as ‘Microvesicles’ (MVs) 
Ectosomes, Microparticles (MPs), plasma membrane-derived microvesicles 
(PMVs), are one in the same entity and for the purposes of this thesis will be 
referred to as microvesicles (MVs). Microvesicles are membrane vesicles 
that are phospholipid rich and that carry various membrane receptors 
including other intravesicular proteins from their parental cells. MVs are 
released by every eukaryotic cell type directly from the plasma membrane 
upon activation, apoptosis, necrosis or through stress. MVs are formed by 
pinching off from the cell membrane and range in size from 0.1 µm to 1 µm 
(Coombes et al., 1999), and platelet MVs, some of the first recognised MVs, 
were shown to have a role in thrombosis and inflammation (Wolf et al., 
1967). Prior to links with inflammation and immune and infectious disease 
as well as cancer biogenesis and spread, MVs were considered inert 
material.  
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1.2.1 Mechanisms of microvesicle biogenesis 
The precise mechanism of MV biogenesis has not yet been fully elucidated 
and it is likely that there are several overlapping pathways, leading to 
different MV sub-types. MV release now appears to be a highly controlled 
process. Cells can be activated by different stimuli and MV release does not 
appear to be a random process such as when the plasma membrane of a 
dying cell undergoing necrotic degradation. Four cell membrane 
phospholipids, namely phosphatidylcholine (PC) and sphingomyelin (SM) on 
the external leaflet of the lipid bilayer and phosphatidylserine (PS) and 
phosphatidylethanolamine (PE) on the inner leaflet maintain cell membrane 
integrity through five enzymes, gelsolin (which is only found in platelets), 
aminophospholipid translocase, floppase, scramblase and calpain (Zwaal et 
al., 1997). In the steady state, phospholipids are moved towards the outer 
leaflet whilst aminophospholipids are moved towards the inner leaflet of the 
lipid bilayer. However, either during cell activation, apoptosis or necrosis, the 
cytosolic concentration of Ca2+ rises, resulting in a change of the steady 
state affecting the ability of the cell to maintain this membrane asymmetry 
and in the stable exposition of PS on the external surface of the plasma 
membrane. 
Cytosolic calcium concentration is indeed a central and fundamental 
condition to initiate MV formation. Gelsolin, in platelets, removes the capping 
proteins at the end of actin filaments (maintaining the cytoskeletal structure) 
resulting in increased Ca2+ levels in the cytosol (and therefore MV release) 
(Piccin, et al., 2007). Increased levels of cytosolic calcium inhibit the 
activation of aminophospholipid translocase that carries out ATP dependent 
transport of PS, against an electrochemical gradient to the inner layer of cell 
membrane from outside (Seigneuret et al., 1984). Floppase or phospholipid 
translocase may work along with aminophospholipid translocase and 
facilitates transport of phospholipids from the inner to the outer leaflet 
(Connor et l., 1992). Increased cytosolic Ca2+ also results in scramblase is 
activated but flippase inhibited thus allowing a random movement of 
phospholipids between both leaflets, leading to a loss within minutes of the 
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lipid asymmetry (Williamson et al., 1995). Lipid scramblase, activated at 
higher cystolic Ca2+ concentrations, allows the movement of phospholipid 
cross the cell membrane and thus PS is expressed stably on the outer 
surface (Andrea et al., 2007; Zwaal et al., 1993). Calpain, again activated by 
increased cystolic Ca2+, cleaves cytoskeletal filaments, and as interactions 
between aminophospholipids on the inner leaflet of the lipid bilayer with 
skeletal proteins are disrupted. The resulting effects on cell shape and 
membrane mechanical stability result in microvesicle shedding and 
eventually in the activation of apoptosis through procaspase 3 and BclxL 
(Andrea et al., 2007); Rho associated kinase 1 (ROCK-1) is essential for 
apoptotic membrane blebbing and membrane blebbing is associated with 
MV release in apoptotic cells. Depending upon the mechanism of MV 
formation their size and constituents vary (Jimenez et al., 2003). 
Release of platelet MVs (often referred to as platelet microparticles, PMPs) 
can occur during cell activation by adrenaline, adenosine diphosphate, 
thrombin, collagen, Ca2+ ionophore A23187, complement membrane attack 
complex (MAC) and shear stress (S. P. Ardoin et al., 2007; Simak et al., 
2006; Horstman et al., 1999). Other stimuli of microvesiculation include 
microbial peptides such as formyl-methionyl-leucylphenylalanine (fMLP) 
(Gasser et al., 2003; Hess et al., 1999), and phorbol esters. MVs also take 
surface proteins and other contents of the originating cell (Martinez et al., 
2005) while they are shed. As well as biological stimuli, shear stresses 
imposed on cells are important mechanical factors able to induce 
microvesicle release from cells. Furthermore, it should be noted that some 
of these MV-inducing stimuli are likely to be additive or possibly synergistic. 
1.2.2 Genetic elements in MV biogenesis 
The ATP-binding cassette transporter A1 (ABCA1 gene) modulates the 
transbilayer distribution of phosphatidylserine (PS) at the outer leaflet of the 
plasma membrane and also controls the initial steps of reverse cholesterol 
transport, that is the release of cellular phospholipids to lipid-free 
apolipoproteins (Combes et al., 2005). Curiously, the ABCA1 transporter is 
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a major element controlling cerebral malaria susceptibility. In this study 
authors have shown ABCA1-/- mice to have significantly reduced numbers 
and pro-coagulant activity of MVs compared to wild type ABCA1 +/+ mice. 
Interestingly it was demonstrated that ABCA1-/- knockout mice in fact 
develop complete resistance to cerebral malaria. It was also shown that red 
blood cells (RBCs) from ABCA1-/- mice have a reduced capacity to 
externalise PS and hence to release MVs. Moreover, flippase activity of 
ABCA1 is largely responsible for the lipid transbilayer remodelling and 
translocation of PS to the external leaflet of the lipid bilayer in the plasma 
membrane (Daleke DL., 2003). MVs contain glycosylphosphatidylinositol-
anchored CD14 molecules and the GM1 (Phu T et al., 2006), both being 
markers of plasma membrane rafts which appear to be enriched on MVs 
(Satta, N et al., 1994; Parton, R. G et al., 1994); it is likely that vesiculation 
to release MVs involves plasma membrane raft domains. 
1.2.3 Composition of MVs 
The composition of MVs largely depends on the state and constituents of 
original cell and type of inducing agent(s) used along with the mechanism of 
MV release. However, the rules of incorporation of different proteins in MVs 
are not yet understood. PMPs express Gplb (CD42b), platelet endothelium 
adhesion molecule (PECAM-1, CD31) (Andrea et al., 2007; Losy et al., 
1999), integrin aIIb ß3 (GpIIb-IIIa)( Schwarz et al., 2004), P-selectin (CD62P) 
(George et al., 1986), CD63 (Tschoepe et al., 1990), CD41a and CD 61 (von 
Ahsen et al., 2001). CD42 found in platelets is not expressed in PMP 
revealing that a differential sorting mechanism is involved in MV formation. 
MVs from endothelial cells express CD31, CD34, CD51, CD54, CD62E (E-
selectin) (Mutin et al., 1997) CD62P (P-selectin), CD105 (endoglin) and 
CD146 (S endo 1). The protein composition very much relies on whether 
MVs are released upon cell activation or apoptosis and the comparison of 
both showed that constitutive endothelial markers (CD31 > CD105) were 
more in MVs from apoptotic cells, while inducible endothelial markers 
(CD62E > CD54 > CD106) (Jimenez et al., 2003; Hussein et al., 2003) were 
27 
 
increased in MVs from activated cells. Furthermore, MVs from apoptotic cells 
have more annexin V and CD31 (Horstman et al., 2004). 
1.2.4 Functions of MVs 
After several years of microvesicle research it is only now becoming clear 
that MV release impacts on a broad range of biological processes, including 
intercellular communication, signal transduction, coagulation and transfer of 
functional receptor proteins, such as the chemokine receptor, CCR5, a co-
receptor for HIV from mononuclear cells to cells not expressing it, and that 
this transfer renders the recipient cells able to be infected (Mack et al., 2000). 
These activities are possible because of the phospholipid rich surfaces of 
MVs and the particular surface molecules they express. One of the early 
biological functions of MV release that was delineated came in the field of 
complement biology. Here it was shown that microvesiculation protects 
against complement attack by removing the C5b-9 membrane attack 
complex (MAC) from the cell surface as shown for polymorphonuclear 
leucocytes (PMNs), oligodendrocytes, and even erythrocytes (Scolding et 
al., 1989; Iida et al., 1991; Campbell et al., 1985). Stein and Luzio coined the 
term ‘ectocytosis’ for the release of right-side-out oriented vesicles 
(ectosomes) from the surface of PMNs attacked by the sublethal 
concentration of complement (Stein and Luzio, 1991). However, the function 
of ectocytosis is not only the removal of C5b-9 complex, but also the specific 
sorting of membrane proteins and also lipids into the shed MVs. Hess et al. 
have provided evidence that when PMNs are stimulated in vitro with formyl-
methionyl-leucylphenylalanine (fMLP) or exposed to calcium ionophores, 
they release small vesicles in minutes which have many of the properties 
expected for MVs due to complement attack (Hess et al., 1999). These MVs 
expressed a specific set of membrane proteins, including the complement 
receptor 1 (CR1), and in addition, proteases such as myeloperoxidase 
(MPO) and elastase, suggesting that they might function as extracellular 
antibacterial organelles as shown later (Timar et al., 2013). There are 
numerous other biological functions that have been described. For example, 
IL-1 is rapidly secreted by THP-1 monocytes, because it is present in the 
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MVs that the cells shed (MacKenzie, et al., 2001). Furthermore, platelet and 
monocyte-derived MVs induce the coagulation cascade and inflammatory 
processes by activating endothelial cells (Nomura et al., 2001; Satta, et al., 
1994; Satta, et al., 1997). In other work MVs from leucocytes, mainly PMN 
or neutrophils were shown to activate endothelial cells (Mack et al., 2000) 
and chondrocytes which were found to continuously release MVs loaded 
wtih annexin I, which induces calcium precipitation and bone formation 
(Anderson, 2003). 
Being smaller in size, MVs can readily be transported through the blood 
stream reaching the cells and tissues, which the cell of origin could not have 
communicated with. MVs can transfer surface molecules like receptors, to 
other cells and exchange membrane and cytoplasmic proteins (Ardoin et al., 
2007; Fritzsching et al., 2002; Barry et al., 1998). PS and tissue factor 
exposed on MVs play a role in the coagulation cascade. Platelets and PMP 
both contribute to haemostasis (Freyssinet et al., 2003). MVs from 
endothelial cells contain von Willebrand factor multimers, which promote and 
stabilize platelet aggregation (Jimenez et al., 2005). MVs from patients 
having bleeding and thrombosis-like disorders have procoagulant activity 
(Nieuwland et al., 2000; Jimenez et al., 2001). MVs are shown to have 
inflammatory properties. PMPs can induce binding of monocytes to 
endothelial cells and promote survival of haematopoietic cells (Baj-
Kryworzeka et al., 2002). P-selectin can possibly promote leukocytes 
aggregation and are found on MVs (Forlow et al., 2000). MVs can also 
secrete IL-1β (Mackenzie et al., 2001) having proinflammatory roles. 
Apart from the above-mentioned biological conditions MVs are also 
associated with many diseases and immune conditions like atherosclerosis, 
diabetes, metabolic syndrome, malignancy, pregnancy, multiple sclerosis, 
rheumatoid arthritis, vasculitis, systemic lupus erythematosus and 
antiphospholipid antibody syndrome. 
Some researchers consider MVs as ‘vectors’ of waste removal which are in 
turn removed by macrophages, but even if that is the case the evidence is 
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mounting that they most likely play other important roles in inflammation, 
even curtailing inflammation as shown for anti-inflammatory cytokine release 
from macrophages that had phagocytosed neutrophil-derived MVs (Gasser, 
2004); by contrast neutrophil MVs express enzymes able to attack 
microorganisms which they may well do at sites of acute infection (Gasser 
et al., 2003), thus likely protecting the organism from excessive inflammation 
at the site of infection. Exosomes for example are able to elicit specific 
immune responses (Andre et al., 2004; Skokos et al., 2003; Thery et al., 
2002). Whilst the MVs released from chondrocytes support ossification 
(Anderson, 2003), endothelial cell, monocyte and platelet MVs enhance 
thrombosis (Sabatier et al., 2002; Satta et al., 1994). 
In yet other studies it was shown, at least in vitro, that platelet MVs are 
capable of increasing the adhesion of monocytes to endothelial cells. MV-
stimulated HUVECs cells increased the expression of ICAM-1, but not that 
of VCAM-1, P-selectin or E-selectin. Receptor complexes on monocytes, 
CD11a/CD18 and CD11b/CD18 were upregulated and MVs induced 
chemotaxis of monocytes (Marcos et al, 2000). Interestingly, the induction 
of monocyte endothelial adhesion through platelet MVs was mimicked by 
arachidonic acid isolated from MVs. In fact, platelet MVs modulate platelet, 
monocyte, and vascular endothelial cell function by the direct effect of MV 
arachidonic acid and by its metabolism to bioactive prostanoids. However, 
platelet activation required prior metabolism of MV arachidonic acid to 
thromboxane A2 (TXA2) (Barry et al., 1998). 
 
1.2.5 Present status of MV isolation 
Differential centrifugation is the most commonly used method for isolation of 
MVs but it has its limitations. This technique involves centrifugation cycles 
to remove cells and debris, followed by high speed ultracentrifugation to 
pellet MVs. Table 1.1 summarises how differential centrifugation has been 
adapted by different authors. Clearly there is no standard centrifugal force 
and time criteria set for isolation of MVs as there are various factors to be 
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considered during centrifugation such as the density of the medium MVs are 
in, and the distance they need to travel to form a pellet. As the centrifuges 
and rotors used by authors differ, the centrifugal force and time have to be 
optimized by each. 
 
 
Table 1.1 Variations in differential centrifugation protocols for isolating 
microvesicles. Adapted from Piccin, A., et al., 2007 
 
Gasser et al., in 2003, used two consecutive runs, 20 min each of 4000 g at 
4°C and concentrated cell culture supernatant 50-fold using Centriprep 
centrifugal filter devices (10,000 MW cut off, Millipore Corporation, Bedford, 
MA, USA) to isolate ectosomes (actually MVs). Interestingly electron 
microscopy of this ectosome sample shows vesicles sized smaller than 
100nm, which does not fit into the defined size for MVs/ectosomes but does 
for exosomes and hence poses a question on the isolation protocol used 
here. Such mistakes may often occur when identifying MVs/ectosomes and 
exosomes. One of the aims of this research is to accurately identify and 
distinguish between MVs and exosomes. 
1.2.6 Microvesicles defend against complement-mediated cell lysis 
Colleagues at the Cellular and Molecular Immunology Research Centre 
found that intracellular Trypanosoma cruzi induces the release of host cell 
derived MVs, which protect the parasite from host complement (Cestari et 
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al., 2012). The mechanism of resistance against complement-mediated lysis 
includes removal of membrane attack complex (MAC). MAC is a C5b-9 
complement protein complex, a membrane-damaging complex that can form 
pores on the membrane leading to lysis of the cell. Exposure to sublytic 
levels of MAC can trigger Ca2+ influx, activation of phospholipases, 
generation of diacylglycerol (DAG) and ceramide, and activation of protein 
kinase C (PKC) and mitogen-activated protein kinase (MAPK) pathways 
(Kraus et al., 2001; Morgan et al., 1985; Niculescu et al., 1993; Shirazi et al., 
1989). CD46, CD55 and CD59, complement regulators, restrict binding of 
complement to the cell surface (Kojima et al., 1983; Meri et al., 1990; 
Nicholson-Weller et al., 1994) thus providing resistance to complement lysis. 
HSP (Fishelson et al., 2001; Gasser et al., 2005) and ERK (Kraus et al., 
2001) are other proteins that provide protection against complement lysis. 
PKC activation depends on ERK and treatment with ERK inhibitor has been 
shown to reduce the number of proteins released upon sublytic MAC 
exposure as observed in K562 cells (Pilzer and Fishelson, unpublished). 
Hence, ERK seems to be involved in MAC removal. Mortalin (found in 
mitochondria, ER, cytoplasm and cytoplasmic vesicles) an HSP70 family 
protein has recently been shown to be involved in MAC vesiculation 
(Wadhwa et al., 2002; Ran Q et al., 2000). Cells release mortalin, soon after 
exposure to sublytic MAC (observed by Pilzer and Fishelson in K562 cells); 
mortalin in binding to C8 and C9 might then enable MAC to be assembled 
to vesicles (Pilzer et al., 2005). 
Cells release MAC upon exposure to sublytic C5b-9 complex by membrane 
vesiculation either by ectocytosis (releasing MVs) or endocytosis followed 
by exocytosis, releasing exosomes. Both these vesicles contain some 
similar proteins that are essential for protection against complement lysis. 
Erythrocytes secrete vesicles on complement attack that are enriched in 
proteins anchored to the plasma membrane via GPI anchors such as 
acetylcholinesterase and decay accelerating factor (CD55, DAF) (Butikofer 
et al., 1989; Whitlow M et al., 1993). In erythrocytes, GPI anchored proteins 
seem to be required for ectocytosis. In epithelial cells and Ehrlich tumour 
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cells (Carney et al., 1985; Kerjaschki et al., 1989; Morgan et al., 1987) C5b-
9 complexes may be subjected to proteolytic degradation upon endocytosis 
(Morgan et al., 1986). C5b-9 complexes on the epithelial cell surface are 
endocytosed in MVBs and then released as exosomes upon exocytosis. 
Both exosomes and MVs are induced in a Ca2+ dependent manner and 
studies suggesting MAC increases intracellular Ca2+ levels have been 
reported (Campbell et al., 1981; Campbell et al., 1979). Regulated 
endocytosis as described earlier is Ca2+ dependent. Increased level of Ca2+ 
upon sublytic MAC exposure may internalize membrane bound complement 
components in the form of cytoplasmic vesicles. Such MAC contained 
vesicles are released upon exocytosis thus eliminating MAC. Increased Ca2+ 
influx causes imbalances in enzyme systems maintaining the integrity of cell 
membranes, resulting in further exposure of PS on the outer surface, in turn 
leading to blebbing and pinching off of plasma membrane to form MVs. MVs 
thus formed upon sublytic exposure to MAC may incorporate cell surface 
bound complement components thus eliminating MAC. 
1.3 Exosomes 
Exosomes are small membrane vesicles that are secreted by all antigen 
presenting cells through a process termed exocytosis. Like MVs, exosomes 
are enveloped by a lipid bilayer but have a diameter of 30 nm to 100nm, this 
being one of their defining criteria. Owing to their smaller size they can only 
be observed using electron microscopy. Microscopic observations have 
revealed them as having flattened spheres, having a ‘saucer-like’ structure, 
although this was subsequently shown to be an artefact from the procedures 
required to prepare samples for transmission electron microscopy (Thery et 
al., 2002). Exosomes arise as internal vesicles of Multi Vesicular Bodies 
(MVBs) and are released upon exocytosis. Exosomes were described, 
initially, as microvesicles containing 5’-nucleotidase activity that were 
released from neoplastic cell lines (Trams, et al., 1981) and also thought to 
be involved in the process of removing cell surface molecules, first observed 
in reticulocytes as a mode of removal of transferring receptor (Keller et al., 
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2006). However, more recent studies have suggested them to have 
important roles in other biological functions, such as immunological 
response(s) and cellular communication. 
1.3.1 Biogenesis of Exosomes 
Eukaryotic cells continually communicate with the extracellular environment 
and other cells by the uptake and secretion of macromolecules whether they 
be proteins, receptor, or nutrients. Endocytosis and exocytosis are the 
mechanisms for uptake and secretion, respectively, of such macromolecules 
(Stoorvogel et al., 2002). 
Earlier studies involving reticulocytes showed them to secrete small 
vesicles, which were endocytic in origin (Thery et al., 2002). These vesicles 
contained transferrin receptors (Pan et al., 1985; Harding et al., 1983) and 
were formed by the reverse budding at the limiting membrane of the late 
endosome. Fusion of the limiting membrane of MVBs with the plasma 
membrane (exocytosis) results in the release of the internal vesicles of 
MVBs (termed intraluminal vesicles and later on release ‘exosomes’). Upon 
release, these exosomes can be purified by a series of low speed 
centrifugation steps followed by high speed ultra-centrifugation cycles of cell 
culture supernatant to pellet the exosomes. The actual fusion of MVBs with 
the plasma membrane was first observed in RBCs (Pan et al., 1983; Harding 
et al., 1984) and later for a variety of cell types. 
1.3.2 Endosomal Origin 
The molecular composition of the purified exosomes is found to be similar to 
the internal vesicles of MVBs (Kleijmeer et al., 2001; Raposo et al., 1996; 
Escola et al., 1998; Thery et al., 1999). Exosomes contained few membrane 
markers compared to the abundant cystolic markers (Stoorvogel et al., 2002) 
indicating them to be different from that of other vesicles shed directly from 
the plasma membrane, in other words MVs. FACS analysis of exosomes 
from different cell types revealed them to be depleted in cell surface 
receptors like Fc receptors in dendric cell (DC) (Thery et al., 2001); CD28, 
34 
 
CD401 and CD45 in T-cell derived exosomes (Blanchard et al., 2002) and 
transferrin receptor in B-cell derived exosomes (Raposo et al., 1996; Clayton 
et al., 2001). Cystolic proteins involved in the endocytic pathway like 
RAB5/RAB7 (Gruenberg et al., 1995), annexin II (Gruenberg et al., 1995) 
and TSG 101 (Babst et al., 2000) were however found on the exosomes. 
Immuno-electron microscopy revealed that the antibodies against the 
cystolic proteins that are found in exosomes, such as HSP70 and annexin 
do not label unlysed exosomes but that the antibodies against the 
extracellular domain of the transmembrane protein, such as MHC class II 
molecules, CD9 and αMβ2 integrin, do (Thery et al., 1999). These vesicles 
do not expose phosphatidylserine (PS) on their outer surface. However PS 
has been observed on the outer surface of exosomes secreted by DCs 
(Thery et al., 1999) and platelets (Heijnen et al., 1999) but to a lesser extent 
(only 18%). These observations have strengthened the hypothesis 
supporting the endocytic origin of exosomes. 
1.3.3 Endosomal Pathway: MVB Biogenesis 
The endosomal system consists of endocytic vesicles, early endosomes, 
late endosomes, MVBs and lysosomes (Stoorvogel et al., 2002). The 
activated transmembrane receptor-ligand complex at the plasma membrane 
is endocytosed, in a clathrin or non-clathrin dependent manner, forming an 
endocytic vesicle. These activated transmembrane receptor-ligand 
complexes were thought to undergo full degradation upon uptake in 
endosomes followed by the fusion of MVB with lysosome; this concept has 
however now been modified in view of more recent findings. 
MVBs are thought to develop from late endosomes (though many have 
considered both to be the same structure) as a result of the accumulation of 
exosomes by intraluminal budding or reverse budding at the limiting 
membrane of the late endosome (Johnstone et al., 2006). A model for MVB 
formation was suggested 30 years ago (Hirsch et al., 1968; van Deurs et al., 
1993). The endocytic vesicle carries biomolecule cargo to the MVB limiting 
membrane. The next step involves sorting of selected cargo to recruit 
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proteins and lipids in MVB followed by dissociation of cargo and later the 
inward budding in the MVB (Stoorvogel et al., 2002) giving rise to exosomes 
or intraluminal vesicles inside the MVB. 
1.3.4 Exosome biogenesis: Cargo sorting 
Proteins and lipids are important for the biogenesis of MVBs and hence 
exosomes. Ubiquitation of selected proteins is one of the most common, 
though not the only protein sorting mechanism in MVBs (Hicke et al., 2001). 
For example, in Saccharomyces cerevisiae ligation of a single ubiquitin 
moiety to the substrate protein serves as a sorting signal for incorporation of 
that protein in MVBs as an internal vesicle. However, ligation of multiple 
ubiquitin units to the substrate protein serves as a signal for degradation of 
the protein (Keller et al., 2006). Here, G-protein coupled receptor (GPCR) 
Ste2 is ubiquitinated and mutation of lysine residues in Ste2 blocks 
downregulation (Keller et al., 2006). Similarly, c-Cbl (ubiquitin ligase for 
EGFR) is required for sorting EGFR in MVBs (Levkowitz et al., 1998). Fifteen 
yeast VPS E class mutant genes are identified and reported to be important 
in MVB biogenesis (Lemmon et al., 2000). Hetero-oligomeric protein 
complex ESCRT-1 in yeast, orthologous to mammalian TSG101, is thought 
to interact with VPS23 to recruit ubiquinated proteins. The selected protein 
cargo near the limiting membrane dissociates and releases ubiquitin, 
ESCRT-1 and clathrin coat (proteins involved in the MVB pathway) before 
assembling into the internal vesicle in MVBs. Tertaspannins are recruited in 
MVBs without ubiquitylation and get incorporated to form rafts (lipid 
rafts)/microdomains in the vesicles (Stoorvogel et al., 2002; Hemleret et al., 
2001). Tetraspannins can interact with many other proteins and so become 
incorporated in the MVBs without ubiquitination. Similarly, clustered proteins 
can be recruited into MVBs. For example, lack of transferrin receptor-HSC70 
interaction results in aggregation and clustering of proteins, which get 
recruited into MVBs and hence in exosomes and which are thus released 
upon exocytosis in association with exosomes (Geminard et al., 2001). 
1.3.5 Exosome biogenesis: Post endocytosis 
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The vesicles inside the MVB may be processed in different ways that are 
driven by their composition and the cell’s requirement. Accordingly, these 
internal vesicles have three fates as illustrated below using a few examples 
and summarised in Fig. 1.1. 
i) Activated transmembrane receptor-ligand complexes are internalised by 
endocytosis and taken up in MVBs. Such receptor-ligand complexes might 
undergo full degradation upon fusion of MVBs with lysosomes. 
ii) The internal vesicles containing MHC-II loaded with antigen peptide fuse 
with the plasma membrane and thus the antigen loaded MHC-II is exposed 
at the cell surface where it can be recognised by CD4+ T cells. 
iii) Upon the fusion of the limiting membrane of MVBs with the plasma 
membrane, internal vesicles of MVBs are released into the extracellular 
space. These vesicles are called exosomes. The process of exocytosis may 
be constitutive (non-Ca2+ triggered), as in EVB transformed B-cells, DCs and 
epithelial cells (Raposo et al., 1996; Thery et al., 1999; van Niel et al., 2001) 
or regulated (Ca2+-triggered) as in mast cells and T-cells (Blanchard et al., 
2002; Raposo et al., 1997). The exact mechanism of these fusions is not 
known. However, a proposed protein mechanism is described, which 
depends on one of the membranes containing v-SNARE [vesicle-
SNAP{soluble NSF(N-ethylmaleimide-sensitive factor)-attachment protein}-
attachment protein receptor] while the other should contain t-SNARE (target-
SNARE) (Thery et al., 2002). 
These three possible fates of the vesicles inside MVBs are outlined in Figure 
1.1 below. 
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Fig. 1.1 Representation of the process of endocytosis and possible 
fates of internal vesicles formed inside MVBs in an antigen presenting 
cell.  
1.3.6 Molecular composition and structure of Exosomes 
Exosomes contain common as well as cell-specific proteins. Therry et al 
observed that 80% of exosomal proteins are conserved between mouse 
(Thery et al., 1999 and 2001) and human DC-derived exosomes (Thery et 
al., 2002). Table 1.2 lists some protein families commonly observed in 
exosomes from different cell types. MHC class I and II (Blanchard et al., 
2002; Wolferset al., 2001); heat shock protein 70 (HSP70) HSC70, HSC73 
and HSP90 (Thery et al., 2001; 2002); and tetraspannins CD9, CD63, CD 
81 and CD82 are a few common proteins found in exosomes. Ubiquinated 
proteins help to load antigen peptide onto MHC molecules. HSPs carry 
misfolded proteins to their degradation site. Mortalin, an HSP70 family 
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protein, is being studied for its possible role in cells’ defence against 
complement lysis (Pilzer et al., 2005). Indeed, Pilzer D. et al., in 2005, 
suggested that mortalin is involved in MAC vesiculation on sublytic 
complement exposure. Further, Graeme I. Lancaster and Mark A. Febbraio 
in 2005 suggested exosome dependent trafficking of HSP70. 
 
 
Table 1.2 Summary of markers, proteins, miRNA, and mRNA found in 
exosomes from cancer cells as described by Henderson and Azorsa, 
2012. 
 
Exosomes also express CD55 and CD59 which have been shown to protect 
against complement mediated lysis (Clayton et al., 2003). The 
Tetraspannins, which are commonly found on exosomes, have four 
transmembrane domains and 2 extracellular domains that can interact with 
many other proteins like MHCs and integrins (as well as with themselves) 
thus allowing them to form large multimeric protein networks. 
Exosomes contain cell-specific proteins that link them with cellular function; 
exosomes from antigen presenting cells (APCs) for example are particularly 
rich in MHC-II. DC-derived exosomes also contain CD89, aMb2, b2 (Thery 
et al., 2002) and EGF factor VIII (Thery et al., 1999); T cell derived exosomes 
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contain T cell receptor and B2 integrin. Additionally, B cell, DC and tumour 
derived exosomes contain a lysosomal associated membrane protein 1 
(LAMP-1) and HLA-DM (Thery et al., 1999; Hammond et al., 1998). Fig. 1.2 
schematically represents the structure of exosomes and other extracellular 
vesicles (microvesicles and apoptotic vesicles) including the location and 
probable  
 
 
 
Fig. 1.2 Summary of the composition of Extracellular Vesicles 
(including Exosomes and Microvesicles (EMVs) and apoptotic 
vesicles). The molecules represented include proteins, lipids and nucleic 
acids. Abbreviations: ARF, ADP ribosylation factor; ESCRT, endosomal 
sorting complex required for transport; LAMP, lysosome-associated 
membrane protein; MHC, major histocompatibility complex; MFGE8, milk fat 
globule-epidermal growth factor-factor VIII; RAB, Ras-related proteins in the 
brain; TfR, tranferrin receptor. Colombo et al., 2014.  
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functions of proteins found in them (Colombo et al., 2014). Additionally, 
CD63 (LAMP3) is particularly enriched in exosomes (Heijnen, H. F. et al., 
1999). 
Despite much proteomic data, miRNA content and long noncoding RNA 
content, little is known about the lipid composition of exosomes. 
Lysobisphosphatidic acid (LBPA) (Kobayashi et al., 1999) and N-lissamine 
rhodamine B sulfonylphosphatidylethanolamine (Vidal et al., 1997) are found 
in exosomes. Exosomes from B cells are rich in cholesterol and 
sphingomyelin (Stoorvogel et al., 2002) both involved in raft formation 
(Stoorvogel and Schwartzman, unpublished results). It has been described 
that tetraspannins are involved in forming raft-like microdomains. 
Glycosylphosphatidylinositol (GPI)-anchored proteins are also incorporated 
into these rafts (Ikonen et al., 2001). 
1.3.7 Functions of exosomes 
Exosomes were initially thought to be involved as part of the machinery for 
removal of surface receptors, in other words as an alternative to lysosomal 
degradation and this role for exosomes was first observed for the removal of 
transferrin receptor from the mature RBCs (Pan et al., 1983). Raposo et al., 
showed that exosomes derived from EBV transformed B cell can stimulate 
CD4+ T cells in vitro, to a lesser extent though, compared to B cells 
themselves (Raposo et al., 1996). Exosomes produced by 0.5 X 106 and 1 
X 106 mouse DCs with tumor peptide produced anti-tumor responses 
mediated by T cells (Zitvogel et al., 1998). Exosomes from DCs carrying 
antigen loaded MHC are indeed found to transfer such MHC-antigen 
complexes among other DCs thus allowing the recipient DCs then to 
stimulate a CD4+ T cell response (Andre et al., 2004; Hsu D.H. et al., 2003). 
Exosomal proteins such as milk fat globule elongation factor 8 (MFG-E8), 
CD11a, CD54, CD9 and CD81 have been shown to mediate the transfer of 
exosomes among DCs (Morelli et al., 2004). Mast cell exosomes when 
incubated with splenocytes for example induced blast formation, proliferation 
and production of IL-2 and INF-γ (Skokos et al., 2001). Also mast cell derived 
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exosomes induced maturation of DCs by regulation of MHC II, CD40, CD80, 
and CD86 (Skokos et al., 2003). Zhang et al., in 2006, made an observation 
supporting the role of exosomes in inflammation showing that synovial 
fibroblast-derived exosomes, derived from rheumatoid arthritis patients 
contained TNF-α, which was sensitive to the L929 cell line. Tumour antigens 
like MART1 positive exosomes can be found in cancer patients, and these 
have been shown to provide protection against tumour establishment (Andre 
et al., 2002). The mechanism involved in this protection is the transfer of 
tumour antigen in DCs, which can then activate cytotoxic T cells (Andre et 
al., 2002). Rabesandratana et al., in 1998, showed that glycosyl-
phosphatidylinositol (GPI)-anchored proteins acetylcholinesterase (AchE), 
decay accelerating factor (DAF-CD55), membrane inhibitor of reactive lysis 
(MIRL, CD59), and LFA-3 were released in exosomes during in vitro 
maturation of reticulocytes (Kinoshita et al., 1986; Rollins et al., 1991). 
Furthermore, DAF and MIRL present on exosomal membranes may play a 
role in regulating membrane attack complex (MAC) formation. 
 
1.3.8 Present status of exosome isolation and purification 
The most commonly used isolation technique for exosomes is differential 
centrifugation followed by purification and identification by sucrose gradient 
centrifugation, which is described in detail in this thesis under Materials and 
Methods. However, the isolation protocol of exosomes has recently received 
attention and protocols have been designed to produce clinical grade 
exosomes with the removal of 90-95% of contamination. Dhellin Olivier et 
al., US patent 6,899,863 B1 accepted in 2005, defines a protocol to isolate 
and purify exosomes for clinical use as claimed by the inventors. The 
technique involves anion exchange chromatography under pressure (ion 
exchange HPLC) using supports such as mixtures of agarose, dextran, etc. 
in the form of beads having a diameter between 0.1 µm and 1 µm. The 
authors also describe the use of gel permeable chromatography in addition 
to anion exchange chromatography for the isolation of exosomes. The 
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authors go on to suggest that although differential centrifugation provides 
sufficiently pure samples for research purposes, it is not suitable for clinical 
use. Essentially, when it comes to the question of production at an industrial 
scale the differential centrifugation technique has its limitations. 
Cheruvanky et al., in 2007, described the isolation of urinary exosomes using 
a nanomembrane ultrafiltration concentrator using commercially available 
nanomembrane concentrators (Vivaspin). Urine samples cleaned of cells 
and debris by 17, 000 g centrifugation for 15 min was added to Vivaspin and 
then centrifuged at 3,000 g for 10 mins. Urinary exosomal proteins were 
subsequently recovered from the concentrator by adding, unheated or 
preheated at 95ºC, 2X solublizing buffer [2X Laemmli buffer with 400 mM 
dithiotheritol (DTT)]. This technique can be used to effectively isolate 
exosomes from very small sample volumes down to ~0.5 ml. 
1.3.9 β-glycyrrhetinic acid 
β-Gycyrrhetinic (β-Gly) (β-Gly) acid is derived by hydrolysing glycyrrhizic 
acid (Sato, T. et al., 2009) from the root of the liquorice plant (Glycyrrhiza 
glabra L.)   (Wu, F et al, 2013).  It’s steroid-like structure, a triterpenoid, 
shown below, has a structural similarity to corticosteroids, (Liu, D et al, 2007) 
and it is because of these structural similarities to steroids, that they are able 
to inhibit metabolic enzymes for adrenocorticosteroids (Ha, Y.M., et al., 
1991). GA is the aglycon of glycyrrhizin, a component of Glycyrrhiza, the 
liquorice plant. When glycyrrhizin is given orally, it is metabolized to GA by 
intestinal flora whereupon it is absorbed into the circulation (Takeda, et al., 
1996). 
This natural steroid is thus able to reduce inflammation and has therapeutic 
value for example for patients with eczema and psoriasis (Kang, et al., 
2014). β-Gly was also shown to enhance the action of hydrocortisone 
(Teelucksingh, S et al, 1990) and to bring about the apoptosis of monocytes 
(Schmidt et al, 1999). Furthermore, in terms of regulating immunity and 
inflammation β-Gly was also shown to inhibit 15-hydroxyprostaglandin 
dehydrogenase and delta-13-prostaglandin, thereby enhancing the action of 
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prostaglandins (Reddy et al,1992). β-Gly is a potent agent which has been 
derivatised to drugs such as carbenoxolone, used to treat ulcers, liver 
disease and been found to be anti-oxidant and immuno-regulatory 
(Chintharlapalli, S et al, 2007). Extracts from the liquorice root have been 
used in traditional Japanese and Chinese medicine for some time where 
they are used to treat ulcers, asthma, hepatitis and eosinophilic (Kroes, B et 
al, 1997). 
1.3.10 Microvesicles as drug delivery vehicles 
The obvious advantage of using a MV as a drug delivery vehicle is that it 
gives the drug it carries an added degree of protection from for example 
immune effector mechanisms. Compared to liposomes for example, MVs 
are much more resistant to complement attack as they carry all the 
complement inhibitory receptors that the parent cell carries (Inal et al., 2012). 
The half-life of MVs in vivo ranges from hours to days (Inal, personal 
communication) so clearly the choice of the cell from which to derive MVs 
for this purpose is an important consideration. One of the most important 
examples of extracellular vesicle (in this case exosomal) drug delivery which 
also addresses the targeting aspect to using any vesicle for drug delivery but 
also is interesting for having used an immune cell derived exosome is the 
seminal work of Matthew Wood in Oxford (Alvarez-Elviti et al., 2011). In this 
study exosomes derived from mouse dendritic cells were used. The study 
showed that these DC exosomes (sometimes called dexosomes) could be 
targeted to the mouse brain by engineering the expression of the neuron 
specific RVG peptide fused to Lamp2b. They went on to show that siRNA 
targeting BACE1, could knock down expression of this protein, which is an 
important therapeutic target in Alzheimer’s disease by 62%. 
1.3.11 Microvesicle interaction with recipient cells  
The manner in which MVs released from one cell interacts with a particular 
target cell is still very much the subject of ongoing research in the field of cell 
biology (Mulcahy et al., 2014). It is broadly believed that there are several 
means of MV-cell interaction, none of which is likely to be exclusive with any 
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one cell and that in fact for any given MV cell interaction that this may occur 
by more than one of these means. Looking at endocytosis, this could be 
mediated as receptor-mediated uptake for example if a protein ligand 
expressed on the surface of a MV is able to interact with its cognate receptor 
on a recipient cell thus triggering receptor-mediated endocytosis. A non-
receptor-mediated form of endocytosis could also be triggered if for example 
macropinocytosis is triggered such as with Epidermal Growth Factor or HB-
EGF (heparin-binding Epidermal-like Growth Factor). This means of uptake 
involved cytoskeletal rearrangement and may result in the MV following a 
degradative pathway or being recycled to the cell surface (Faille, D., et al., 
2012). If a MV interacts with a recipient cell by fusion, it is still not known if 
this is true fusion or hemi-fusion. Ongoing research in this field is using 
techniques such as lipid mixing with a lipid dye called octadecylrhodamine 
or various PKH dyes but also the more elegant FRET (Fluorescence 
Resonance Energy Transfer) by microscopy. It is also being speculated that 
any kind of MV-cell fusion may be preceded by some protein-protein 
interaction.  
1.3.12 The Cancer Epidemic 
There are almost 200 different types of cancer in humans, which can 
commence in a wide range of body tissues and then metastasise into other 
body tissues. There is also a range of identified causes of cancer which 
include viral infections (e.g. human papilloma virus, bacterial infections (e.g. 
Helicobacter pylori) or parasitic infections (e.g. Schistosoma mansoni) old 
age, mutations, diet, weight, environmental factors including environmental 
pollutants and life style practises. According to Cancer Research UK 
(cruk.org) and the Office of National Statistics (ona.gov.uk) cancer is the 
leading cuase of death in the UK, in 2015 accounting for 28% of deaths 
which was ahead of cardiovascular diesease at 26% e.g. heart disease and 
stroke The 530,000 deaths recorded in 2015 represent an increase of just 
over 5.5% compared to that in 2014. These increases are not wholly 
unexpected with an ageing population, but it is also important to 
acknowledge that patient survival has doubled in the last 40 years.  
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The European Prospective Investigation into Cancer and Nutrition (EPIC) is 
a study investigating the relationships between diet, lifestyle and the 
incidence of chronic disease including cancer. This is one of the largest 
cohort studies in the world, with over 0.5 mi participants from 10 European 
countries over the course of 15 years. The EPIC study is headed by Prof. 
Riboli (Imperial College London) and Dr. Romeiu and Brennan (International 
Agency for Research on Cancer, Lyon). The study accumulated over 6 
million person-years. As shown in the table below, over 47,000 participants 
were diagnosed with cancer (13,000 breast; 3,500 lung; 5,300 colorectal and 
5,100 prostate). There were 37,000 deaths and 8,500 participants 
developed at least two deadly diseases, including cancer, cardiovascular 
diseases and diabetes. As a result, epidemiological studies of co-morbidities 
were thus also possible. Just this year EPIC has resulted in a plethora of 
studies on cancer, nutrition and with some recommended life style changes 
(Assi et al, 2016; Bakker et al, 2016; Emaus et al, 2016; Merritt et al, 2016) 
including reducing prothrombocytic microenvironments (Rak, J et al, 2006).  
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Table 1. Number of incident cancers and deaths in EPIC in 2010 
Sex Country N Person-
Years 
No. of 
incident 
cancers 
No. of incident 
deaths 
Women France 74 
524 
1 103 492 7313 4038 
 
Italy 32 
577 
394 213 2594 978 
 
Spain 25 
808 
352 213 1466 775 
 
United 
Kingdom 
60 
970 
775 025 5141 5001 
 
Netherlands 29 
751 
379 272 2607 1843 
 
Greece 16 
614 
159 377 577 833 
 
Germany 30 
255 
341 989 2101 991 
 
Sweden 30 
329 
422 044 3400 2507 
 
Denmark 29 
875 
352 610 3658 2190 
 
Norway 37 
200 
406 473 2357 975 
 
Total 367 
903 
4 686 708 31 214 20 131 
Men France 0 0 0 0 
 
Italy 15 
168 
188 503 1268 730 
 
Spain 15 
630 
209 831 1421 1197 
 
United 
Kingdom 
26 
917 
335 112 3160 4586 
 
Netherlands 10 
260 
130 580 563 543 
 
Greece 11 
947 
106 722 560 1313 
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Germany 22 
833 
253 868 2342 1845 
 
Sweden 23 
494 
320 353 3406 3273 
 
Denmark 27 
178 
311 900 3591 3359 
 
Norway 0 0 0 0 
 
Total 153 
427 
1 856 869 16 311 16 846 
 
 
By 2015, the number of cancers that may develop in the cohort is projected 
to increase to more than 96 000 and will include approximately 25 000 cases 
of breast cancer, 12 000 of colorectal cancer, 8000 of lung cancer, 10 000 
of prostate cancer, 2000 of gastro-intestinal cancer, 4400 of bladder cancer, 
2500 of pancreatic cancer, 3700 of endometrial cancer, 1000 of liver cancer, 
and 1300 of thyroid cancer (Table 2). A large number of incident cancer 
cases with prospectively collected lifestyle data and blood specimens will 
allow EPIC to address state-of-the-art hypotheses about the etiology and 
prevention of several forms of common and rarer cancers. 
Table 2. Sex-specific expected frequency of major cancer sites available 
by 2016 
Sex Breast Colorectal Lung Prostate Stomach All 
cancers 
Men 0 4907 4152 10 771 1198 32 334 
Women 24 899 7669 3852 0 1010 64 242 
Total 24 899 12 576 8004 10 771 2208 96 576 
 
The new cancer strategies adopted in England (CRUK.org) include early 
diagnosis, immediate access to the appropriate treatment and importantly 
disease prevention which includes lifestyle changes such as stopping 
smoking, improved diet and exercise. As reported by CRUK in 2011 
(cruk.org/preventable) these measures include stopping smoking, drinking 
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less alcohol, moderate exposure to sun, consumption of less processed food 
and red meat, eating a high-fibre diet, reducing salt intake, doing exercise, 
reducing exposure to asbestos, certain infections such as HPV,  minimising 
exposure to radiation, e.g. x-rays,  breastfeeding, and reducing time on HRT. 
There are many environmental pollutants associated with disease in general 
but also cancer As shown in a small study of umbilical cord blood carried out 
in the US in 2004 (http://www.ewg.org/research/body-burden-pollution-
newborns#.WcJUsdWPKJA) up to 287 chemicals and pollutants were 
detected including polyaromatic hydrocarbons, pollutants derived from 
burning petrol, which accumulate in the food chain and that are linked to 
cancer. Perfluorinated chemicals, polychlorinated biphenyls, organochlorine 
pesticides, polychlorinated dibenzodioxins, all also linked to cancer were 
also found. 
Over 40% of cancer cases in the UK are linked to fourteen life-style factors 
(Parkin et al., 2010). The higher proportion of males (45%) versus females 
(40%) is attributed to differences in smoking habits. Over half a million 
cancers are deemed preventable in the UK over a 5 year period 
(www.cancerresearchuk.com 2014) by changing lifestyle. Examples include 
fasting, hydration and detoxification strategies which represent a more 
holistic approach to health akin to one of the oldest such medical systems, 
that of Ayurvedic medicine using herbal products (Pole, 2012) and other 
plant extracts (http://www.cancerresearchuk.org/about-cancer/cancer-in-
general/treatment/ 
complementary-alternative-therapies/individual-therapies/ayurvedic-medicine).   
MVs released by tumor cells are detectable in patients with cancer and their 
number in the circulation correlates with poor prognosis. Due to their 
pleiotropic effects, MVs may play a role in the prothrombotic state associated 
with cancer as well as in cancer development and progression. Recent 
findings show that Microvesicles can be involved in the epigenetic 
reprogramming of neighbouring cells (Camussi et al., 2011; Quesenberry, 
2008, 2010, 2012). With the current advances in MV detection and 
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characterisation and general use in as diagnostic tools, it may be that in the 
near future that cancer progression and regression may be monitored by 
assessing MV types and levels. 
 
 
1.4 Aims of thesis 
MVs and exosomes are shed by most eukaryotic cells constitutively (without 
stimulation) and upon exposure to inducing agents (induced). The Isolation 
techniques in place do not give absolutely pure preparations of either 
membrane vesicles and hence results obtained using these isolation 
techniques are likely to give inaccurate associated functions with vesicle 
type. Both MVs and exosomes have similar proteomes and biological 
functions and furthermore a correct identification becomes necessary when 
dealing with either of them.  
Using previously established properties, such as size, enrichment of specific 
marker proteins etc., the aim was to use sucrose gradient density 
centrifugation (currently used to purify exosomes) to also isolate MVs and to 
test novel filtration methods for the isolation of plasma MVs. A further aim 
was to use this methodology to make measurements of plasma MV levels in 
donors and to begin to look at various factors that may affect these levels 
such as gender, age, and for the first-time fasting status.  
The possibility of using MVs as drug delivery vehicles was also to be 
investigated, at first from the point of seeing how they interact with potential 
target cells, in particular to ascertain whether membrane fusion occurs, 
which would be important for delivery of intravesicular content into the target 
cell cytosol. The effect of β-Glycyrrhetinic acid, derived from liquorice was 
also investigated on erythroleukaemia cells and its capacity to limit cellular 
proliferation estimated upon delivery within MVs. 
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2. Materials and Methods 
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2.1 Solutions and reagents 
RPMI1640, FBS, Antibiotics, PBS, Sucrose, HEPES buffer, PMA, Anti CR1 
antibody, FITC, octadecyl rhodamine (R18), DAPI, Fluorescein 
isothiocyanate (FITC) conjugated anti-human CD107a (LAMP-1) antibody, 
anti-goat IgG antibody, anti CD11b antibody, Phycoerythrin (PE) and FITC 
conjugated anti AnnexinV antibody and PE conjugated anti CD63 (LAMP-3) 
antibody. All fluorescence conjugated antibodies were from SIGMA. 
2.2 Cell culture 
THP-1 (Human acute monocytic leukaemia cell line) cell cultures were 
maintained in complete medium - RPMI 1640 with 10% fetal calf serum 
(FBS) and 1% antibiotic. Minimum of 2x106 cells per ml was maintained in 
sets of three 20ml flasks at 37°c. Cells were split twice a week into the fresh 
medium and the supernatant was stored at 4°C till further requirement. 
2.3 Isolation of MVs and exosomes 
Majority of the work in this research was on isolation protocol for MVs and 
no stage inducing agents were used. Different isolation protocols were used 
involving 2 common steps 
1) Centrifugation of cell culture for 5 mins at 160g to pellet cells and collect 
supernatant (SN). 
2) Cell free SN is centrifuged again twice at 4,000g for 30 mins to remove 
the cell debris (clean SN). 
NOTE: SN was stored at 4°C, if not required to process immediately at any 
of these two steps. The temperature was set at 14°C for all centrifugation 
cycles unless otherwise mentioned. 
2.3.1 Differential centrifugation 
Clean SN was subjected to ultracentrifugation for 1 hr and 30 mins at 
200,000g/40,000rpm (in sorvall ultracrimp 35ml centrifuge tubes – 
40000rpm max.) or for 2 hrs at 150,000g/30,000rpm (in sorvall ultracrimp 
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11.5ml centrifuge tubes – 30,000rpm max) to pellet MVs. SN was collected 
and ultracentrifuged for 16 hrs at 200,000g or 18 hrs at 150,000g to pellet 
exosomes. To wash MVs and exosomes, pellets were resuspended in 1ml 
PBS (in 1.5ml eppendorf tubes) and centrifuged at 25,000g for 60 mins to 
regain a pellet, which was again resuspended in 200 µl PBS and stored at -
80°c till further requirement. At the later stage in the research, clean SN was 
first sonicated for 4 mins, to any break MVs or exosomes that might have 
aggregated to form clusters, and then subjected to high speed 
ultracentrifugation step. In one of the experiment CD63 preincubated MV 
sample was split into 2 equal aliquots and one of them was filtered with 0.22 
µm filter. Both were then subjected to FACS analysis. 
Few experiments required to have both exosomes and MVs in a single 
preparation. A MVs and exosomes (MV + ex) mixed sample was obtained 
by 16hrs centrifugation at 200,000g or 18 hrs centrifugation at 150,000g of 
clean SN. The pellet so obtained was washed in 1ml PBS and again 
resuspended in 200 µl PBS as described in earlier steps. [All high-speed 
ultracentrifugation was performed in Sorvall SE 90 Discovery centrifuge 
(unless otherwise mentioned) using sorvall T-865 fix-angled rotor – thanks 
to IBCHN department London Metropolitan University]. 
2.3.2 Sucrose gradient 
40% to 10% continuous decreasing sucrose gradient was made in 11.5ml 
sorvall ultracrimp tubes using gradient mixture. The gradient was allowed to 
settle undisturbed for 90 mins. MV + ex sample (in 200 µl PBS) was kept in 
an ultrasonic bath for 4 mins and then layered on top of the gradient and 
centrifuged for 90 mins at 150,000 g in the sorvall fix-angled rotor (T-865) or 
for 60 mins at 200,000 g in Beckman’s swinging bucket rotor. Ideally, eleven 
1ml fractions were collected from the top of the tube (it was not possible to 
collect all equal 11 fractions every time due to difficulties in drawing a sample 
with a syringe) and the pellet was resuspended in 200 µl PBS. The density 
of each fraction was measured by weighing and 20 µl of the sample from 
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each fraction and pellet was subjected to FACS analysis to check the 
number of vesicles. 
Two approaches were used to eliminate sucrose for the fractions i) 
centrifugation for 90 mins at 25,000 g or ii) overnight dialysis followed by 
centrifugation at 25,000 g for 60 mins. Alternatively, fractions were pooled in 
2 groups i.e. Pool 1 (P1- fractions 1-6 from top) and Pool 2 (P2- fractions 7 
and later from top) and dialyzed as described later and then centrifuged for 
60 mins at 25,000 g to pellet P1 and P2. Pellet obtained during sucrose 
gradient centrifugation step would be referred as sucrose gradient pellet 
(SGP) from here on to avoid any confusion. 
 
Dialysis 
Adequate length of dialysis membrane was cut and clipped form one end 
and the sample was introduced from other end and clipped. The membrane 
was kept in a container having PBS in 100 times the volume of the sample 
to be dialyzed. The container was kept overnight on a magnetic stirrer. 
Sample from inside the membrane was collected into eppendorf and 
centrifuged to pellet vesicles, which was then resuspended in 200 µl PBS 
that was either processed as per the requirement or stored at -80oC. 
 
2.3.3 Filter recovery 
This was a novel protocol designed with the basic idea to recover the bigger 
vesicles that do not pass through the filter. Clean SN was kept in an 
ultrasonic bath for 4 mins and vortexed for 30 secs. A filter membrane with 
uniform pore size of 0.22 um was placed in the filter apparatus and screwed 
up tightly. 13-15ml of clean SN was passed through the filter before 
membrane blocked. The filtrate was collected in 50 ml tubes for exosomes 
isolation. The filter was then unscrewed and the filter membrane was 
reversed and placed back in the filter apparatus and tightly screwed. Two 
approaches were used from here on 
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2.3.3.1 MVs without high speed centrifugation 
1ml of PBS was passed through the filter, after reversing the membrane as 
described above, and the filtrate was collected in a 1ml eppendorf tube. Filter 
membrane was taken out from the apparatus and was cut into 6-7 pieces so 
they can fit in eppendorf tube that contains the filtrate. This eppendorf tube 
was then kept in ultrasonic water bath for 4 mins and then vortexed for 1 
min. Filter pieces were removed from the tube and the sample was stored at 
-80°C or processed as required. 
2.3.3.2 MVs concentrated by high speed centrifugation 
4 ml of PBS was passed through the filter after reversing the membrane and 
the filtrate was collected in 20 ml tube. The membrane was placed back to 
its original position in the filter apparatus. And again, clean SN was passed 
through the filter till the membrane was blocked (roughly 9-10ml). Filter 
membrane was again reversed and 4 ml PBS was passed through that was 
collected in the same 20 ml tube containing filtrate. Filter membrane was 
taken out, cut into 4-5 pieces and was kept in the tube with the 8ml filtrate. 
This tube was kept in an ultrasonic bath for 4 mins and vortexed for 1 min. 
Eight 1ml aliquots were taken in eppendorf tubes that were centrifuged at 
25, 000 g for 30 mins to form a pellet. SN was discarded and all pellets were 
taken together resuspended in 200 µl PBS. 
2.4 FACS analysis 
All FACS analysis was performed on Guava EasyCyte Plus system and 
express plus assay was used for all sets of experiments in 96 wells plate. 
FACS was mainly used to determine the relative fluorescence as a result of 
FITC or PE conjugate antibody that binds the sample and to determine the 
number of vesicles. All experiments involving FITC and PE conjugate 
antibodies were performed in dark followed by incubation in dark at 4°C on 
a shaker unless otherwise stated. 
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2.4.1 FACS for differential centrifugation and filter recovered samples: 
For antibody binding assay (on FACS) of differential centrifugation samples 
a standard protocol followed for all antibodies. In general, 20 µl of exosomes 
and/or 20 µl of MVs sample were taken from 200 µl aliquots. 5 µl of FITC 
conjugate anti LAMP1 antibody, 5 µl of PE conjugate anti CD63 antibody, 
FITC conjugate anti CD11b antibody was added to 20 µl of sample in 
individual microfuge tubes and the volume was topped up to 100 µl with PBS. 
This preparation was incubated overnight. Samples were washed by 
centrifugation at 25,000 g for 60 mins to remove excess unbound antibody 
and to pellet antibody labelled vesicles that were resuspended in 200 µl PBS 
and subjected to FACS analysis to detect green and yellow fluorescence 
intensities. In a similar manner 20 µl of filter recovered MVs and 20 µl of 
differential centrifugation MVs samples were incubated overnight with 5ul 
FITC conjugated anti annexin V antibody and the volume was topped up to 
100 µl with HEPES buffer. The preparation was washed and subjected to 
FACS analysis as described earlier. Unlabelled exosomes or unlabelled 
MVs (in a few experiments isotype control FITC conjugated anti IgG antibody 
was used) were used for FACS settings and also as controls. Settings were 
made to observe maximum possible population on forward scatter (FSC) Vs. 
side scatter (SSC) on plot 1, on green and yellow fluorescence on a log scale 
on plot 2. Population shift, depending upon fluorescence that is produced 
due to binding of FITC or PE conjugated antibody to the sample was 
compared to the unlabelled control on marker2 region in plot 3 (marker3 
region was not used and was set at 0%) for either green or yellow 
fluorescence. 
 
2.4.2 FACS for sucrose gradient sample 
20 µl of the sample from sucrose gradient fractions and the pellet was 
subjected to FACS analysis for quantification of vesicles in each sample. In 
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a few experiments, exo + MV pellet in 200 µl buffer (PBS for antibody 
[LAMP1, CD63, CD11b] and HEPES for annexinV) was incubated overnight 
with 50 µl FITC conjugated anti LAMP1 antibody and PE conjugate anti-
annexinV antibody. The preparation was subjected to sucrose gradient 
ultracentrifugation at 150,000 g for 90 mins and the fractions were collected 
as described earlier. 200 µl of the sample from each fraction was loaded in 
96 wells plate and observed on FACS for fluorescence intensity due to FITC 
and PE conjugated antibody binding to vesicles. Unlabelled exosomes/MVs 
form differential centrifugation was used for settings and as controls. 
2.4.3 Expression of CD63 as marker for vesicles in pool 1 and of CD11b 
as marker for vesicles in pool 2 
P1, P2 and SGP that were in 200 µl PBS suspension were divided in 4 equal 
aliquots (set1, set2, set3 and set4) into 12 eppendorf tubes and volume in 
each was topped up to 100 µl adding PBS. On day one, 20 µl of antibody 
was added to set1 (P1, P2 and SGP) and incubated overnight in the dark on 
a shaker at 4°C. On the second day, 5 µl of FITC was added to set 1, 5 µl 
FITC to set2 and 20 µl of FITC conjugate anti IgG antibody to set3. All tubes 
were then incubated overnight. Excess unbound was removed after washing 
with PBS by centrifugation at 25,000 g for 60 mins. SN was discarded and 
the pellet was resuspended in 200 µl PBS. Set4 was unlabelled samples. All 
12 samples were again spilt into 2 equal sets giving a total of 24 samples. 
One of these sets was filtered using 0.22 µm Millipore filter and hence named 
filtered set viz. FP1, FP2 and FSGP. A clear understanding of pooling and 
naming is given in results. Set4 samples were used in FACS analysis for 
settings. All 24 samples were loaded on 96 wells plate and the volume was 
topped up to 200 µl using PBS and subjected to FACS analysis. 
 
 
 
2.5 Protein estimation assay (BCA) 
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BCA assay was performed only when the equal concentration of protein 
samples was required in the experiments. Mainly it was used before running 
SDS-PAGE or agarose gel and doing ELISA to measure TGF-β in MVs and 
exosomes. 
Nine bovine serum albumin (BSA) standards with concentration ranging 
from 0 µg/ml to 2,000 µg/ml were made by serial dilutions in distilled water. 
Working reagents were made as stated in thermo scientific BCA kit protocol. 
200 µl working reagent was added to all required wells in 96 wells plate. 20 
µl of required exosome or MV samples were lysed using 5 µl 1X triton lysis 
buffer. 25 µl of nine BSA standard and samples were loaded into the wells 
with 200 µl working reagent. The plate was agitated gently for 30 secs and 
incubated at 37°C for 30 mins. After incubation the samples were allowed to 
cool at room temperature for 5 mins and absorbance was measured at 562 
nm using FLUOstar Omega microplate reader. The protein concentration of 
samples was estimated by comparing absorbance to that of standards. 
 
2.6 SDS-PAGE 
2.6.1 Sample preparation for SDS-PAGE 
All required samples - MVs from differential centrifugation and filter recovery; 
exosomes; filtered and unfiltered pools and pellet samples from sucrose 
gradient centrifugation were lysed with 1X triton lysis buffer and centrifuged 
at 5,000 rpm for 5 mins. SN that contains proteins was collected and protein 
concentration was estimated using BCA kit and was equalized in all the 
samples. 5ul bromophenol blue and 1 µl DTT were added to every sample 
and heated at 95°C in water bath for 5 mins. 
The 10 % gel was placed in the electrophoresis apparatus with tris buffer. 
The comb was removed from the top of the gel and 20 µl samples were 
loaded into the wells. Molecular weight markers were also loaded. 20 mA 
current was passed through the gel for 2 hours or until the dye front had 
reached the bottom of the gel. 
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The gel was then stained as described below. Firstly, Coomassie stain was 
prepared by dissolving 0.4 g of Coomassie blue R350 in 200 ml of 40% (v/v) 
methanol in water with mixing.  The solution was then filtered to remove any 
insoluble material and 200 ml of 20% (v/v) acetic acid in water added.  The 
final concentration was 0.1% (w/v) Coomassie blue R250, 20% (v/v) 
methanol, and 10% (v/v) acetic acid. To stain the gel, it was gently agitated 
in Coomassie stain for 1 h. To prepare the destain solution 500 ml of HPLC- 
grade methanol was added to 300 ml of water.  100 mL of acetic acid was 
then added and, after mixing, the total volume adjusted to 1 L with water.  
The final concentrations were 50% (v/v) methanol in water with 10% (v/v) 
acetic acid.  To destain, the gel was covered with several volumes of destain 
solution and mixed overnight at room temperature. A piece of tissue in the 
destain solution meant aspiration of the destaining solution was not needed 
until the next day. Destaining was continued until the protein bands became 
distinct with little background staining. 
If the bands were not clearly visible due to suspected lower concentrations 
of protein in the sample, silver staining for maximum sensitivity was 
performed according to the protocol described below. Silver stained gels 
were then photographed and compared to Coomassie blue stained gel. 
Bands in different lanes were analysed to detect presence/absence of 
proteins or level of protein expression in different samples. 
2.6.2 Silver Staining Procedure 
Silver staining is over 100 times more sensitive than Coomassie Brilliant 
Blue R25o staining of proteins and is particularly useful for detection of low 
abundance proteins, allowing detection of down to 0.05 - 0.6 ng of protein 
per band. Silver Staining uses silver nitrate to bind proteins at a weakly acidic 
pH and these silver ions are subsequently reduced to metallic silver by 
formaldehyde at an alkaline pH.  
Preparation of working solutions for silver staining 
1. Preparation of fixative solutions: 
59 
 
Prepare the following two gel fixing solutions as outlined. The prepared 
solutions can be stored in tightly closed bottles at room temperature. Add 
the reagents to the clean glass bottles. 
 
Gel fixing solution 1:  
Ethanol 50 ml 50% (v/v)  
Glacial acetic acid 10 ml 10% (v/v) 
Deionized water 40 ml  
 
Gel fixing solution 2: 
Ethanol 60 ml 30% (v/v) 
Deionized water 140 ml  
 
2. Preparation of staining solutions: 
Prepare the following four gel staining solutions using reagents provided in 
the kit. For best results the solutions should be prepared the same day prior 
to staining. Add the formaldehyde only immediately prior to staining. The 
provided volumes are sufficient for staining one mini-gel (8 x 10 cm, 0.75-
1.5 mm thick). Mark clean glass bottles and add the indicated volumes of 
reagents. 
Sensitizing solution: 
Sensitizers concentrate 0.4 ml  
Deionized water to 100 ml  
 
Staining solution: 
Staining reagent 4 ml  
Deionized water to 100 ml  
Formaldehyde 54 μl*  
* Add immediately prior to use. 
Developing solution: 
Sensitizer concentrate 10 μl  
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Developing reagent 10 ml  
Deionized water to 100 ml to 100 ml to 100 ml 92 ml 
Formaldehyde 27 μl*  
* Add immediately prior to use. 
Stop solution: 
Stop reagent 8 ml 
Deionized water 92 ml 
 
Before using the Developing reagent was checked for precipitation and if so 
precipitated salts were redissolved by warming the solution at 37°C, before 
cooling back to room temperature. 
 
To carry out silver staining, firstly the gel was placed in a staining tray and 
rinsed briefly with deionized water. After adding 100 ml of gel fixing solution 
#1, the gel was microwaved for 30 s at maximum power, taking care not to 
boil the solution. The tray was then gently mixed for 10 min. If necessary the 
staining could be stopped at this stage or if necessary continued overnight. 
After discarding the gel fixing solution #1, gel fixation was carried out twice. 
For this, 100 ml of gel fixing solution #2 was added and the solution once 
more microwaved for 30 s at maximum power. After gently mixing for 10 min, 
washing was carried out twice. For this 100 ml of deionized water was added 
with gently mixing for 20 s and then discarded. For sensitizing and washing 
100 ml of sensitizing solution was added with gentle mixing for 1 min and 
then discarded. Washing (100 ml deionized water and gentle mixing for 20s) 
was carried out twice. For staining, 100 ml of staining solution was added for 
20 min with mixing, the solution discarded and washing as before being 
performed twice. To develop the gel 100 ml of developing solution was 
added with gentle mixing for 4 min until the protein bands appeared 
distinctly. The developing solution was discarded and the reaction 
terminated by adding 100 ml of Stop solution with gentle mixing for 5 min. 
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The gel could then be stored in deionized water having discarded the stop 
solution. 
2.7 Detection of nucleic acids in isolated MVs and exosomes by 
agarose gel electrophoresis 
A 0.8% agarose gel was prepared in 1X TAE (Tris Acetate EDTA) and wells 
were created using a comb. 5 µl exosomes, differential centrifuged MVs and 
SGP was lysed using 1X of 15 µl of triton lysis buffer. Samples were 
centrifuged for 5 mins at 5,000 rpm (using a bench top microfuge, 
Eppendorf) and SN was collected. 5 µl bromophenol blue premixed with 
ethidium bromide (EtBr) was added to all the samples. 5 µl molecular weight 
marker was loaded in the first well followed by 20 µl samples. 60 mA current 
was applied until the dye front had travelled about 75% of the total length of 
the tray. The gel was subsequently taken to the UV light box and 
photographs taken. 
2.8 ELISA for TGF-β1 of isolated microvesicles and exosomes 
Quantikine Human TGF-β1 kit was purchased from R&D systems. Protocol 
given in the kit was followed. In brief 50 µl of Assay diluents RD1-21 was 
added to each well followed by addition of 50 µl standard/control/activated 
sample. The plate was covered with tape and incubated for 2 hrs at room 
temperature. All wells were washed 3 times with 400 µl wash buffer. 100 µl 
of TGF-β1 conjugate was added to each well and incubated for 2hrs at room 
temperature followed by a wash as described in the previous step. 100 µl of 
substrate solution was added and incubated in dark for 30 mins at room 
temperature. Finally, a 100 µl stop solution was added to each well and 
readings were taken immediately on an omega microplate reader at 450 nm. 
The plates are pre-coated with a monoclonal antibody specific for TGF-β1. 
Any TGF-β1 present in sample/control/standard will be immobilized on the 
plates (first incubation) while unbound would be removed upon wash. Later 
a polyclonal antibody specific to TGF-β1 is added to sandwich TGF-β1 that 
was immobilized. Unbound antibody is again removed by washing followed 
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by addition of substrate that will develop the colour proportional to the 
amount of TGF-β1 present in the sample. 
2.9 Cytokine array analysis of isolated microvesicles and exosomes 
Human cytokine array panel A array kit from R&D Systems that can detect 
multiple cytokines in a single sample was used and protocol given in the 
array kit was followed. In brief, selected capture antibodies are spotted in 
duplicate on nitro-cellulose membranes. Equal aliquots (as measured by 
BCA kit) of lysed exo + MVs, filter recovered MVs and exosomes were mixed 
with biotinylated detection antibodies and incubated with Human cytokine 
array panel A array of different membranes. Washing was performed 
followed by addition of Streptavidin-Horseradish Peroxidase and 
chemiluminescent detection reagents. The light produced at each spot in 
proportion to the amount of cytokine bound was imaged and developed for 
1-10 mins by exposure to X-ray. Images were taken and the coordinates 
were compared to the reference coordinates given in kit. 
 
2.10 Histopaque-1077 procedure for monocyte isolation 
In a 15-ml conical centrifuge tube, 3.0 ml HISTOPAQUE-1077 (Sigma 
Aldrich) was added and this was brought to room temperature.  3.0 ml whole 
blood was carefully layered onto the HISTOPAQUE-1077 which was then 
centrifuged at 400 g for 30 min at RT. (Centrifugation at lower temperatures, 
such as 4°C, may result in cell clumping and poor recovery). After 
centrifugation, the upper layer was carefully aspirated with a Pasteur pipette 
to within 0.5 cm of the opaque interface containing mononuclear cells, the 
upper layer is discarded. The opaque interface was then carefully 
transferred, with a Pasteur pipette, into a clean conical centrifuge tube. 10 
ml Isotonic Phosphate Buffered Saline Solution was then added, with mixing 
with gentle aspiration. The tube was then centrifuged (250 g; 10 min) and 
the supernatant aspirated and discarded. The cell pellet was resuspended 
in 5.0 ml Isotonic Phosphate Buffered Saline Solution and mixed by gentle 
aspiration with a Pasteur pipette followed by centrifugation at 250 g for 10 
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min. Washing was repeated, the pellet is resuspended in 5 ml isotonic PBS. 
As heavy contamination with RBC and platelets was found with this 
procedure, even when a buffy coat was used instead of whole blood, Ficoll-
Hypaque procedure (below) was used.  
 
2.11 Ficoll-Hypaque procedure for monocyte isolation (adapted form de 
Almeida MC, et al., 2000) 
Firstly, EDTA anticoagulated fresh blood was centrifuged at 400 x g for 35 
min. 
In a separate 15-ml conical centrifuge tube, 3.0 ml Ficoll-Hypaque gradient 
(density= 1.070, Sigma Aldrich) was added and the mixture brought to room 
temperature. The buffy coat layer was carefully layered on the Ficoll-
Hypaque and this was centrifuged (400 g; 35 min). The supernatant was 
carefully transferred with a Pasteur pipette, onto a slightly hyperosmolar 
Percoll gradient (density = 1.06 g/mL) in another clean conical centrifuge 
tube.  
Isosmotic Percoll was prepared by mixing one volume NaCl 1.5 M with nine 
volumes of Percoll (Pharmacia, density =1.130 g/mL) and hyperosmolar 
Percoll by mixing 1:1 (v/v) isosmotic Percoll with PBS/Citrate (NaH2PO4 1.49 
mM; Na2HPO4 9.15 mM; NaCl 139.97 mM; C6H5Na3O7.2H2O 13 mM; pH 
7.2). After centrifugation (400 g; 35 min) the supernatant was carefully 
aspirated without disturbing pellet into another clean centrifuge tube to which 
was added 5 mL of Phosphate Buffered Saline into with gentle mixing and 
centrifugation (250 g; 10 min). The cell pellet was resuspended in 5.0 ml 
Isotonic Phosphate Buffered Saline Solution and mixed by gentle aspiration 
with a pasteur pipette. This washing was repeated and the cell pellet finally 
resuspended in isotonic PBS. 
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3. Development of Sucrose gradient- and 
reverse filtration-based methodology to isolate 
microvesicles and exosomes 
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3.1 Introduction 
Since the ‘formalisation’ of the extracellular vesicle field by the founding of 
the International Society for Extracellular Vesicles, in 2012 and the holding 
of its first meeting in April of that year in Gothenburg, the community has 
been grappling with the lack of standardisation of extracellular vesicle 
isolation and analysis. Four years on, despite position papers published in 
the prime extracellular vesicle journal (Witwer et al., 2013) and working 
groups having been set up to address the issue, it is still clear from a look at 
the literature in this field that besides there being little standard practise in 
operation, many research groups are continuing to address the issues of 
isolation and analysis with a view to improving existing techniques. This is a 
fast-changing field in which groups are finding inconsistencies in previously 
established procedures and then attempting to rectify the problems.  
The aim of this first section of the thesis was to explore alternative 
methodologies capable of isolating microvesicles (MVs) and exosomes with 
high yield and a high degree of purity. The most used method is that of 
differential centrifugation. It was decided to explore the possibility of using 
filtration and sucrose gradients which are currently used to show that 
exosomes have been isolated. 
Although it may be important to separate MVs and exosomes for example 
when they need to be used as therapeutic vehicles, in terms of studying a 
population of vesicles released from a cell with a view to understanding a 
biological process, it may actually be preferential to work with extracellular 
vesicles (EVs) (that is MVs and exosomes) this being more representative 
of what is released from cells. If MVs or exosomes are investigated in terms 
of their relative contribution to say disease pathology, however, then it 
should be born in mind that running vesicles through some kind of density 
gradient, such as a sucrose gradient, whilst likely yielding a vesicle 
population that is highly pure, certainly from the point of view of surface 
proteins that they may have acquired, this may actually not represent a very 
‘physiological’ vesicle. 
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3.2 Materials and Methods 
The detailed procedures for isolation methods adopted in this chapter are 
described fully in Chapter 2, the Materials and Methods chapter of this 
thesis. The exosomes and microvesicles (MVs) used in this study were 
isolated from THP-1 monocytes.  In Figures 3.1 and 3.2 summary flow charts 
of these procedures are summarised. Fig. 3.1 outlines the standard 
procedure of differential centrifugation which is widely used to isolated MVs, 
after removal of cellular debris by a centrifugation at 25,000 g for 1h. Also, 
in Fig. 3.1 the use of a sucrose gradient has been outlined. This is used as 
a way of isolating exosomes but has so far not really been considered as a 
possible means of isolating microvesicles, probably because it was thought 
that they are less likely to have a specific buoyant density, as for exosomes, 
(1.12-1.18 g/ml) (Heijnen et al., 1999; Inal et al., 2012) because of their large 
variation in described diameter (ranging from 100 nm up to 1 μm). In this 
case two pools of fractions were analysed for MVs and exosomes. Finally, 
in Fig. 3.2 a novel method in which a mixture of exosomes and MVs was 
filtered is described. Essentially this procedure involved passing the EMVs 
(exosomes and MVs), having removed cells and cell debris by low speed 
centrifugations at 4,000 g through a Millipore filter of pore size 0.22 μm. Most 
of the MVs are likely to deposit on the membrane, the smaller exosomes (50 
– 100 nm) being found in the filtrate. Upon reversal of the membrane, the 
deposited MVs could be washed. The possibility of carrying out a light 
sonication of the EMV mixture was also investigated with a view to breaking 
down any exosome clumps in order to improve purity and yield of exosomes 
and microvesicles respectively. 
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3.2.1 Flow cytometry analysis of isolated exosomes and microvesicles 
To prepare settings and controls, unless otherwise stated, EMVs, whether 
exosomes or MVs as isolated from a range of methodologies were diluted 
four-fold in PBS. The settings for flow cytometry were adjusted to observe 
the maximum number of possible events in the forward versus side scatter 
plots (plots #1 and #2), and such as to obtain a bell-shaped histogram in plot 
#3 (GRN-HLog or YLW-HLOg). 
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Fig. 3.1 Differential centrifugation and sucrose gradient isolation of 
MVs and exosomes. Use of differential centrifugation using 25,000 g to 
isolate MVs and using the resultant supernatant to isolate exosomes at 
150,000 g for 18 h (1).  The use of a sucrose gradient (10-40% sucrose; 
150,000 g for 90 min) and the pooling of fractions into two pools, to isolate 
exosomes and microvesicles (2)  
  
1. Differential Centrifugation
2x 4,000 g/30 min → S/N  (supernatant)
S/N  25,000 g/ 90 min → MVs +anti-CD63  
Not filtered
0.22 μm filtered (to remove MVs)
↓
Exo (in filtrate)
S/N 150,000 g /18h
↓
Exo (pellet)
2. Sucrose Gradient
150,000 g/18h → Exo + MVs    →  Water sonication  (5 x 1min)
10-40% sucrose gradient
150,000 g/90 min
Fraction #
1
2
3
4
5
6
7
8
9
10
11
SGP (sucrose gradient pellet)
11 fractions from the top
To remove sucrose:
1. 25,000 g/90 min
2. O/N dialysis; 25,000 g/60 min
Pool 1 (fractions 1-6 from top)
Pool 2 (fractions 7-bottom)
Dialysed; 25,000 g/1h
P1 pellet
P2 pellet
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Fig. 3.2 Filtration and reverse filtration to isolate exosomes and MVs. 
“S/N” as prepared in Fig. 3.1 under ‘differential centrifugation’ (by removal 
of cells and cell debris) but containing a mixture of exosomes and MVs was 
then filtered through a 0.22 μm pore size filter. This was treated either as 
shown in (a) or (b) in which the filter was reverse-filtered, washed and 
sonicated to remove MVs.   
  
3. Filtration
S/N water sonicated (4 min); vortexed 30s
0.22 µm filter
(a) 
filter reversed
Cut membrane; water sonicate 4 min;
Vortex 1 min; remove filter → MVs
(b) 
filter reversed
MVs MVs
1 ml PBS 4 ml PBS
4 ml filtrate
10 ml PBS
filter right way up
filter reversed
4 ml PBS
cut membrane
into 4-5 pieces
4 ml filtrate
add
water sonicate 4 min; 
vortex 1 min
25,000 g, 30 min → MV pellet 
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3.3 Results 
3.3.1 Differential centrifugation of microvesicles (MVs) and exosomes 
Differential centrifugation was carried out according to the method outlined 
in Fig. 3.1. Two exosome markers, Lysosome Associated Membrane 
Protein, LAMP-1 and the tetraspannin, CD63 were used and the best current 
marker of MVs, phosphatidylserine (observed by staining with AnnexinV-
FITC).  
To observe the maximum shift in the fluorescence intensity in samples 
labelled with FITC or PE conjugated antibody, gating was performed. This 
was carried out in one of two ways. Either the marker #2 region in plot #3 
was set from the point of intersection of histograms to the end, whereupon 
events in this region were considered as positive events, or else a 
rectangular gate was placed in plot #2 with GRN-HLog versus YLW-HLog 
scales on the same coordinates and scales (as for plot #3) and events 
occurring in this gate being taken as positive data. Once these gatings had 
been set, the same settings were applied for controls as well as labelled 
samples. 
In the assay for Lysosome Associated Membrane protein 1, LAMP-1, 
unlabelled exosomes as well as those stained with FITC-conjugated anti IgG 
antibody (isotype control) were used as controls. Exosomes pre-incubated 
with FITC conjugated anti LAMP1 antibody (exo + LAMP-1 antibody) 
resulted in 41% positive events compared to 7% for MVs (Fig. 3.3). 
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Fig 3.3 Lysosome associated membrane protein-1 (LAMP1) is more 
highly expressed on exosomes than microvesicles. Binding of 
Exosomes and MVs on GRH-HLog scale using IgG FITC isotype control. 
 
      
Fig. 3.4. LAMP-3 (CD63) is more highly expressed on exosomes than 
microvesicles. MVs and exosomes, pre-incubated with an anti CD63-PE 
antibody, on YLW-HLog scale. 
MVs (CD63, 8%)
exosomes (CD63, 48%)
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Fig. 3.5. Microvesicles have a greater exposition of phosphatidylserine 
(PS) on their surface than exosomes. MVs and exosomes, pre-incubated 
with annexin V-FITC, on YLW-HLog scale. 
 
  
100 101 102 103 104
Fluorescence Intensity
0
30
Ev
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ts
MVs (85% AnV-+ve)
Exosomes (15% AnV-+ve)
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Exosomes were also stained with PE conjugated anti CD63 antibody and 
this resulted in 48 % positive events on the YLW-HLog scale while MVs 
alone gave 8%, suggesting that CD63, is indeed more highly expressed on 
exosomes than MVs. By way of negative control, unlabelled exosomes and 
MVs were used and these were set at 2% positive events, the histogram 
showing a comparison of the relative fluorescence intensities upon binding 
to an anti-CD63 antibody, Fig. 3.4. As a marker for MVs, the binding of 
Annexin V-FITC to indicate phosphatidylserine exposition, was used. Whilst 
MVs (25,000 g pellet) gave 85% positive events with AnV-FITC, there were 
only 15% with exosomes (Fig. 3.5). 
In an experiment to begin to understand the merits of filtration in terms of 
MV and exosome isolation, a sample of MVs that had been pre-incubated 
with anti-CD63 antibody was divided into two equal groups, one of which 
was filtered through a Millipore filter of pore size 0.22 µm. Both groups were 
then observed by flow for fluorescence (yellow). It was observed that there 
was a significant decrease in the number of vesicles in the filtered group, 
reduced from 3.1 x 106 to 2.1 x 104 as enumerated by flow cytometry. It was 
notable that there was a significant, concomitant increase in fluorescence 
intensity in the filtered sample, increasing from 4% in the unfiltered sample 
to 54% in the filtered sample (Fig. 3.6), suggesting that the filtered sample 
was enriched for exosomes. 
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Fig. 3.6. Enrichment of exosomes after filtration through a 0.22 μm pore 
size filter. An EMV (exosome and MVs) sample (devoid of cells and cell 
debris by centrifugation (2x 4,000 g, 30 min) was pre-incubated with PE 
conjugated anti CD63 antibody, and analysed by flow cytometry for % 
fluorescence before and after filtration. The Y-axis represents percentage 
fluorescence intensity for each sample. 
  
B
e
f o
r e
 f
i l
t r
a
t i
o
n
A
f t
e
r  
f i
l t
r a
t i
o
n
0
2 0
4 0
6 0
8 0
C D 6 3
%
 f
lu
o
r
e
s
c
e
n
c
e
 i
n
t
e
n
s
it
y
75 
 
Although Fig. 3.5 shows increased PS exposition on MVs compared to 
exosomes and colleagues at CMIRC have continually shown this to be the 
case for the last 6 years (Ansa-Addo, E. et al., (2010) Anti-Baffour, S. et al., 
(2010); Hind, E. et al., 2010;   Cestari et al., (2012); Inal et al., (2012) ; Inal 
et al., (2013); Stratton et al., (2013); Stratton et al., (2015a); Stratton et al., 
(2015b); Kholia et al., (2015)) the lack of any other described markers of 
MVs has prompted a search by CMIRC for alternative markers. Proteomic 
analysis (Inal, unpublished personal communication) indicated that there 
may a significant difference in expression level of some of the integrin 
proteins between exosomes and microvesicles. Flow cytometry of MV and 
exosome expression of CD11b (αM integrin), was therefore perfomed, using 
the settings described above and using PE conjugated CD11b antibody. This 
indeed showed that MVs express more CD11b (51 % positivity) compared 
to 13 % of positive events for exosomes. Unlabelled MVs and exosomes 
were used for settings and as control and were set at 3% positive events. 
Fig 3.7, below, shows the histogram to compare the relative fluorescence 
intensities of exosomes and MVs sample when stained with PE-conjugated 
anti CD11b antibody. 
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Fig. 3.7. Microvesicles express higher levels of αM integrin (CD11b) 
than exosomes. Both vesicle types were pre-incubated with anti-CD11b-
PE antibody on YLW-HLog scale. 
 
  
Exosomes (CD11b, 13%)
MVs (CD11b, 51%)
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3.3.2 Phosphatidyl serine exposition on MVs isolated by filtration 
versus MVs isolated by differential centrifugation.  
Microvesicles were isolated by filtration as outlined in Fig. 3.2 and by 
differential centrifugation as outlined in Fig. 3.1 (1). Annexin V (AnV) binding 
was then used to assess relative phosphatidylserine (PS) exposition and this 
confirmed that the vesicles recovered from the filter were indeed MVs. FSC 
vs SSC dot plots of both of these samples appeared similar to those that had 
been described at various times in the literature (Inal et al., 2010). For these 
experiments unlabelled MVs obtained after differential centrifugation was 
used for settings and control, and gated as described earlier. In detail, 
marker #2 on plot #3 was set from 100 to 10,000 on the GRN-HLog scale, 
giving 27 % positive events, for the control, in the marker #2 region. As a 
result, the population of MVs incubated with FITC conjugated annexin V 
shifted higher on the GRN-HLog scale. Under the same settings, the MVs 
obtained by differential centrifugation when incubated with FITC conjugated 
annexin V gave reading of 42% positivity and vesicles isolated by filtration 
gave readings of 49 % positivity. Annexin V binding on vesicles isolated by 
filtration was thus 7% higher than on MVs isolated by differential 
centrifugation and thus non-significantly different (Fig. 3.8).  
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Fig 3.8. Annexin V-positively labelled vesicles (PS-positive) isolated by 
differential centrifugation and those isolated by reverse filtration are 
not significantly different in their levels of PS exposition. AnnexinV 
binding on GRN-HLog scale, for MV isolated by differential centrifugation 
and b) filter recovered MVs, on GRN-HLog scale 
 
 
  
MVs (diff. centrifuged)
AnV labelling (42%)
MVs (reverse 
filtered) AnV
labelling (49%)
(a) (b)
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3.3.3 Sucrose gradient isolation of EMVs (exosomes and 
microvesicles) and analysis using Annexin V and anti-LAMP 1 
The samples of exosomes and microvesicles (so-called S/N, i.e. EMVs free 
of cells and cellular debris) collected after low speed (4,000 g / 2X 30 min) 
centrifugation were isolated as described earlier in the materials and 
methods section. This time unlabelled exosomes were used as a control and 
to create the settings. The degree of Annexin V binding averaged at 8%, in 
the first 6 fractions from the top of the gradient and this increased 
significantly to 20% in the 9th fraction, 38% in 10th fraction, and back to 12% 
in 11th fraction (Fig. 3.9A) and 30% in the sucrose gradient pellet (SGP) (not 
shown). 
Interestingly, the percentage of LAMP1 expression was higher in the top 
fractions, specifically 18% in 1st, 34% in 2nd and 32% in 3rd, then falling to 
an average of 10% for the remaining fractions (Fig. 3.9B).  
It should be noted that unlabelled SGP when applied to the flow cytometry 
for observing side scatter versus granularity (FSc v SSc), that the vesicles 
produced a typical tapered dot plot as might be expected for MVs (Fig. 3.9C).  
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Fig. 3.9. a) AnnexinV and b) LAMP1 binding in sucrose gradient 
fractions. c) FSC Vs. SSC dot plot for SGP. 
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3.3.4 Use of Sucrose gradient and analysis of pools of fractions 
obtained for expression of αM integrin (CD11b) and CD63 (Lysosome 
Associated Membrane Protein, LAMP-3) 
The sample of EMVs was isolated as described before and the experimental 
procedures for sucrose gradient were performed as described in the 
Materials and Methods section. Samples were read on the GRN -HLog scale 
and FITC conjugated anti IgG antibody was taken as the isotype control. The 
primary antibodies were not conjugated and so samples were incubated with 
FITC to be able to observe fluorescence on the flow cytometer 
(GuavaEasyCyte). In addition, samples that had been labelled with FITC 
were read and used as a control to enable removal of any background 
fluorescence produced by the fluorescein (FITC) itself.  
In comparing samples labelled with FITC compared to those labelled with 
FITC conjugated with anti IgG antibody it was found that there was actually 
a very high background (i.e. high non-specific binding). It was therefore 
decided to use FITC as a standard control to look for a shift in fluorescence 
intensities in the sample population. The Marker #2 region on plot #3 was 
set at ~15% positive events for FITC labelled samples, on GRN-HLog scale. 
The same settings were then applied to IgG and samples labelled with a 
primary antibody (CD63 and CD11b). FITC-conjugated anti IgG antibody 
labelled samples are in fact excluded from the graph in Fig. 3.10 due to the 
extremely low percentage of binding. All unfiltered samples (incubated with 
FITC conjugated anti-CD63/CD11b antibody) showed significant CD63 and 
CD11b binding that increased from 58% (P1) and 50% (P2) to 82% for SGP. 
Interestingly, the percentage of fluorescence intensity decreased from 27% 
in FP1 and 7% in FP2 to 4% in FSGP. 
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Fig. 3.10. Detection of CD63-expressing exosomes in pool #1 
recovered from a sucrose density centrifugation as well as CD11b-
expressing MVs in pool #2 and MVs in the pellet. (A) Pool #1 vesicles 
recovered expressing CD63 and (B) pool #2 vesicles expressing CD11b. (C) 
sucrose gradient pellet and filtered sucrose gradient pellet vesicles 
expressing CD11b. Isotype control is excluded from the graphs as binding 
was very low.  
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SGP2 (CD11b) FSGP2 (CD11b)
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3.4 Flow cytometric analysis of microvesicles and exosomes purified 
by sucrose gradient and reverse filtration suggests that both MVs and 
exosomes can be isolated by sucrose density gradient centrifugation. 
The use of flow cytometry analysis of EMVs aims to be able to detect the 
expression of a particular marker ideally able to distinguish microvesicles 
(MVs) and exosomes. In previous work Thery et al., in 1999 suggested that 
exosomes derived from dendritic cells are LAMP-1 positive. Also, THP-1 
acute monocytic leukaemia cells express LAMP-1 and this protein can be 
released in association with exosomes. This was shown in the lab at CMIRC 
and the work presented here confirms binding of LAMP-1 antibody on 
exosomes by flow cytometry (Fig. 3.3). Although it has largely been 
suggested that MVs are typically not expressing cytosolic and lysosomal 
marker proteins, it was nevertheless found that low percentages of MVs do 
actually express LAMP-1. Exosomes are particularly enriched for CD63 
(LAMP3) (Heijnen et al., 1999) compared to MVs as shown by Western 
blotting and corroborated by the results presented here for MVs and 
exosomes isolated by differential centrifugation and analysed by flow 
cytometry (Fig. 3.4). It was also found that the expression of CD11b is higher 
in MVs compared to exosomes (Fig. 3.7) and that MVs have a higher level 
of AnV binding indicating PS exposition on MVs compared to exosomes (Fig. 
3.5) as was also found by Heijnen et al., 1999). 
It is well accepted that exosomes have a natural buoyant density in sucrose 
density gradients in the range 1.12 and 1.18 g/ml (Heijnen et al., 1999; Inal 
et al., 2012) but very curiously nothing has ever been reported as to whether 
MVs might reside within a sucrose gradient. Flow cytometry of fractions 
obtained from sucrose density gradients gave some tantalisingly interesting 
results in which fractions were found to have fewer numbers of vesicles than 
SGP, the sucrose gradient pellet. Furthermore, the forward versus side 
scatter plots (FSc v SSc) of all the fractions were similar (data are not shown) 
and yet significantly different from SGP (Fig. 3.9c) In looking carefully at the 
FSc v SSc dot plot for SGP there can be discerned the first clue that the 
SGP could actually indeed be MVs. Annexin V is the most common marker 
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associated with MVs, having a high affinity for PS, the exposition of which is 
widely regarded as a characteristic and distinguishing feature of MVs, but 
not exosomes. Fractions towards the bottom of the tube (where the bigger 
particles would be retained, and therefore amongst the vesicle population, 
presumably MVs) were found to have higher annexin V binding compared to 
the top fractions (where smaller particles are likely to be retained, 
presumably exosomes). Alongside the annexin V binding results it was 
possible to carry out LAMP1 binding assays. Here it was observed that 
fractions towards the top of the sucrose gradient had a higher binding of 
LAMP-1 compared to the bottom fractions. It is known from previous studies 
that LAMP-1 is a lysosomal protein associated with exosomes. Taking all the 
data together, including FSc Vs SSc of SGP, and annexin V and LAMP-1 
binding as obtained from the isolation of MVs and exosomes using the 
sucrose gradient, it is clear that SGP and the two fractions above it contain 
the majority of the MV population (SGP being the least contaminated of the 
three). Furthermore, the fractions above likely contain a mixed population of 
smaller MVs and exosomes and first 5 fractions likely contain mainly 
exosomes. By using fluorescent antibody staining it has thus been possible 
to detect exosomes as well as microvesicles by flow cytometry. Essentially 
the use of anti-LAMP-1 FITC conjugated antibody showed vesicles 
presumed to be exosomes in the higher fractions obtained from the sucrose 
gradient whilst in the lower fractions vesicles were detected that stained 
positively with annexin V-FITC (and hence presumably microvesicles). 
Subsequent to this work other members of the Cellular and Molecular 
Immunology Research Centre in unpublished work indeed confirmed the 
nature of the vesicles obtained from the sucrose gradient by electron 
microscopy. Of interest to the field of Extracellular Vesicles isolation and 
analysis, the sucrose density gradient can be used according to the data 
presented to separate and purify both MVs and exosomes.  
The vesicle sample obtained through filtering resulted in a similar FSc v SSc 
dot plot and similar histogram, due to Annexin V-FITC binding as was 
obtained for the differentially centrifuged sample (Fig. 3.8). Of note and an 
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important new development for EMV isolation methodologies, when using 
filtration, the supernatant was gently sonicated for 4 minutes in a water 
sonicator before passing through the filter (0.22 µm pore size) in order to 
break up most of the exosomes that may have aggregated into clumps.  As 
a result, any small MVs, exosomes and other debris smaller than 0.22 µm 
will pass through the filter into the filtrate whilst any vesicles and debris 
greater than 0.22 µm will be retained by the filter. A further washing step of 
the vesicles recovered on the filter would then be recommended to obtain a 
cleaner sample. Also, of note the integrity of exosomes after sonication was 
maintained, no breaking up of exosomes (or MVs) being detectable by 
transmission electron microscopy (not shown). 
The expression of CD11b has not hitherto been described in exosomes. In 
the work presented in this chapter, using pools of fractions obtained from 
sucrose density gradients, the unfiltered samples, SGP1, SGP2 and SGP 
were found to be positive for CD11b/CD63, which was not the case for the 
filtered samples. There was also a significant loss of CD11b/CD63 
expression in the filtered samples, FSGP1, FSGP2 and FSGP, although 
there were other differences, such as that the loss in CD63 expression being 
from 58% (SGP1) to 27% (FSGP1), compared to a much greater reduction 
from SGP (82%) to FSGP (4%) upon filtration through the 0.22 µm filter.  It 
is important to note, however, that at this point samples were not sonicated 
prior to filtration and hence that there was a possibility that exosome clusters 
were retained in the filter; however, FP1 still retained CD63 binding up to 
27%. The reason for a decreasing CD11b expressing sample in the lower 
fractions (pool 2), upon filtering might be that the larger vesicles settling in 
these lower fractions, were being removed upon filtration. Any CD11b 
positivity is completely lost in FSGP2 and FSGP; this is evident from the 
CD11b fluorescence values being beneath or at best equal to those for 
isotype control.  From the results obtained for SGP1 and FSGP1 it can be 
said that exosomes are CD63 positive but that because of the data obtained 
using the SGP (sucrose gradient pellet) that CD11b is highly expressed by 
MVs (SGP results).  
86 
 
 
 
 
Fig. 3.11. Coomassie Brilliant Blue staining of 10% reducing gel for 
exosomes, differential centrifuged MVs and MVs isolated by filtration. 
3μg protein (as determined by a BCA protein assay) was loaded for each 
sample. Asterisk denotes protein uniquely expressed in exosomes and 
arrows denote protein uniquely expressed in MVs. Samples were separated 
electrophoretically at 100V for 3h and then stained in Coomassie Brilliant 
Blue R250. 
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3.5 Comparative analysis of protein profile of isolated microvesicles 
and exosomes 
MVs isolated by differential centrifugation were compared with those isolated 
by filtration by SDS-PAGE and Coomassie Brilliant Blue staining. 10% 
resolving gels were used to also separate exosomes. As can be seen from 
Figure 3.11, distinct proteins bands can be seen in all three samples. The 
largest number of bands, lie within the 40 to 80 kDa range for the sample of 
MVs separated by differential centrifugation. There were some differences 
also noted such as an approximately 31 KDa protein (asterisked) expressed 
in exosomes not being expressed in other samples and a 25 KDa protein 
(arrows) expressed in differentially centrifuged MV and MVs isolated by 
filtration, not being expressed in exosomes (Fig. 3.11). 
In further experiments, pools obtained from the sucrose gradients of vesicles 
that had not been filtered or that had been filtered were run on 10% resolving 
gels. However, the exceedingly low protein concentrations (below ng level) 
meant that bands were not visible with Coomassie Blue staining (Fig. 3.12a) 
and therefore silver staining was employed (Fig. 3.12b). The latter revealed 
many protein bands, notably some proteins that were expressed in SGP but 
not in other samples, such as a protein band of ~60 kDa (asterisked). This 
protein appeared to be also lost in the FSGP sample. By contrast, a 100 kDa 
band (marked with the symbol °) was strongly expressed in SGP and FSGP 
but is weakly expressed in all other samples.  
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Fig. 3.12. Sucrose gradient samples of MVs and exosomes analysed by 
SDS-PAGE and Coomassie blue and silver staining. Coomassie blue (a) 
and silver staining (b) of 10% reducing gel with sucrose gradient samples (3 
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μg per lane). Samples were separated electrophoretically at 100V for 3h and 
then stained in Coomassie Brilliant Blue R250. 
3.6 Agarose gel electrophoresis of isolated microvesicles and 
exosomes 
The final means of analysis of isolated MVs and exosomes employed was 
to look at nucleic acids in the samples obtained. Therefore SGP, differentially 
centrifuged MVs and exosomes were analysed by agarose gel 
electrophoresis and ethidium bromide staining and all three indicated the 
presence of nucleic acids after exposure to UV. Where there was little or no 
electrophoresis of nucleic acid out of the well (in a 0.8% gel) it was assumed 
that such bands represented genomic DNA (gDNA). The sample of 
differentially centrifuged MVs showed two more bands, larger than 10 kb, 
which were absent from the exosome or SGP samples, suggesting the 
presence of contaminating DNA fragments being co-purified in the pellet 
after high speed ultracentrifugation to isolate MVs (Fig. 3.13A). Of interest, 
when MVs were lysed and only the intravesicular contents separated by 
agarose electrophoresis (Fig. 3.13B) there were no such similar bands of 
presumed gDNA visible (D. Stratton, personal communication). Firstly, of 
note, the MVs collected in the sucrose gradient pellet (SGP) are clearly 
devoid of contaminating gDNA present in the differentially centrifuged pellet. 
This suggests that centrifugation through the sucrose medium has removed 
gDNA from the MVs. As the MVs collected in 3.31A were collected by 
centrifugation at 25, 000 g for 60 min, which had been the centrifugation 
routinely used at the start of this project, the constitutively released MVs in 
Fig. 3.13B were centrifuged at 11,000 g. Once more this highlights the 
problem of co-isolation of associated macromolecules (such as gDNA) or 
possibly of various soluble proteins by higher speed centrifugation. 
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     A 
B 
Fig. 3.13 Nucleic acids in samples of Exosomes and Microvesicles 
(sucrose gradient pellet and differentially centrifuged microvesicles 
and exosomes). (A) Unlysed samples of MVs isolated by sucrose gradient 
(SGP) and differential centrifugation together with unlysed exosomes were 
run on a 0.8 % agarose gel, stained with ethidium bromide (1 µg/ml for 1 
minute) and viewed on a UV transilluminator.  (B) Constitutively released 
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MVs (cMVs) and exosomes were gently lysed with RIPA buffer and similarly 
electrophoresed on a 0.8% agarose gel (from D. Stratton, PhD thesis, 2013). 
3.7 Comparison of residual surface cytokine, TGF-β1, by ELISA, on 
microvesicles isolated by differential centrifugation and filtration  
Another important analysis of EMVs that needed to be made was that of the 
cytokine TGF-β1. This is of particular interest as it is a cytokine that is carried 
on the surface of MVs (Ansa-Addo et al., 2010), and that can be removed 
from parent cells upon vesiculation. (Ansa-Addo, et al., 2010). It is also 
known to be present as an inactive protein within a latent complex that is 
released upon activation by low pH or by the action of plasmin or even 
interaction with integrin proteins (Khalil, 1999; Klingberg et al., 2014).  
A TGF-β1 ELISA was therefore used to estimate TGF-β1 in filter purified 
MVs versus those isolated by differential centrifugation. On the basis of the 
nature of the method it might have been expected that the shear forces 
involved in differential centrifugation as opposed to filtration might result in a 
comparatively greater loss of surface TGF-β1 from the centrifuged MV 
sample. To make the comparison possible, equal protein concentrations of 
both samples were estimated using a BCA protein assay kit. As shown in 
Figure 3.14, the concentration of TGF-β1 in samples of MVs recovered by 
filtration was just over 100 pg/ml while unexpectedly being two-and-a half-
fold higher at 250 pg/ml for the sample of MVs obtained by differential 
centrifugation (Fig. 3.14). Perhaps it is in fact the MVs recovered by filtration 
that does not have any cellular-derived TGF-β1 associated because of the 
nature of the purification method, and the level of TGF-β1 detected 
represents that which is truly on the MVs. Indeed, the higher levels of TGF-
β1 on the ultracentrifuged samples might simply be due to cellular levels of 
TGF-β1 being co-purified. 
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Fig. 3.14. Higher levels of the surface cytokine TGF-β1 are recovered 
by differential centrifugation than by filtration. TGF-β1 level as tested by 
Quantikine human TGF-β1 ELISA kit (R&D Systems) for MVs recovered by 
filtration and those recovered by differential centrifugation.  
 
  
f i
l t
e
r e
d
 M
V
s
c
e
n
t r
i f
u
g
e
d
 M
V
s
0
1 0 0
2 0 0
3 0 0
[
T
G
F
-

1
]
 (
p
g
/m
l)
f i l t e r e d  M V s
c e n t r i f u g e d  M V s
93 
 
In effect the differentially centrifuged MVs appear to give a strongly false 
positive reading for surface TGF-β1 which is likely due to biding or 
association of cellular TGF-β1 that is getting incorporated into the pellet of 
vesicles after high speed centrifugation. Current studies at CMIRC are 
looking at the expression of TGF-β1 in MVs, their specific location and 
importantly their means of activation and release as an active 25 kDa 
homodimer able to interact with the cognate receptor on recipient cells. 
 
3.8 Cytokine array of MVs and exosomes obtained by filtration and 
differential centrifugation 
The MVs with exosomes sample was used as a reference to determine the 
presence or absence of particular cytokines in MVs purified by filtration in 
comparison with the exosome sample. In summary, all the cytokines found 
in the MVs + exosomes sample were present in the MVs only sample, but a 
few particular ones were absent in the exosome samples (Figure 3.15 and 
Table 3.1A). Sixteen cytokines were found in the samples and these are 
shown in bold in Table 3.1B. Table 3.1A gives a comparison of ten of these 
cytokines, which were present in the MVs + exosome sample and in the MVs 
sample; interestingly half of these were not or were only weakly expressed 
on exosomes.  As a result of this study it is possible to propose candidate 
proteins that would warrant further investigation as possible markers of MVs 
(as opposed to exosomes). The paucity of MV markers and plethora of 
exosomal marker proteins means the results of such cytokine arrays provide 
important clues to possible future markers. As a point of interest, it may seem 
strange that C5a would be detected, as this very small anaphylatoxic peptide 
is released as a result of the C5 convertase enzyme complex cleaving 
complement C5 and this would only occur upon complement activation 
which actually was the way the MVs were prepared, the releasing cells 
having been stimulated with sublytic complement in the form of the normal 
human serum used to stimulate them. This has been shown to indeed be 
due to complement lysis as MVs are not produced if the NHS is depleted of 
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complement C9 or when it is heat inactivated. Exosome release does not 
need the stimulation of cells and no complement C5 was detected with 
exosomes, suggesting that its presence (on MVs) is less likely to be due to 
a co-isolation by centrifugation.  Although C5a would not form part of the 
membrane attack complex (C5b-9), one of the first functions of MV release 
from cells was proposed by complementologists, many years ago, namely 
to remove deposited, potentially lytic MAC complexes from the plasma 
membrane of cells (Morgan et al., 1985, 1986, 1987).   
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Fig. 3.15. Cytokine array showing the expression of 36 growth factors 
cytokines and acute phase proteins in samples of MV and exosomes. 
Samples were lysed with Triton X-100 and placed on the cytokine 
microarrays. Membranes were processed as described by the 
manufacturers, essentially by exposing the membranes with lysed MVs and 
exosomes to the detection antibodies, chemiluminescent signals being 
developed by exposure to the substrate luminol. Microarrays were then and 
developed by 10 mins exposure to X-ray film. Controls are the two duplicate 
dots of high intensity in row 1 and the one duplicate dot in row 10. 
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MVs+Exosomes MVs Exosomes 
C5a + - 
IL-1α + - 
IL-32α + + 
RANTES + - 
IL-12 p70 + + 
G-CSF + - 
IL-1ra + + 
IL-13 + + 
IL-6 + + 
MIF + + 
CCL-1 + - 
IL-17E + - 
(A) 
NO A B C D E 
1 Control - - - Control 
2 C5a IL-1 α IL-10 IL-32 α RANTES 
3 CD154 IL-1 β IL-12 p70 P-10 SDF-1 
4 G-CSF IL-1 ra IL-13 I-TAC TNF-α 
5 GM-CSF IL-2 IL-6 MCP-1 sTREM-1 
6 GRO-α IL-4 IL-17 MIF - 
7 I-309 IL-5 IL-17E MIP-1α - 
8 sICAM-1 IL-6 IL-23 MIP-1β - 
9 IFNγ IL-8 IL-27 Serpin E1 - 
10  - - - Control 
(B) 
Table 3.1. (A) A comparison of the presence or absence of the cytokines 
detected on MVs and exosomes. (B) Cytokines found present at the 
respective coordinates on the cytokine microarray are shown in bold. The 
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remaining cytokines that were potentially detectable but not found in either 
exosomes or MVs are in non-bold.  
3.9 Purified exosomes are less able to block phagocytosis of apoptotic 
bodies than are microvesicles 
Macrophages were obtained from 48 h after adding 1 µM PMA to THP-1 
monocytes as shown by increased CD11b expression (Fig. 3.16A-C). These 
differentiated cells also had enhanced expression of CD14 (not shown). The 
resulting macrophages had the capacity to carry out phagocytosis as shown 
in Fig. 3.16D-F in which apoptotic bodies (stained in red with 
octadecylrhodamine [R18]), the nucleus being stained blue with DAPI (Fig. 
3.16E) that had been opsonised with complement (heat-inactivated Normal 
Human Serum, NHS).   MVs labelled with FITC seemed to have been 
phagocytosed by macrophages along with the R18 labelled apoptotic bodies 
(ABs). (Yellow = Green + Red, White = Red + Green + Blue) (Fig. 3.16F). 
As shown in Figure 3.17, where phagocytosis was assessed quantitatively 
by flow cytometry, it was seen that if macrophages were given an excess of 
MVs, that this competed with the uptake of apoptotic bodies, and that 
although exosomes could also diminish phagocytosis, it was not as effective 
as the reduction achieved with MVs. 
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Fig. 3.16. PMA-differentiated macrophage phagocytosis of apoptotic 
bodies is reduced more effectively by microvesicles than exosomes. 
Fluorescence microscopy was obtained as follows: In (A) macrophages are 
labelled with anti-CD14-FITC antibody and stained with DAPI. In (B) 
macrophages were incubated for 1 h with R18-labelled apoptotic bodies 
(from Jurkat cells) and then stained with DAPI. In (C) macrophages were 
incubated for 1 h with R18-labelled Jurkat apoptotic bodies (FITC labelled) 
and then stained with DAPI. In panels (D-F) FITC is green, DAPI blue and 
R18 red. Yellow fluorescence is produced when red and green fluorescence 
combines while white fluorescence indicating all three fluorescence colours 
merging. All images were taken at 40X magnification. 
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Fig. 3.17. Fluorescence intensity of uptake into macrophages by 
phagocytosis of R18-labelled apoptotic bodies (ABs) in the presence 
of unlabelled MVs or exosomes. Uptake was negligible at 4°C and was 
reduced significantly by blocking anti-phosphatidylserine receptors (anti-
PSR) on the macrophages. The reduction of phagocytosis of ABs by 
providing competing MVs was however reversed when competing MVs had 
their exposed PS blocked with AnV. The error bars represent standard error 
of the mean, S.E.M. from 3 experiments in triplicate.  
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3.10 Discussion 
Protocols to isolate and analyse exosomes and microvesicles are continually 
being re-evaluated. This has especially been the case and indeed one of the 
objectives of the International Society for Extracellular Vesicles since it was 
founded in 2012. The first meeting of ISEV was held in April of that year in 
Gothenburg and it was very apparent that researchers in the field of 
exosomes and microvesicles were very often using quite different 
procedures, as was communicated to me by Professor Inal, who chaired a 
session on ‘Isolation and analysis of microvesicles.’ as highlighted in our own 
meeting, ‘Microvesiculation and Disease,’ hosted at London Metropolitan 
University 5 months later (Inal et al., 2013). The current standard procedures 
are recommended in an article in the Journal of Extracellular Vesicles 
(Witwer, et al., 2013) and include differential centrifugation for the isolation 
of microvesicles with the additional sucrose gradient for exosomes.  
The work presented herein began by comparing the exposition of PS on MVs 
isolated by differential centrifugation with that of MVs isolated by a novel 
filtration protocol developed at the start of this thesis. This turned out not to 
be that different (49% PS exposition, as AnV+ vesicles for those isolated by 
filtration versus 42% for MVs isolated by differential centrifugation) and this 
work also confirmed the use of PS as a marker of MVs (85% AnV+) versus 
exosomes (at only 15% AnV+). As there are a plethora of markers used to 
identify exosomes, it was also important to confirm MV markers and to this 
aim it was shown that exosomes are positive for LAMP-1 (41%) and LAMP-
3/CD63 (48%) but that MVs were comparatively negative for both markers. 
Presence of αM integrin (CD11b) was confirmed as a useful marker for MVs 
with 51% positivity versus only 13% for exosomes. That filtration or ‘reverse 
filtration’ the term used to more accurately describe the method developed 
resulted in an enrichment of exosomes, was shown by the increase in CD63 
expression from 5% before filtration to 55% after filtration.   An interesting 
finding which has not been reported hitherto was the flotation of MVs in a 
sucrose gradient and the apparent concentration within a comparatively 
wider range of fractions ranging in density from 1.12 to 1.16 g/ml, with the 
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exosomes concentrating within a tighter range of 1.04 to 1.05 g/ml. This may 
reflect the greater heterogeneity of size of MVs as reported earlier (Stratton 
et al., 2015) in the nanosight profile of average microvesicular size, but of 
more relevance still due to the variation of protein content, and therefore the 
density of MVs (Stratton et al., 2015). As a final comparison of MVs isolated 
by differential centrifugation versus those isolated by filtration, the level of a 
cytokine that is found on the surface of the MV, TGF-β1 (Ansa-Addo et al., 
2010) was compared. As this cytokine is released as a 25 kDa homo-dimer 
tethered to the extracellular matrix in a latent complex (LAP) it was deemed 
a sensitive marker for the harshness of the two isolation procedures. 
Although the level of TGF-β1 was greater on the MVs isolated by differential 
centrifugation compared to those isolated by filtration, the difference was 
marginal and non-significant. The comparison of vesicles should instead 
have been performed on exosomes where to centrifuge these much smaller 
(100 nm in diameter) vesicles, much higher centrifugal forces (100,000 g) 
are required as opposed to 11,000 to 15,000 to be able to pellet the larger 
MVs (100 to 1000 nm in diameter). When MVs isolated by differential 
centrifugation were run on an agarose gel and stained with ethidium bromide 
it was apparent that there was contaminating genomic DNA, which would 
favour a further step of sucrose density gradient centrifugation in order to 
‘clean up’ the samples of contaminating macromolecules such as DNA. This 
would be of paramount importance if MVs are to be used as therapeutic or 
drug delivery vehicles. 
In comparing MVs and exosomes, isolated by both procedures it is still very 
important to make any comparative studies of physiological parameters of 
these vesicle types as such comparisons are very few; for example, whereas 
there are now numerous studies highlighting proteomic analysis of MVs or 
exosomes there are barely any such comparative studies. The cytokine 
array analysis of MVs and exosomes isolated revealed potential markers at 
least for monocyte MVs that warrant further investigation, including 
RANTES, G-CSF, CCL-1 and IL-17E. 
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Finally, exosomes were compared with MVs for their capacity to block the 
phagocytosis of apoptotic bodies (ABs). It was assumed that the exosomes 
having lower levels of exposed phosphatidylserine, that they would be less 
able to inhibit the process compared to MVs. This was following on from 
previous studies that had shown MVs to inhibit the ability of macrophages to 
phagocytosis apoptotic cells (Antwi-Baffour, 2010). The hypothesis was 
confirmed and it was indeed found that exosomes were less able than MVs 
to inhibit the phagocytosis of ABs. This sort of information should be borne 
in mind especially when considering vesicle-mediated delivery of drugs with 
respect to the type of target cell, and for example whether it expressed PS 
receptors. Using cMVs (constitutively released MVs) and sMVs (formed after 
stimulating cells) which both express different levels of phosphatidylserine 
(PS) it would also be interesting to compare their relative ability to inhibit the 
macrophage induced phagocytosis of ABs. 
 
 
 
 
 
 
 
 
  
103 
 
 
 
4. Development of improved reverse filtration 
methodology for clinical isolation of MVs, and 
its use in making physiological measurements 
of plasma MV levels in the population 
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4.1 Introduction 
In the previous chapter a sucrose density gradient which is used in the 
procedure to isolate exosomes was used to see if MVs could also be 
isolated. One potential advantage of running MVs through a sucrose 
gradient is that the viscosity of the sucrose can itself provide a degree of 
‘washing’ of the vesicles and to remove any macromolecules that can 
potentially be co-purified during high speed centrifugation. One important 
physical factor that must be considered by any procedure that involves 
centrifugation is that of the potential for shear forces to physically break apart 
the MVs. To this end, another procedure, with the potential to separate out 
vesicle populations according to size, that could be considered, is that of 
filtration. Using a filter with a pore size of 0.1 µm, which based on current 
knowledge is the closest to a size at which MVs and exosomes can be 
separated, it would be hoped that MVs would be retained on the filter and 
exosomes pass through into the filtrate. These new methodologies, adapted 
for a clinical laboratory, could then be used to enumerate plasma MV levels 
within a population and to try to relate their levels to various parameters such 
as age, gender, fasting status, etc.   
The standard and most often used protocol for the isolation of MVs involves 
differential centrifugation. Such protocols typically result in much 
contamination of MV pellets with exosomes mainly because the lower size 
limit of vesicles that can be pelleted at a particular centrifugation force covers 
a range of vesicle sizes. Furthermore, there is the problem that many of the 
smaller vesicles, typically exosomes are able to form clumps and therefore 
be centrifuged at the same force as some of their larger vesicle counterparts, 
MVs. 
Once a novel method for isolation of plasma MVs is developed, the aim will 
be to make measurements of plasma MV levels in the population and to 
make preliminary assessments of any influences of gender, age, fasting and 
smoking status on these MV levels.  
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4.2 Materials           
0.2 µm Polysciences Polybead Microspheres 
Annexin V- PE 
Annexin V- Binding Buffer 10x Concentrate 
Biocleanse Biocidal cleaner 
BD FacsCalibur Flow Cytometer Analyser 
BD Plastipak 2.5 ml Syringe 
BD TruCOUNT  Tubes 
Calcium Ionophore A23187 
DiMethyl SulfOxide (DMSO) 
Dulbacco’s Phosphate Buffered Saline (DPBS) 
Hanks' Balanced Salt Solutions (HBSS) 
Horiba ABX Diagnostics P120 Haematology Analyser 
Millipore 0.1 µm Hydrophillic Durapore membranes 
Swinnex 13mm filter holders 
Wooden Applicator sticks 
 
4.3 Methods          
4.3.1 Analysis of MVs by flow cytometry and enumeration of MVs using 
Trucount beads  
MV measurement was carried on filtered citrate plasma. Annexin V-PE was 
used to detect phosphatidylserine (PS) on the surface of MVs, AnV-PE 
positive vesicles being quantified in the FL-2 channel. The absolute count of 
MVs was calculated on the analysis template using the Trucount tube lot 
number information and expressed in number of MVs/ml.   
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4.3.2 Specimen Requirements 
Samples were collected in 1.8 mL vacutainer tubes containing 100 μL of 1M 
Sodium Citrate 1mL blood (0.109M, final concentration). Venous blood (1.8 mL) 
blood was drawn slowly and gently into a syringe, and immediately transferred to 
the tube. The use of a vacutainer was avoided to ensure that the cells would not 
become activated, resulting in increased microvesiculation and giving falsely 
elevated results. Ethical approval for this work was obtained from Hammersmith 
Medicines Research and from the ethics committee of the Dept. of Health and 
Human Sciences at London Metropolitan University. 
 
Samples were processed within 1 hr of drawing the blood and analysed 
within a time frame of 3h. Samples that had been centrifuged and from which 
MVs isolated were on occasion frozen at -20°C, until further analysis. 
Samples were however never repeatedly freeze/ thawed. 
4.3.3 Isolation of MVs and exosomes by filtration using a filter of pore 
size 0.1 µm 
4.3.3.1 Preparation of samples 
Within 1 hour of being collected, samples were labelled with a lab reference 
number (LRN) and centrifuged at 160 g for 5 min followed by two 
centrifugations for 30 min at 4,000 g. All the aliquots and transfer tubes for 
the same sample were labelled with the same LRN. This enabled correct 
tracking, storage and retrieval of samples when required. 
 
The plasma samples (0.5 ml) were collected in a labelled microfuge tube for 
reproducibility and to enable a comparison of sample stability. Samples were 
then stored immediately at -20ºC.  
The remaining 0.5 ml of plasma was then filtered using a Swinnex 13 mm 
filter holder with a 0.1 µm sized Millipore Hydrophillic Durapore filter placed 
inside. The O-ring was positioned on top of the filter. Each sample was 
passed through a filter holder using a disposable 2.5 ml BD Plastipak syringe 
inserted at the female inlet. The filtrate containing exosomes was used for 
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further analysis if needed.  The MVs (of average diameter 0.1-2 µm) were 
thus deposited on the filter membrane. 
The filter membrane was then carefully removed using a new set of 
disposable wood applicator sticks for each sample, discarding sticks after 
use.  The filter was placed in 3 ml PBS in a 15 mL conical tube (this volume 
having been kept consistent across all samples). Sonication of the conical 
tubes for 15 min at RT, was followed by 5 min of very gentle vortexing to 
remove all MVs from the filter membrane. During vortexing the tube 
containing the membrane was placed at an angle to enable the vibrating 
liquid to help remove MVs from the membrane. The filter membrane was the 
removed & discarded from the conical tube using new applicator sticks for 
each sample. All used filter holders were soaked in Biocleanse Biocidal 
cleaner for 15 mins followed by sonication for a further 15 mins to 
decontaminate and rinsing five times with distilled water. After air drying over 
an absorbent paper towel in a cupboard to prevent dust collecting they were 
ready to be re-used. 
4.3.3.2 Preparation of controls 
Within 1 h of being taken, samples were stimulated with 1 mM Calcium 
Ionophore A23187 (mixed Ca2+, Mg2+ salt). The resulting early apoptosis and 
cell activation resulting from the stimulation of plasma cells with Calcium 
Ionophore A23187, was deemed cause an increase of intracellular calcium 
resulting in a subsequent increase in the general number of MVs. 
 
To prepare the Calcium Ionophore A23187 reagent, 10µl 50mM Calcium 
Ionophore concentrate was added to 250µl HBSS and 240 µl DMSO. This 
was used within one hour of preparation and kept protected from light. To 
stimulate the plasma cells, 36 µl of the prepared Calcium Ionophore A23187 
reagent was added to each 1.8 ml citrate tube to give a final concentration 
of 20 µM. The citrate tubes were incubated in a 37ºC incubator for 1 hour 
and filtered as for samples using 1 ml plasma. 
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4.3.4 Staining Method 
4.3.4.1 Staining samples with AnV-PE 
The PBS supernatant was discarded carefully such as to ensure that the 
pellet of MVs was not disrupted. The pellet was then resuspended in 100 µl 
AnV Binding Buffer (AnVBB) mixing thoroughly with a Gilson pipette. In this 
way the original 0.5 ml of plasma sample was concentrated 5-fold. The re-
suspended MV pellet (100 µl) was then transferred from the conical tube to 
a Trucount tube where it was stained with 5 µl Annexin V-PE (annexin V 
conjugated to phycoerythrin, PE). The reaction mixture was incubated for 15 
min at RT in the dark and 395 µL of 1x AnVBB (prepared in situ from 10x 
Binding Buffer concentrate) added to each tube. The results were analysed 
by flow cytometry within 1 hour. 
4.3.4.2 Preparation of controls for flow cytometry 
Once the PBS supernatant had been carefully discarded, the MV pellet was 
re-suspended in 200 µl PBS (5x concentrate). Aliquots (100 µl each) were 
frozen in a BD Falcon tube. The aliquots were then ready for use as positive 
and negative controls. These controls (as described in the table below) were 
stained on the day of use and run within 1 hour.  
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Table 4.1. Annexin V PE staining method for controls: 
 
 
4.3.5 Calibration/Quality Control 
A 3-colour calibration was performed daily, using BD CaliBRITE 3 beads 
(SLE017).  The calibration reports of the ‘lyse-wash’ and the ‘lyse-no wash’ 
assays were printed out, signed and dated and filed in the FACSCalibur 
Calibration data file. 
Polystyrene beads (0.2 µm) were run as a size control before each batch of 
samples (displayed in the histogram). 
 
4.3.6 Sample Acquisition and analysis using the BD FACSCalibur flow 
cytometer (running samples manually) 
Having opened the appropriate acquisition template in Facsdrive1/ 
Acquisition Templates folder, the Acquire menu was selected, followed by 
‘Connect to cytometer,’ whereupon the Browser window would open 
automatically. It could also be opened from the windows menu by selecting 
Show Browser. The appropriate instrument settings were then opened by 
selecting Instrument Settings and Open from the Cytometer menu and 
Reaction Negative Control Positive Control / 
Patient Samples 
MVs re-suspended in PBS 100µl 100µl 
AnV- PE stain ----- 5µl 
AnV 
Binding 
Buffer 
Pre-
incubation 100µl 100µl 
 Post-
incubation 
300 µl 295 µl 
Total reaction volume    500µl 500µl 
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selecting FACStation G4/1.25/WT, BD Files, Instrument Setting Files, and 
the relevant settings, MV settings.  Once the settings had been chosen it 
was necessary to click the Set icon, then Done. 
 
It was also necessary to choose the correct location for saving the data to 
be acquired in the Browser window, by clicking on Change next to Directory. 
The appropriate folder e.g. Facsdrive1/HMR code/Date/Time point/Patient 
file was then selected. Sometimes it was necessary to create the above files. 
 
Throughout Sample ID was the laboratory reference number (LRN); Patient 
ID, was any or all of the following: patient initials and D.O.B & Randomisation 
Number. 
 
To check the speed of acquisition, Counters from the Acquire menu was 
selected, to open the counters window. The following shortcuts were used: 
Apple 1,2, 3 and 4 to open Detectors/Amps; Threshold; Compensation and 
Status windows.  These could also be accessed from the Cytometer menu. 
 
Fluidics was pressurised by flicking the black knob between the sheath and 
waste reservoirs from ‘vent’ to ‘pressurise’ whilst ensuring the cytometer to 
be set on LOW for MV detection, and RUN.  The sample was first gently 
mixed and then placed in the sample injection port (SIP).  With the Set-up 
ticked Acquire was selected. The operator then had to acquire until sufficient 
events had accumulated to be able to judge the gates. Adjustments were 
made if necessary and then pause and abort clicked. 
 
With the Set-up unticked, Acquire was selected. The cytometer then 
acquired the pre-set number of events and the data was automatically saved 
(10,000 in this investigation).  This was continued until all tubes had been 
analysed. The details of the next subject were then entered in the Browser, 
the location to which they were to be saved selected and then the samples 
run. 
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Once the run was complete, the SIP (SLE016) was cleaned.  To optimise 
the uptake of FACSClean and FACSRinse, the cytometer had to be set on 
HI.  When the clean was finished, 1 mL distilled water was aspirated, and 
RUN selected (on HI) for another 5 min. 
 
4.3.6.1 Analysis of flow cytometric data 
The data was analysed after the acquisition was complete, to ensure that 
the correct populations for obtaining the mean count of MVs had been 
selected and gated. For this the appropriate analysis template was opened 
from the Facsdrive1/ Analysis Templates folder. The light scatter and FL-1 
was set at logarithmic gains, and 10,000 total events were collected during 
each sample analysis. These events were processed by an Apple computer 
in conjunction with the Cellquest Pro Software (BD Biosciences UK). After 
identifying MVs, their absolute counts were calculated automatically on the 
analysis spreadsheet after inputting the following formula provided by BD 
Biosciences UK: 
#   of  events  in  region  containing  MVs X  #   of    beads   per   test * 
# of events in absolute count bead regionTest volume (mL) 
= MV ABSOLUTE TOTAL COUNT 
 
* this value is found on the TruCount Absolute Count Tube foil pouch label, 
and will vary from lot to lot. 
 
Each data file was printed and analysed. To print, Apple and P were pressed 
simultaneously. 
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4.3.7 Statistical analyses        
The precision of the methodology was determined by calculating percentage 
coefficient variance (% CV). Boxplots were used to indicate MV absolute 
count spread amongst the human population, and the various variables (age, 
gender, fasting status, etc.) looked at. Regression Analysis for the Age 
variable, and t-Tests were performed to test the significance of the 
differences in the produced number of MVs using SPSS Version 17 .0. 
Statistical significance was considered when p-values were less than 0.05. 
4.4 Results 
4.4.1 Development of a new method for MV isolation based on filtration 
In terms of developing novel methods for MV isolation it is necessary to 
remember the other vesicle type that cells release, namely the exosome. 
Figure 4.1 presents a reminder of the two vesicle types being considered 
here. The exosomes have an endocytic origin, being formed by the 
intraluminar budding of a multivesicular body and being released on the 
fusion of the MVB with the plasma membrane; their size is typically 50 – 100 
nm and they expose much lower levels of phosphatidylserine (PS) than MVs. 
The larger MVs (100 – 1000 nm) are released directly from the plasma 
membrane, this process being initiated by an increase of intracellular 
calcium.  
One goal of the filtration protocol, as opposed to any differential 
centrifugation protocol, and as summarised in Fig. 4.2 was to yield a 
population of MVs with as little contamination with exosomes as possible. 
The protocol designed was to be used to isolate MVs and exosomes from 
venous blood. For this purpose, 1.8 ml was collected in a vacutube 
containing 109 mM Na citrate. After centrifugation (2,200 g; 15 min) 0.5 ml 
of plasma was then subjected to a light sonication (five one-minute pulses) 
in a sonicating water bath. The reason for adopting this approach was that it 
has been previously reported that exosomes may form clumps (Heijnen et 
al., 1999; Zakharova et al., 2007) and therefore would be likely to co-purify 
with MVs. The resulting EMVs comprising MVs and exosomes were filtered 
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through a Millipore filter of pore size 0.1 µm. It was then possible to recover 
exosomes from the filtrate, exosomes averaging at 50 – 100 nm in diameter, 
whilst MVs were recovered from the filter itself by 5 x 1 min sonication’s in a 
sonicating water bath followed by gentle vortexing for 1 min. Finally, the MVs 
were collected by centrifugation at 25,000 g for 30 min. As demonstrated by 
Stratton, D (personal communication) and shown in the appendices (Fig. 
A1), MVs could also be isolated with much reduced centrifugation speeds 
(e.g. 10,000 g, 1 h).  
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Fig. 4.1 Microvesicle (MV or MV) and exosome biogenesis from a 
typical eukaryotic cell. As a result of endocytosis, early endosomes and 
formed which may either recycle to the surface or form MultiVesicular Bodies 
(MVBs) by intraluminal budding to form IntraLuminal Vesicles (ILVs) (A). The 
ILVs are released as exosomes as the MVB fuses with the plasma 
membrane (B). Microvesicles (MVs), sometimes called Plasma Membrane-
derived Vesicles (MVs) or even ecosomes are released (D) directly by 
budding form the plasma membrane upon activation resulting in increases 
of cytosolic calcium concentrations, or in early apoptosis, resulting in loss of 
membrane asymmetry, cleavage of the actin cytoskeleton by calpain. The 
MVs lie in the range 100 – 1000 nm in diameter whilst exosomes range from 
50 – 100 nm. Exosomes carry tetraspanin proteins such as CD63 and 
expose less phosphatidylserine (PS) than MVs.  
 
MVs
early 
endosome
exosomes
multivesicular
body
A
B
C
D
actin 
calpain 
phosphatidylserine 
tetraspanin, eg. CD63 
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Fig. 4.2 Summary of newly developed filtration-based protocols (A) and 
of existing, modified differential centrifugation-based methods for 
MV/exosome isolation. (A) After collection of venous blood in a vacutube, 
and low speed centrifugation, plasma (0.5 ml) is gently sonicated (5 x 1 min 
pulses) in a sonicating water bath and then passed through a 0.1 µm pores 
size millipore filter. MVs are recovered from the filter by sonicating as before, 
gentle vortexing and finally centrifugation (25,000 g/60 min) MVs so obtained 
were analysed by annexin V binding using a Facs Calibur™flow cytometer 
and counted using TruCount beads. In (B) a differential centrifugation 
protocol is outlined that can be used to separate MVs and exosomes. Firstly, 
samples are centrifuged (160 g for 5 min and then twice at 4,000 g for 30 
min). This removes all cell debris and the supernatant is then gently 
sonicated in a sonicating water bath (5 pulses for 1 min each) to disrupt 
exosomes clumps. MVs are collected by centrifugation (25,000g for 1h). 
They are then washed and identified by AnV labelling as PS-positive using 
a flow cytometer. 
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As an added confirmation that the two vesicles subtypes had been isolated, 
the vesicles obtained by filtration (MVs) and the filtrate (exosomes) were 
analysed by electron microscopy (Figure 4.3) to ascertain a size range. They 
were additionally analysed for particular marker proteins by ELISA or flow 
cytometry. The MVs isolated ranged typically from 200 nm to 1200 nm (Fig. 
4.3A) and the exosomes were much less heterogenous in size, most of them 
consistently measuring 100 nm in diameter (Fig. 4.3B). These readings were 
obtained for n=500 vesicles. Size is a particularly useful parameter to 
distinguish the smaller exosomes from MVs. Looking at specific markers it 
was found that TGF-β was expressed at 5-fold greater levels on MVs than 
exosomes (Fig. 4.3C) and that PS was expressed at least at 3-fold greater 
levels also on MVs (Fig. 4D). CD63 which is regarded as a marker for 
exosomes was expressed at 2-fold greater levels than found on MVs (Fig. 
4.3E). The filtration methodology, therefore, seemed to result in a very good 
separation of MVs and exosomes.  
 
4.4.2 Calibration of flow cytometer using calibration beads and use of 
Trucount beads 
Every day that the flow cytometer (FACSCalibur) was used, and before any 
new batch of samples was analysed, 20 µM of calcium ionophore was used 
to stimulate the quality control plasma. Great care was taken not to ‘spike’ 
all samples in the study to ensure that there would be no problems with inter-
individual variations in response to the stimulus.  By maximizing the general 
number of plasma MVs in the QC plasma, this ensured there to be enough 
MVs to gate the flow cytometer and to be able to generate quantifiable 
results.  
 
Furthermore, calibration beads (0.2 µm) were run every day before 
overlaying the donor samples. Both were gated for AnV (G2) and also with 
no gate. The Trucount bead population was also included. To validate that 
the AnV-positive MVs samples being observed at different wavelengths (FL1 
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and FL2) were in fact the same population (p < 0.001), Kolmogorov Smirnov 
statistics was employed and histograms overlaid. As shown in Figure 4.4A, 
where a representative display of unstimulated blood is shown revealing AnV 
positive MVs, of diameter ≥ 200 nm, the MVs are found in the box with a 
hashed line. Using the formula described in the material and methods 
section of this chapter, (considering the Trucount bead count to be 50595.00 
[Lot no. 2731]), Fig. 4.4B, the calculation of the absolute MV count revealed 
a number of 168473.86 /ml. 
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Fig. 4.3 Electron microscopy of MVs and exosomes isolated by 
filtration to show average diameter in nm and detection of specific 
markers as a means of delineating the main two different vesicle types 
(ranging up to 1200 nm). Ms (A) and exosomes (B) were collected from the 
filter (A) and from the filtrate and prepared by negative staining for electron 
microscopy. MVs ranged from 100 nm to 1200 nm in diameter, whilst 
exosomes ranged from 50 to 100 nm. By ELISA (C), TGF-β1 was more 
highly expressed on MVs (as determined after lysis with 1% (v/v) Triton X-
100, and there was a greater exposition of PS, as determined by AnV-FITC 
binding using the Guava EasyCyte flow cytometer (D). However, as 
expected there was more of the tetraspanin, CD63, expressed on exosomes 
than MVs (E). 
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Fig. 4.4 Flow cytometric analysis of MVs isolated by filtration using a 
Facs CaliburTM flow cytometer. MVs isolated from unstimulated peripheral 
blood using the newly developed filtration method were analysed using a 
Facs Calibur™ flow cytometer. Trucount beads were used and those MVs 
with a diameter of greater than 200 nm that had also stained positive for 
Annexin V-PE, are indicated within the dashed box on the dot plot (A). These 
were counted and an absolute MV count determined (B) using the formula, 
those MVs of diameter greater than 0.2 μm and staining positive for annexin 
V-PE binding, shown in the dashed box on the scatter plot (A) were 
enumerated and an absolute MV count calculated (B) using the formula 
indicated in B and in Materials and Methods. 
Absolute MV count (before activation) = 1913/1149 x 50595/0.5 
= 168474 MVs/ml
A
No. of events in region containing MVs X    No. of beads per test *  = MV count
No. of events in absolute count bead region      Test volume (mL)
B
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4.4.3 Use of the newly developed MV and exosome isolation protocol 
to assess plasma EMV levels within the population. 
Having developed the filtration method for isolation of MVs and exosomes, 
this protocol was used to ascertain plasma MV levels firstly to simply 
establish a normal baseline reference range within a sample of the healthy 
human population. For this a total of 57 subjects was used, both male and 
female, and of age ranging from 19 to 71 years.  
4.4.3.1 The effect of freezing and thawing on MVs levels measured 
Unlike much of the recent literature suggesting MV levels measured to be 
increased upon freeze/thaw (Piccin et al., 2007) in this study when MVs 
levels were compared between freshly prepared samples and from those 
that had been frozen (-20°C), no significant difference was noted (p=0.226), 
Fig. 4.5A. Of note, however the samples that had been frozen at -20°C in 
the current study were only thawed once, about 30 minutes prior to analysis. 
These findings suggest that frozen MV samples, frozen and thawed once 
will give as reliable results in terms of MV numbers as freshly obtained MV 
samples. Frozen samples can therefore be used with confidence in any 
routine laboratory analysis. Therefore, in terms of reproducibility MV counts 
can be validated even if not freshly prepared. 
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Fig. 4.5 Freezing has no effect on plasma MV levels and there is no 
different in plasma MV levels between males and females. Plasma MVs 
were counted as described in materials and methods using the Facs Calibur 
flow cytometer. Comparing the same plasma MV samples, freeze/thawing 
had no effect on the measurable MV levels (A) (n=38) and there was a 
negligible difference between males and females (B) (n=26 male; n=31 
female). The results are presented as mean ± Standard Deviation. 
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4.4.3.2 Gender has no effect on plasma MV levels   
To begin to compare mean plasma MV levels between males and females, 
26 males and 31 females were compared (Fig. 4.5B). This data enabled a 
normal baseline reference range to be defined, as shown in the box plot in 
Fig. 4.5B as 0.55 x105  – 1.8 x 105 MVs/ml. For males the reference range 
is slightly smaller, 0.65 x105 – 1.35 x 105 MVs/ml, the lowest quartile starting 
at a slightly higher level with males. It was also noted that females had a 
higher median (1.25 x105 MVs/ml) compared to males (0.95 x 105 MVs/ml). 
As a result, it was possible to state that on the basis of gender there was no 
significant difference in plasma MV levels (p = 0.160). 
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4.4.3.3 Age has no effect on plasma MV levels measured 
We had expected that the older subjects in the sample measured would have 
higher levels of MVs due to an increased general amount of cell death, 
apoptosis and associated MV production, but this was not observed (Fig. 
4.6). The slightly elevated level of plasma MVs in younger subjects observed 
may be attributable to the higher cell turnover or metabolism, in younger 
subjects. By contrast elderly individuals may have reduced cell turnover or 
waste elimination. In either age group elevated plasma MV levels may then 
be indicative of disease.  
 
4.4.3.4 Subjects in a fasting state appear to have higher base plasma 
MV levels than those in a non-fasting state 
In this study, the possibility of obtaining subjects that could be compared in 
terms of plasma MV levels for fasting (which for the purposed of the study 
was defined as having had nothing to eat or drink, except water, for 12 h) 
and non-fasting was limited. In fact, only 4 subjects from the whole cohort 
were analysed both fasting and non-fasting and this was in great part due to 
the inconvenience logistically to the volunteer donors as well as to have to 
incorporate various other variables in the study. Within a large clinical trial, 
however, a much more statistically viable number of donors matching the 
fasting/non-fasting criteria would be met. Even though the population size 
was small (n = 4), using an independent sample t-test (not having assumed 
equal variances), a statistical significance was found, Fig. 4.7. 
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Fig. 4.6. Effect of age on plasma MV levels. MVs isolated from plasma 
were enumerated as described. Comparing the same plasma MV samples, 
although most samples were obtained from donors in the 20–30 age range, 
there was no effect of age on MV levels (n=57).   
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Fig. 4.7. Effect of fasting on plasma MV levels. MVs isolated from 
plasma were enumerated as described. Comparing the same plasma MV 
samples, although only four samples could be compared between the 
same donors after fasting or non-fasting, MVs levels were higher after 
fasting).   
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4.4.3.5 Smokers have reduced levels of plasma MVs 
As shown in Figure 4.8 plasma MV levels were significantly reduced in 
smokers compared to non-smokers. Although cigarette smoking is likely to 
contribute more than one component capable of inhibiting MV release, it was 
considered that nicotine, as calpeptin, which is capable of inhibiting 
apoptosis (Dasgupta et al., 2006) could therefore and therefore be at least 
one of the components of cigarette smoking likely to inhibit 
microvesiculation, as microvesiculation is believed to be one of the effects 
of early apoptosis (Inal et al., 2012).  
In vitro experiments were therefore performed in which increasing 
concentrations of nicotine were employed to see if this would result in 
decreasing levels of early apoptosis in THP-1 leukemic monocytes, as 
measured by annexin V binding, as well as decreasing levels of MV release; 
similar results were expected with calpeptin.  and indeed, found to be the 
case (Fig. 4.9). As for calpeptin, nicotine was found to dose-dependently 
decrease the number of cells in early apoptosis (AnV+, 7AAD-) but not those 
in late apoptosis (AnV+, 7AAD+) and to also cause a decrease of MV release, 
as the cells were treated with increasing concentrations of nicotine, up to 
~50 µM. 
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Fig. 4.8. Smokers have significantly reduced levels of plasma MVs 
compared to non-smokers. MVs isolated from plasma were counted using 
the FacsCalibur flow cytometer as described. Comparing the same plasma 
MV samples, smokers had reduced MV levels. 
 
 
  
n o n - s m o k e r s m o k e r
0
5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
2 0 0 0 0 0
2 5 0 0 0 0
3 0 0 0 0 0
3 5 0 0 0 0
M
V
s
/m
l
*** 
128 
 
 
Fig. 4.9. Nicotine and calpeptin both decrease levels of cells in early 
apoptosis and also decrease microvesiculation levels, measured as 
number of MVs/ml. MVs isolated from plasma were counted as described. 
Increasing doses of nicotine (A) or calpeptin (B), reaching saturation at 50 
μM, dose-dependently decreased annexin V binding, as a marker of early 
apoptosis, as well as the number of MVs released. These latter experiments 
with calpeptin and nicotine were repeated twice in triplicate. 
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4.5 Discussion 
4.5.1 Sample preparation for MV isolation 
Pre-analytical variables are of paramount importance with regard the 
measurement of MVs as has been underlined by researchers in the field 
(Ahmad et al 2005). In the same vein, the documentation of methodology is 
also essential before analysis is begun. In preliminary work in this study, 
plasma MV data was obtained from homogenizing Platelet-Free Plasma 
(PFP), using the ABX PentrP60 Haematology Analyser, which eliminated 
erythrocytes, platelets and leukocytes, and other such sources of cell debris, 
that could interfere with measurements. The result was a comparatively pure 
plasma sample that could be used in flow cytometry analysis, but that 
needed further purification by filtration through a 0.1 µm pore size 
membrane, to remove smaller debris, thus retaining all > 0.1 µm material on 
the membrane filter. To be sure that the sample was not lost, this was 
subsequently subjected to gentle sonication in a sonicating water bath and 
also to gentle vortexing in Dulbecco’s PBS (DPBS) prior to staining with 
Annexin V-PE. 
 
4.5.2 Preparation and analysis of controls for flow cytometric 
enumeration of microvesicles 
MV release was raised by the use of calcium ionophore which stresses cells 
and increases levels of early apoptosis. In this way MV Control Results were 
able to provide an optimal way of determining whether the staining 
procedures were working properly. On every day that samples were run, by 
omitting the stain in the negative control on every day that samples were run 
and comparing this to the number of AnV positive events in the negative 
control (7609) to the positive control (stained) (5161), it was clear that only 
MVs positively stained for were being counted (in the gate set) indicating the 
stain was working prior to batch analysis every day. 
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4.5.3 Flow Cytometry Analysis Templates 
The use of flow cytometry templates allows large amounts of data to be 
overlaid and thus collated for each donor. Calibration bead (0.2 µm) (purple) 
were run every day before overlaying donor samples. Both calibrations 
beads and donor samples were gated for AnV (G2) (green) and with no gate 
(pink). The Trucount bead population is also visible. Flow cytometry analysis 
templates allow a lot of data to be overlaid and collated per patient result. 
0.2 µm calibration beads (purple) were run every day before samples could 
be overlaid with the patient sample, both gated for AnV(G2) (green) and with 
no gate (pink). The Trucount bead population is also visible. The KS stats & 
Overlaid histograms also validate that the AnV+ MV samples being looked 
at on the different wavelengths (FL1 & FL2) are the same population (as p = 
<0.001).   
 
4.5.4 MV Absolute Total Counts 
This study has resulted in the development of a novel filtration-based method 
for the isolation of plasma MVs that are PS-positive (by staining with 
Annexin-V-PE). By taking measurements from healthy donors (n=57) it was 
found that plasm MV levels fell in the range 0.51-2.82 x 105 MV/ml. If the 
number of cells in venous blood is considered as ~5 x 106 cells/ml, the level 
of release can be considered as about 1 MV per 32 blood cells. This is 
comparable but as might be expected lower than the release figures from 
cells in culture where it was found to be about 1 MV per 8 monocytic 
leukaemia cells, which as I found and report in chapter 5 release twice as 
many MVs as their normal peripheral blood monocyte counterparts. As 
discussed below, the filtration method was then used to see the effect of 
various parameters and it was found that neither freeze thawing, gender or 
subject age significantly affected the absolute MV count. Fasting gave a 
wider spread and higher levels however (0.9-1.5 x 105 MVs/ml), in the order 
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of 3-fold higher; this could be considered to be an estimates normal baseline 
fasting reference range.       
 
4.5.5 Smoking Status affects plasma MV levels 
The number of subjects that could be obtained for comparing the effect of 
smoking versus non-smoking on plasma MV levels was limited. This was 
mainly due to the inability to recruit more smokers, hence a randomised 
sample of four non-fasting, non-smoking subjects was compared against 
four non-fasting smokers. It was found that the non-smoker group had a 
wider spread of MVs (especially the 2nd and 3rd quartiles), with a slightly 
increased median in comparison to the smoking group (>10,000). However, 
due to the small population size no inference could be made on statistical 
significance (p =  0.326 (>0.05  Paired t-Test). Experiments were also carried 
out on THP-1 monocytic leukaemia cells and in the same way that calpeptin, 
a known inhibitor of apoptosis, resulted in decreasing levels of early 
apoptosis (AnV+ cells) and decreasing levels of MVs released, nicotine (and 
it should be noted that THP-1 cells are indeed positive for nicotine receptor 
[Morgan et al., 2001]) had the same effect. 
 
4.5.6 Freezing does not affect plasma MV levels  
MVs in the plasma samples that were not frozen were compared to those 
that had been frozen and then thawed (-20ºC group) (n=36). As shown in 
the Boxplots very similar total counts of MVs, with a Median of 119744.8 and 
134937.4, for the Freshly Prepared and Frozen Groups, respectively was 
found, there being no significant differences.  
 
4.5.7 Fasting increases plasma MV levels 
The Boxplot figures shows that the Fasting group had a wider spread 
(especially the 3rd and 4th quartiles), (2.8 x 105 – 5.8 x 105) MVs/mL This 
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can be defined as the normal baseline Fasting reference range, in 
comparison to the Non- Fasting group reference range (0.98 x 105 – 1.5 x 
105) MVs/mL.  
The median was also greatly increased (3.8 x 105) MVs/mL, which is almost 
3-fold in comparison to the non-fasting group (1.1 x 105) MVs/mL. Although 
the population size of this group is small (n=4) there is a statistical 
significance as an independent sample t-test (p value = 0.005 (equal 
variances not assumed) <0.05. However, this was not observed as a paired 
sample t-Test (p value=  0.117 >0.05 as the sample size was too small. 
The transmission of the stain fluorescence to the flow cytometer may also 
be a factor. 
There are various reasons why the absolute MV concentrations appear to 
be raised in subjects that had fasted. This may be due to other compounds 
found in the plasma in the non-fasting state. For example, there may have 
been lipaemic samples (a factor that often interferes with many routine 
laboratory tests). Whether samples were lipaemic was actually not noted, 
but importantly is something that should be considered in future studies. 
Furthermore, any food or other related contaminants could easily increase 
turbidity, thereby inadvertently masking or reducing MVs or even interfering 
with AnV labelling of the MVs, because of increases of the viscosity of 
plasma. A recent study enumerating plasma-derived microvesicles and 
exosomes also showed an increase postprandially in the MV gate delineated 
using MegamixTM beads (160 nm-500 nm in diameter) (Sodar et al., 2016). 
This showed an increase in the number of MV-sized vesicles1.5h, 3h and 6h 
after a meal. It should be noted that the fasting samples measured in this 
thesis were overnight but they also showed elevated levels of plasma MVs 
compared to non-fasting. The work by Sodar et al., showed interestingly that 
some of these increased MV levels up to 4 h postprandially compared to up 
to 30 min postprandially could be accounted for by cyclomicrons which are 
lipoprotein particles made up mainly of triglycerides but also phospholipids, 
cholesterol, and proteins and are responsible for transporting dietary lipids.  
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4.5.8 Age does not affect plasma MV levels   
Scattergraph of Age vs Non-Fasting MVs is fairly randomly scattered, 
suggesting no correlation. ANOVA Statistics for The Correlation Coefficient 
was very low (p = 0.755>0.05 (at 95% Confidence interval) and hence is 
unlikely to be correlated. Age is hence not significant enough to be an 
explanatory variable.  
If any trend there is a slightly negative correlation, such that as Age 
increases MV levels decrease. Regression Analysis Model Summary shows 
the R2 value of 0.005 x 100= 0.5% of MV total count variation is explained 
in this model using age as the independent variable. It is expected that the 
older subjects of this population would have higher levels of MVs due to an 
increased general amount of cell death, hence apoptosis and MV production. 
A healthy life style may result in less disease whereas by contrast elderly 
individuals may have reduced cell turnover waste elimination etc, and these 
same elevated levels may cause concern.  
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4.6 Conclusion 
The data presented in this chapter summarises the development of a novel 
filtration method for the isolation of microvesicles (and potentially of 
exosomes). An important advantage over differential centrifugation is that 
larger volumes can be processed and that therefore this method would serve 
well in the clinic and in a research, lab setting where cell culture supernatants 
could be easily processed. The flow cytometer chosen for this study and for 
which instrument settings and methodology were validated was the BD Facs 
CaliburTM. This instrument and the methodology developed would allow for 
use of this technology as a high throughput test. It has not been possible as 
yet to compare the Facs Calibur with the other main flow cytometer type that 
relies on a different technology whereby fluid is sucked up (e.g. Guava 
EasyCyte 8HT and 12HT) which would be less likely to have a clinical 
setting, being more likely to be used in research laboratories. It would be 
important to be able to compare samples on these two flow cytometers. 
Furthermore, since the MV measurements were made on circulating plasma 
MVs, it would be interesting to also make measurements on MVs isolated 
from lymph. The differentiation of different plasma MVs from their cell of 
origin by using specific markers is also an ongoing improvement being 
investigated at the Cellular and Molecular Immunology Research Centre.   
When plasma MV levels were measured in a small cohort of normal donors 
(n=57) it was found that were levels were compared to age of donors, 
Regression Analysis gave an R2 value of 0.005, in other words that only 
0.5% of variation in total MV count could be explained in this model using 
age as the independent variable. Freezing plasma MV samples seemed to 
have no effect on the number of MVs that can be measured. This of course 
has no bearing on the functional capacity of frozen versus non-frozen MV 
samples, but is important to know where enumeration of MVs is needed. 
Gender also had no bearing on measurable plasma MV levels. 
The finding within this study that plasma MV levels appear increased in the 
fasting state suggest that fasting status should be considered when 
measuring plasma MV levels and that this should be a new standard adopted 
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in MV enumeration, in the same way that other fasting analytes, such as 
glucose, are measured in routine laboratories. 
4.6.1 Fasting and Intermittent Fasting 
The lysosome is an organelle that contains enzymes that digest proteins, lipids 
and carbohydrates. Lysosomes are sometimes found with whole organelles or 
other cellular components within them and the way these components are 
delivered to them is via autophagosomes, organelles that themselves form 
around damaged proteins and damaged organelles. As a result of autophagy 
(Mizushima et al, 1998), cells can quickly obtain energy and acquire building 
blocks for cellular renewal. Autophagy is thus essential as a response to 
cellular starvation and stress. In terms of removal of damaged and therefore 
potentially harmful proteins but also other macromolecules such as RNAs, in 
an attempt to maintain a healthy cell, it is now being shown that, in addition to 
autophagy, exosomes may be involved in the removal of these damaging 
molecules (Baixauli et al, 2014). This work describes how the role of exosomal 
removal of intracellular stress, by removal of damaged and harmful proteins in 
exosomes, may co-ordinate with the autophagy/lysosomal pathway to 
preserve the homeostasis of cellular proteins. 
 A fast is a period (whether intermittent or extended) without eating or drinking 
and may be performed for a range of reasons, including medical, spiritual or 
for weight loss. Certain fasts may allow the taking of fluids such as water, tea 
or coffee but some fasts have no fluids. Fasting is a world-wide practice and 
is found in most religions, including Hinduism, Christianity and Islam. For the 
prevention and as part of treating of certain chronic diseases, clinical trials 
would still need to be carried out to see the health benefits. From current 
observations it is already possible to see that fasting in medically supervised 
cases (up to 500 kcal intake per day) for periods of 1 to 3 weeks, besides 
giving a rest to the digestive system is useful in the treatment of chronic pain, 
metabolic syndrome, hypertension and in rheumatic disease. 
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5. Promonocytic cell-derived MVs and 
exosomes: analysis of fusion with target cells 
and potential use as therapeutic vehicles in 
Chronic Myeloid Leukaemia 
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5.1 Introduction 
5.1.1 Chronic Myeloid Leukaemia (CML) 
Every year about six hundred people are diagnosed with this particular form 
of leukaemia. CML, a myeloproliferative condition which is also known as 
Chronic Granulocytic Leukaemia results from a change at the genetic level 
in a pluripotent stem cell. This change is in fact a translocation of the ABL 
gene from chromosome 9 to 22 containing the BCR gene (Gupta, R., 2003; 
Hehlmann et al., 2007). Figure 5.1 represents the described translocation 
and shows how the chimeric gene BCR-ABL is formed on the Philadelphia 
chromosome (Ph), essentially by fusion of the chromosome 9-derived ABL 
oncogene with the region in chromosome 22, t (9,22) q (34, q11) (Mauro and 
Druker, 2001). As the BCR-ABL tyrosine kinase becomes overexpressed 
this leads to the chronic phase of the disease, in just under 70% of patients, 
where up to 30% of blast cells are located to the bone marrow or blood. In 
this phase blood counts (which may be part diagnostic, over 1 x 1010/litre) 
are very high, with an abnormally high level of myeloid cells at various 
differentiation stages, including neutrophils and may lead to gout. With the 
uncontrolled proliferation and effective evasion of the immune system, the 
disease moves to the blast-crisis phase (Howard, M., 2008) where over one 
third of the blasts are in the blood/bone marrow and which is accompanied 
by other features such as thrombocytosis, and splenomegaly. CML is more 
common in older people (Bain, B., 2004). As a result of immune effector 
mechanisms, CML often goes undiagnosed for up to five years before a 
diagnosis is made and treatment commenced. 
The standard treatment for CML today includes chemotherapy using 
spryceli, imatinib and tasigna (Pray, L., 2008) or radiotherapy and for high-
risk patients, stem cell transplants may be used (Howard, M., 2008) 
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Fig. 5.1 Translocation of the Philadelphia chromosome through BCR-
ABL fusion produces an increase in leukemic cells (Tanaka, R et al., 
2008) 
An understanding of the pathology of the disease at the molecular level has 
brought about a number of therapies, including ones based on interferon, or 
tyrosine kinase inhibitors of BCR-ABL which limit the proliferation of myeloid 
cell through the induction of apoptosis. Another important therapy is that of 
allogeneic stem cell transplantation. Unfortunately, the blast phase of the 
disease is untreatable at the moment (Goldman, 2009) which is why it is 
imperative that novel drugs are developed capable of very specifically 
limiting the proliferation of blast cells.  
5.1.2 Erythroleukaemia cell line, K562  
The K562 erythroleukaemia cell line was obtained from a chronic myeloid 
leukaemia patient (CML patient) in blast stage crisis (Lozzio and Lozzio, 
1975). Morphologically these cells are essentially undifferentiated blast cells, 
positive for the Philadelphia chromosome and carry mutated p53 and which 
are strongly positive for acid phosphate (Koeffler, H. and Golde, D., 1980); 
K562 cells have a doubling time of 12 h. The cytoplasm is basophilic and 
they have granulocyte-specific enzymes in the cytoplasm (Gewirtz et al., 
1982) although they do not stain with Sudan black unlike the staining pattern 
seen for granulocytes. K562 cells do not have lymphocytic markers and as 
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they are derived from precursor cells or erythrocytes, unlike their more 
mature counterparts, lack the Ia antigen (Koeffler, H and Golde, D, 1980). 
Furthermore, K562 cells lack Igs, and receptors for EBV and Herpes-like 
virus as well as MHC I receptors, meaning they are unable to inhibit NK cell 
activities.  K562 cells do, however, strongly express Fc receptors but are not 
phagocytic. 
K562 cells can be induced to express erythroid cell markers such as 
sialoglycoprotein or glycophorin (Andersson,1979). Furthermore, these cells 
can be differentiated along the megakaryocyte lineage or to progenitors of 
granulocytes, monocytes/macrophages or erythrocytes (Gewir, A. et al., 
1982). 
5.1.3 β-Glycyrrhetinic acid 
β-Gly the structure of which is shown in Fig. 5.2 has been shown to inhibit 
11-β-hydroxysteroid dehydrogenase (Edwards and Stewart, 1991), an 
enzyme found in the kidneys, inhibition of which results in the accumulation 
of hydroxycortisone.  
In other interesting work β-Gly was found to have anti-inflammatory 
properties by inhibiting the complement-mediated inflammation. β-Gly has a 
direct anti-inflammatory effect by selectively inhibiting a complement 
cascade. β-Gly was specifically shown to inhibit the classical pathway of 
complement activation but not the alternative and it was found that this 
inhibition happened, dose-dependently, at the level of complement C2, 
allegedly by binding to C2 and in so inhibiting its subsequent cleavage by 
the serine protease complement C1 (Kroes, B. et al., 1997).  
Working with a different myeloid cell line, HL-60, it was shown that β-
Glycyrrhetinic inhibits proliferation of these leukemic cells (Liu, D. et al., 
2007). On the breast cancer cell line, MCF-7 β-Glycyrrhetinic in combination 
with glycyrrhizin, the combination therapy was found to be toxic and to 
induce apoptosis as shown by TUNEL staining (Sharma, J. and Ward, P., 
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2012). On this basis I wanted to see the efficacy of β-Glycyrrhetinic on K562 
cells.  
 
 
 
Fig. 5.2 18α-Glycyrrhetinic acid and 18β-Gly molecular structures. 18α 
is a much rarer optical isomer than the 18β- form (Kang et al., 2014). 
 
 
In the last ten years β-Gly together with the derivative drugs developed has 
been investigated for its anti-cancer properties. Most significantly a synthetic 
analogue of β-Gly called CDODA-me has been found to inhibit the 
proliferation of prostate, colon and pancreatic tumour cells without affecting 
surrounding healthy cells (Chintharlapalli et al, 2007). As most tumour cells 
are able to resist pathways leading to apoptosis, the vast majority of cancer 
drugs are designed to interfere with this pathway β-Glycyrrhetinic and its 
derivatives were found to render the human leukemic cell line, HL60 
apoptotic by acting on the role mitochondria play in apoptosis (Liu et al,2007) 
but the action on different tumor cells may involve other mechanisms that 
limit proliferation. β-Gly has also been shown to inhibit Gap junctions and 
hemi-channels in a range of cancers.   
  
141 
 
5.1.4 Aims 
In this chapter I have begun to address the pathways of biogenesis of MVs 
by looking at potential pharmacological inhibitors of MV release. It is known 
that MVs contribute to tumorigenesis and tumour growth and that they are 
involved in promoting angiogenesis. Furthermore, MVs released from 
cancer cells may act as decoys and interfere with antibody-based 
immunotherapies. As was shown by the Inal group, inhibition of MV release 
from prostate cancer cells rendered the cells sensitive to chemotherapeutic 
drugs, both in vitro and in vivo, such that 100-fold lower concentrations of 
docetaxel could be used with the same efficacy (Jorfi et al., 2015). The 
reason for this was that as shown by Inal and others, tumour cells expel 
cancer drugs through the release of MVs. Therefore, an understanding of 
the release of MVs from cells has a very important potential application in 
the development of cancer therapeutics.  
In this chapter I have also endeavoured to test the potential of a drug derived 
from liquorice, β-Gly, firstly on its own against K562, an erythroleukaemia 
cell line. In addition, I aimed to investigate firstly whether monocyte-derived 
MVs could bind K562 cells, by using a lipid mixing or octadecylrhodamine 
dequenching assay, and if so, whether monocyte-derived MVs harbouring 
β-Gly could limit proliferation and/or induce apoptosis of K562 cells, in other 
words to see if they could be used as drug delivery vehicles. As another 
strategy, using one of the drugs shown to limit MV release, it was to be used 
in conjunction with an anti-cancer drug, such as β-Gly, to see, following on 
from previous work (Jorfi et al., 2015), whether this would enhance the 
efficacy of the cancer drug by inhibiting its efflux from the cancer cells. 
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5.2. Materials and Methods 
5.2.1 Cell culture 
Cryogenic vials containing K562 cells were removed from liquid nitrogen and 
placed into a water bath at 37°C for about 5 minutes, to let the cells thaw. 
Each vial was then disinfected with 95% ethanol (IMS 95) and then 
transferred aseptically into a centrifuge tube with 10 ml of RPMI 1640 
medium, centrifuged at 160 g for 5 min. The pellet was gently resuspended 
in complete growth medium (CGM) and placed at 37°C in a humidified 
incubator (5% CO2). CGM is used for maintaining the cells and comprises 
500 ml RPMI 1640, 50 ml 10 % Foetal bovine serum (FBS), and 5 ml of 100 
x Penicillin / Streptomycin to prevent bacterial growth. Cells were then 
maintained and regularly cultured to carry out different experiments. 
To minimise the chance of contamination, all cell culture procedures were 
carried out under aseptic conditions. Biosafety cabinets represent the 
simplest and cheapest way to provide aseptic conditions and were used in 
this experiment. 
Gloves were worn at all time and IMS was used to wipe hands and the 
outside surfaces of containers, flasks, pipette tip box, pipettes, and 
centrifuge tubes before being placed inside the cabinet. Sterile 10 ml 
graduated wide tips (individually wrapped), with an appropriate pipette 
pump, were used to pour media and cells directly into or from the flask, using 
tips only once to avoid cross contamination. 
Cells were sub-cultured every 2-3 days to prevent confluency of the cells in 
the culture flask (high confluency) and ensure optimal density for continued 
growth and proliferation. Following seeding and lag phase, cells will proceed 
to the log phase (exponential growth) until the till their number exceeds the 
capacity of the medium to sustain further growth, and cell proliferation 
decreases or stops altogether. 
After transferring the cell suspension (in the culture flask) directly into a 
sterile 50 ml centrifuge tube under aseptic conditions, centrifugation was 
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carried out at 160 g for 5 minutes. The supernatant containing dead cells 
debris was removed with the use of a 10 ml sterile tip taking care not to 
disturb the pellet containing the live cells. 5 ml of RPMI 1640 (used here to 
wash the cells) was then added, followed by centrifugation at 160 g for 5 
minutes. The pellet was resuspended in 5 ml of RPMI 1640 and 
centrifugation repeated once more resuspending in an equal volume to then 
make additional dilutions. A 1:20 dilution was then carried out (1 ml of cells 
in RPMI 1640 mixed with 19 ml of CGM) in a 75 cm2 culture flask, aiming to 
produce a seeding density of approximately 1x106 cells/ml. As already 
mentioned a higher density could affect the capacity of the medium to 
sustain further growth. However, a density that is too low could prevent the 
cells to produce communication signals and growth factors, hence affecting 
their growth and proliferation. The flask was subsequently incubated at 
37°C, 5% CO2. 
Cells were viewed under an inverted microscope at 24-hour intervals to 
check on their health status and investigate any morphological changes 
taking place during growth and differentiation. 
 
 
5.2.2 Cell count and study of normal growth pattern of K562 cell line 
Cells were maintained and sub-cultured as necessary and on the first day of 
the experiment cells were washed with RPMI 1640 (see washing procedure 
above), and the pellet resuspended in 5 ml of RPMI 1640. 10 μl from this 
was transferred into an Eppendorf tube, together with 10 μl of 0.5% trypan 
blue, mixed thoroughly via pipetting the entire volume up and down 6-10 
times, and the count then performed soon after by using a haemocytometer 
or the flow cytometer (see below). 
The haemocytometer had been previously prepared by cleaning the 
chamber and the cover slip with bio guard, and then cover slip dried and 
fixed in position. 10 μl of the homogenous suspension was applied to the 
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edge of the cover slip and allowed to be sucked up by the capillary action 
taking care not to overfill the chamber. The chamber was placed in the 
inverted microscope under a x10 objective, focusing on the grid lines, 
particularly on one set (of four) of sixteen corner squares, counting the cells 
in every square including those located on the boundary lines on the right or 
bottom. An estimate of the number of cells per ml was calculated and 
subsequent dilution with Complete Growth Medium (CGM) was performed 
under aseptic conditions to achieve a seeding density of 5x104 cells/well. 
400 μl was then pipetted into each of three wells (three replicates) in the 
centre of a 24-well microtitre plate. A fresh pipette tip was used each time 
and the plate only uncovered immediately before inserting the tip into the 
well to avoid contamination. 
Also counts performed with the haemocytometer give the number of cells 
per ml. However, the cells had to be seeded at a density of 5x104 cells/well 
where the final volume in each well is 400 μl. The plate was subsequently 
incubated at 37°C, 5% CO2. The count of viable cells was then evaluated 
over a period of four days. 
On each day a 10 μl aliquot from each well was transferred by using a 2-20 
μl pipette (mixing of cells in the well was performed with the tip of the pipette 
prior to the transferring process), under aseptic conditions, in three separate 
clean eppendorf tubes (using tips only once). The tubes were then labelled 
(replicate 1, 2, and 3) and 10 μl of trypan blue was added prior to counting. 
As above for every replicate individual counts for each of the four sets of 
sixteen corner squares in the chamber were performed and averaged. After 
completion of a successful count the 96-well microtitre plate was then 
replaced in the incubator. 
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5.2.3 Cell count and study of growth pattern of K562 cell line in the 
presence of β-Gly  
The K562 erythroleukaemia cell line was seeded into a 24-well plate along 
with different reagents (histamine, imidazole, and 18β-Gly) at a density of 
2x104 cells per well in triplicate. To observe the dose response of the 
chemicals on the cells, the reagents were added at a range of concentrations 
(1 μM, 5 μM, and 10 μM,). A set of control samples (where no reagent was 
added) prepared in triplicate was also set up to compare the normal growth 
pattern of the cells with the growth pattern of the cells seeded along with the 
reagents, allowing observation and analysis of any variation taking place. 
Counts were performed using a haemocytometer as above but over a 3-day 
period (see results/discussion).  
5.2.4 Trypan blue (cell viability) assay 
Trypan blue at 0.5 % w/v was used to calculate the percentage viability of 
K562 cells, cells that were alive being distinguished from those that were 
dead by observing whether they had absorbed the blue stain (dead) or not 
(alive).  It was important to not overstain (leaving the cells in trypan blue for 
more than 3 minutes because after this the dye becomes cytotoxic and can 
affect the results. For all experiments, cell viability at the start of an 
experiment was >95%. Having counted the numbers of blue and white cells, 
the percentage viability was calculated using the following formula.  
% of viability = (No. of viable cells / total No.of cells) x 100  
5.2.5 Cell viability using a Guava EasyCyte flow cytometer 
The ViaCount Assay from Guava Millipore represents a quicker and more 
accurate assay for viability that the haemocytometer method described 
above. This method was carried out exactly as described by the 
manufacturers. Essentially 175 µl of well-mixed suspension of K562 cells 
was taken from the 24-well plate into an Eppendorf tube where 25 µl of 
Guava ViaCount Reagent was added before analysis on the Guava 
EasyCyte. 
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5.2.6 Microvesicle Isolation and Quantification 
The K562 cells were seeded in 12 well plate 6x104 cell per well and the total 
volume of 1ml per well. Three different concentrations of β-GA were used, 
40μmol, 50 μmol, 60 μmol and volume used were 4 μl, 5 μl,6 μl respectively. 
Control samples and test samples made in triplicate and the experiment was 
followed twice. The culture plate was incubated for 24 h at 37 ° C/ 5% CO2. 
After 24 hours, cell morphology was observed using the inverted 
microscope. Cell culture in each well was suspended properly using a 
sterilized pipette tip and transferred to 15ml centrifuge tubes labelled 
appropriately. The 4 centrifuge tubes (control sample, test samples 1 μM, 10 
μM and 50 μM β-Gly) were first centrifuged at 4,000 g for 5 min to remove 
the cells. The supernatant was then centrifuged at 4,000 g for 1 h to remove 
cell debris. The supernatant was then transferred to labelled Eppendorf 
tubes and centrifuged at 15,000 g for 99 minutes (Micro centrifuge 5417R). 
Finally, the supernatant was carefully removed without disturbing the 
microvesicle-containing pallet and the MVs were suspended in 100 µl of 0.22 
μm pore size filtered PBS.  
A 10µl of microvesicles suspension was diluted in 190µl of PBS and placed 
into 96 well plate in triplicate. A calibration sample was prepared by 
suspending 5µl of the control sample with 195µl filtered PBS. Then the 
microvesicles were quantified on Guava EasyCyte flow cytometer using 
Easy Check software. Bar graphs for test samples were generated against 
control sample.  
5.2.7 Lipid mixing or octadecylrhodamine dequenching fusion assay to 
assess membrane (microvesicle/recipient cell) fusion  
A fluorescence increase was used to monitor the fusion of THP-1 cell derived 
MVs to recipient (K562) cells. Essentially such fusion activity would be due 
to the fusion activity involving octadecyl rhodamine B chloride (R18) with 
which the MVs were labelled and the unlabelled cells. The protocol was a 
modified version of one used in this lab before (Ansa-Addo et al., 2010). MVs 
(30 µg protein/ml) were labelled in 1 mM R18 (30 min/room temperature) in 
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10 mM MES buffer (10 mM MES (Sigma); 5 mM KCl; 145 mM NaCl). 
Unincorporated R18 was removed by passing the labelled MVs through an 
Exosome Spin Column, with a molecular cut off of 3000. To estimate the 
fluorescence of 15 μg R18 labelled MVs, the fluorescence after the 
unincorporated probe was removed was compared to that before removal 
by using a spectrofluorometer (560 nm excitation/ 590 nm emission). After 
equilibrating for 20 min, 1 x 106 K562 cells were added to the R18-labelled 
THP-1 MVs and the experiment continued for a further half an hour before 
adding 0.3 % (v/v) Triton X-100 as well as 50 mM octylglucoside, a non-ionic 
surfactant to obtain maximum probe dilution. The percentage Fluorescence 
Dequenching, FD, was determined as a percentage using the formula [Ansa-
Addo et al., 2010]  
%FD=((F-Fi)/Fmax-Fi)x100, as before (Ansa-Addo et al., 2010) where Fi is 
initial fluorescence and Fmax the fluorescence after lysis with detergent. 
 
5.2.8 Assay for haemoglobin  
10 x 106 cells were washed with ice-cold PBS and lysed in 0.25 % Triton X-
100 in PBS for 15 min. After pelleting the lysates (600 g; 20 min) the 
supernatant was decanted and 10 µl from this added to 2 ml of 5 mg/ml 
tetramethylbenzidine (TMB) in glacial acetic acid and a further 2 ml of 30 % 
hydrogen peroxide for 15 min. To find the level of haemoglobin (in pg/ml), 
the absorbance of the solution was measured at 600 nm and the reading 
interpolated on a standard curve and shown in bar charts as fold increase 
compared to haemoglobin levels in untreated control K562 cells.  
As an alternative TMB staining (microscopic) protocol, TMB solution, freshly 
prepared as described above was used with 1 X 106 cells (in saline) at a 
ratio of cells to TMB solution of 1:2 for 30 min in the dark and stopped by 
adding 0.2 ml of saline.   Five hundred cells were counted (at the 48 h time 
point of the experiment) and the number of TMB-stained cells indicating the 
presence of heme containing globin tetrameric forms, noted. Hemin at a 
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concentration of 20 µM was used as a positive control for induction of 
erythroid differentiation of K562 cells. 
5.2.9 Statistical Analysis   
Statistical analyses carried out included unpaired t test and one-way analysis 
of variance (ANOVA). This was carried out using GraphPad Prism software, 
version 6 (GraphPad Software, SanDiego, CA). Differences giving P values 
<0.05 were considered statistically significant. 
 
5.3     Results 
5.3.1 MVs can be released from K562 cells by sublytic complement and 
inhibited by interfering with lipid rafts, and by using inhibitors of 
calpain and Rho-associated coiled-coil containing protein kinase 
(ROCK). 
The pathways leading to MV biogenesis have not yet been fully elucidated 
but certain factors stimulating MV release have been known for some time. 
In most cases MV release is accompanied by a sharp (approximately 5-fold) 
rise in intracellular calcium concentrations, [Ca2+]i from an average in a 
resting cell of 100 nM to 400-500 nM upon stimulation. The rise in [Ca2+]i in 
cells may arise from intracellular stores or from the extracellular 
environment. The way intracellular calcium levels may rise from an 
extracellular influx usually involves stimulation of a calcium channel or by 
means of cell surface pores such as calcium ionophore or as created by 
sublytic complement activation upon a cell resulting in a membrane attack 
complex (MAC). In the presence of an extracellular source of calcium, given 
that the intracellular environment is maintained at a low concentration, 
calcium will flood the cytosol. This in turn sets off the process of 
microvesiculation. As a result, the enzymes that maintain the asymmetry of 
the lipid bilayer are no longer able to do so, resulting in the exposition of PS 
as well as the activation of calpain which cleaves the actin cytoskeleton 
resulting in a small blebbing of the plasma membrane. 
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When THP-1 promonocytic cells were stimulated with a sublytic 
concentration of complement (5 % normal human serum) this resulted in a 
significant rise of released MVs (an over 1000-fold increase) (Fig. 5.3). That 
this is due to sublytic complement was shown previously by using  
 
 
Fig. 5.3 Promonocytic Leukaemia cells release MVs upon stimulation 
with sublytic complement and a phorbol ester.  THP-1 promonocytes 
were treated with 5% NHS (normal human serum) as a source of sublytic 
complement to release MVs as measured on the Guava EasyCyte. PMA (1 
nM) which also stimulates macrophage terminal differentiation also 
stimulated a release of MVs from THP-1 cells but at a five-fold lower level. 
heat-inactivated NHS as a source of complement proteins (Ansa-Addo, E. 
et al., 2010, Stratton, D., et al., 2014) as well as by removal of one of the 
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terminal complement proteins, C9 (Ansa-Addo et al., 2010 and Antwi-
Baffour et al., 2010). These MVs showed the characteristic, tapering 
forward/side scatter dot blot (Figure 5.4). Using NHS (complement) as a 
positive control for stimulation MV release the effect of the protein kinase C 
activator, PMA (phorbol 12-myristate 13-acetate) was tested and found to 
increase MV release 100-fold compared to untreated control. 
It was next decided to test a range of likely (unknown) or previously implied 
inhibitors of MV release. To begin with, EGTA was tested as a chelator of 
extracellular calcium. The Rho-associated coiled-coil containing protein 
kinase (ROCK) was also used, Y27632 as well as the calpain inhibitor, 
calpeptin. In addition, methyl β-cyclodextrin was also tested as a depletor of 
cholesterol as well as chlorpromazine, a known inhibitor of clathrin-mediated 
endocytosis (Fig. 5.5). 
All reagents tested, excluding chlorpromazine, significantly reduced MV 
release from K562 cells. This was useful information because as 
researchers in the MV field it provides a useful range of inhibitors of 
microvesiculation, beyond calpeptin. This is not only useful in providing 
pharmacological agents that can potentially inhibit cancer-promoting MV 
release as well as a wider range of agents to choose from regarding drug 
resistance but also a range of drugs that to achieve such inhibition in a 
targeted manner may be incorporated into targeting MVs that could deliver 
such drugs specifically to tumour cells. 
The type of cell that could be considered as a source of targeting MVs is the 
THP-1 monocyte. This would be for two reasons, firstly that it has been used 
before by our group to demonstrate membrane fusion with the parent cells 
(THP-1) and secondly that monocytes are chemoattracted to tumour sites 
by a range of chemokines including CXCL12 (SDF-1α). I found that AML-
M5, acute monocytic leukaemia cells (THP-1) produce more MVs that 
peripheral blood monocytes (Fig. 5.6) and for this reason decided for the 
sake of these initial in vitro experiments to use THP-1 cell-derived MVs as 
drug delivery vehicles. Obviously, this work, if to be furthered would have the 
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potential of using the patient’s own monocyte MVs, as a very desirable form 
of personalised medicine. 
This thesis has focused on the use of microvesicles (MVs) but the other type 
of vesicle, the exosome (which together with apoptotic bodies) 
encompasses what is termed Extracellular Vesicles, would also potentially 
make a useful drug delivery vehicle. Exosomes are much more 
homogeneous in size than the larger MVs, but their smaller volume may well 
limit their usefulness. Comparing MVs and exosomes it was decided to 
compare their PS exposition which has been shown to be greater on MVs 
even though some authors have challenged this lately. As perhaps such 
variation may be cell-specific, PS exposition on monocyte MVs versus 
exosomes was compared. THP-1 monocyte MVs were shown to stain 
positively for Annexin V-FITC and for the monocyte marker, CD14 (Fig. 5.7). 
As the more desirable exosome or MV drug delivery vehicle, in terms of 
personalised medicine, would be a patient-derived monocyte, and because 
PS exposition may be important for involvement in the fusion process with 
recipient cell as shown before (Ansa-Addo, E., 2010), the degree of Annexin 
V-FITC binding was compared between monocyte-derived MVs and 
exosomes (Fig. 5.7 and Fig. 5.8). In accordance with previous data from the 
Cellular and Molecular Immunology Research Centre, it was clearly found 
that monocyte-derived MVs expose PS to a far greater degree than 
monocyte-derived exosomes (Fig. 5.6). The implication that PS plays a role 
in MV-target cell fusion is that in previous work from this lab, blocking of MV 
exposed PS with unlabelled annexin, limited significantly the degree of lipid 
mixing observed (dequenching assay using octadecylrhodamine labelled 
MVs). In this sense it would be preferable to use MVs as opposed to 
exosomes from monocytes to initiate any drug delivery. 
Carrying on the comparison between monocytic leukemic cell derived EMVs 
(exosomes and microvesicles) electron microscopy showed morphologically 
and in terms of size there to be no difference (Figs. 5.9 and Fig. 5.10). 
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Fig. 5.4 Forward/Side Scatter plot for MVs released from THP-1 cells. 
A typical dot plot for size (forward scatter) versus granularity (side scatter) 
as obtained for THP-1 MVs showing a typical tapering shaped plot.  
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Fig. 5.5   MV release from K562 erythroleukaemic cells stimulated by 
sublytic complement can be inhibited by a range of pharmacological 
inhibitors. K562 cells were stimulated with 5% NHS for 20 min after pre-
treatment for 30 min with chlorpromazine, EGTA, Y-27632, calpeptin, Y-
27632 combined with calpeptin and methyl Beta Cyclodextrin and 
chlorpromazine.  MV levels were measured using the Guava EasyCyte. The 
results are presented as mean ± Standard Deviation. 
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Fig. 5.6 Promonocytic leukaemia cell line (THP-1) releases more MVs 
than primary monocytes. An equivalent number (3x106/ml) of 
promonocytic leukaemia cells, THP-1 and primary peripheral blood 
monocytes were treated with sublytic complement and resulting levels of 
MVs recorded.  
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Fig. 5.7 Microvesicles released from THP-1, monocytic leukaemia cells 
show exposition of phosphatidylserine and are positive for CD14. THP-
1 MVs were labelled with annexin V-FITC as were exosomes after isolation 
from cells. THP-1 MVs were also identified by positive staining with anti-
CD14 (the Lipopolysaccharide receptor).  Analysis was on the Guava 
EasyCyte flow cytometer.       
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Fig. 5.8 Microvesicles released from peripheral blood primary 
monocytic cells show exposition of phosphatidylserine and express 
CD63. Peripheral blood primary monocyte MVs were labelled with annexin 
V-FITC as were exosomes after isolation from cells. Monocytic MVs were 
also identified by positive staining with anti-CD14 (the Lipopolysaccharide 
receptor).  Analysis was on the Guava EasyCyte flow cytometer.          
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Fig. 5.9 Transmission electron microscopy of THP-1 monocyte 
exosomes (A) and microvesicles (B). Bar, 100 nm. Exosomes and 
microvesicles were isolated from THP-1, acute monocytic leukaemia cells 
and prepared for electron microscopy as described in Materials and Methods 
and viewed on a JEOL JEM-1400Plus Transmission Electron Microscope.  
A
B
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Fig. 5.10 Transmission electron microscopy of primary peripheral 
blood monocyte exosomes (A) and microvesicles (B).  Bar, 100 nm. 
Exosomes and microvesicles were isolated from peripheral blood monocytic 
cells and prepared for electron microscopy as described in Materials and 
Methods and viewed on a JEOL JEM-1400Plus Transmission Electron 
Microscope.  
A B
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5.3.2 THP-1 MVs fuse/hemi-fuse with K562 erythroleukaemic cells 
To be able to use MVs as drug delivery vehicles with the intention of 
delivering chemotherapeutic drugs to tumour cells in the case of 
erythroleukaemia, it was considered paramount to establish whether MV 
derived from monocytic cells (whether monocytic leukemic cells, e.g. THP-
1) or from peripheral blood monocytes are capable of fusion with acceptor 
K562 erythroleukaemic cells. The simple assay of choice was that of lipid 
mixing (or dodecylrhodamine, R18 dequenching). A perhaps more 
convincing method of establishing membrane fusion would be Fluorescence 
Resonance Energy Transfer (or FRET); the other problem is that lipid mixing 
may not tell us whether the MV-cell membrane fusion is in fact hemi-fusion. 
Electron microscopy was also used to show that the membrane of the R18-
labelled MVs was indeed intact (5.11A) and flow cytometry was used to show 
that the MVs released from cells are indeed labelled with R18 (Figure 5.11B). 
It was then possible to mix the R18 labelled THP-1 monocyte-derived MVs 
with unlabelled recipient K562 cells. Figure 5.11C shows a significant 
increase in fluorescence, within 2 min, indicating fusion or hemifusion. That 
transfer of label had not occurred spontaneously without any degree of 
fusion/hemifusion, was confirmed by repeating the experiment at 4°C, 
whereupon no R18 was transferred to the recipient K562 cells. Several 
experiments were also included to indicate any factors that were important 
to mediate the subsequent fusion. It was thought that a degree of protein-
protein interaction might be needed as a prerequisite to membrane fusion so 
surface protein was removed from the MVs by a gentle treatment with trypsin 
as described before (Ansa-Addo E.A. et al., 2010). Some protein interaction 
did indeed seem to be needed as surface proteins did indeed seem to be 
needed for lipid mixing. Phosphatidylserine on the MV surface was also 
shown to be needed by blocking membrane fusion with annexin V. Finally, 
increasing the amount of recipient cell membrane made available by 
increasing the number of cells, also increased fusion. 
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Fig. 5.11 Octadecylrhodamine-labelled THP-1 MVs fuse/hemifuse with 
K562 erythroleukaemia cells. R18 labelled MVs remain intact after 
labelling. Bar, 250 nm (A). Flow cytometry shows that THP-1 MVs are 
labelled with R18 (B). Lipid mixing assay shows marked increase in 
fluorescence indicating fusion/hemifusion with K562 membrane, within 120s 
of mixing MVs and cells. No fusion occurs are 4°C or when surface protein 
removed from the MVs or when phosphatidylserine on the MV surface was 
blocked with annexin V (dotted lines), (C).  
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Researchers at the Cellular and Molecular Immunology Research Centre 
have previously shown that a chemotherapeutic drug can be deliverable via 
MVs (Jorfi et al., 2015). In that case the drug was an alexa fluor 488-labelled 
methotrexate. In this thesis I have shown that THP-1 promonocytic MVs can 
fuse or hemi-fuse with K562 cells. The eventual aim was to see whether MVs 
loaded with a drug derived from liquorice, called β-Gly, which has been 
shown to be effective in either inducing apoptosis or limiting the proliferation 
of a range of cancer cells, could do so against the erythroleukaemic cell line, 
K562. To this aim I first wanted to confirm that β-Gly has an effect on K562 
cells and to make a rudimentary analysis of the nature of this process and 
to then and try the drug loaded in MVs to see whether the concept of using 
THP-1 MVs as drug delivery vehicles has any credence. In effect this 
preliminary study is an attempted proof of concept.  
5.3.3 β-Gly limits the proliferation of K562 cells 
Firstly, 10 µM of β-Gly was used to see its effect on the proliferation of K562 
cells in culture. By day 5 in culture it was very apparent that β-Gly has 
significantly limited proliferation compared to control and that this effect had 
started with increasing effect from day 3 (Figure 5.12). To see whether this 
effect was dose-dependent, β-glycyrretinic acid was used at increasing 
doses from 1 to 5 and 10 µM β-Gly. As is shown in Figure 5.13, the dose-
dependent reduction in K562 cell number began to be dose dependent from 
day 3 but was only really significant by day 5. In conducting these studies on 
the capacity of beta-glycyrretinic acid to limit proliferation of K562 cells, the 
possibility arose that unlike some studies which had reported an increase in 
apoptosis, as a possible explanation for the decrease in cell numbers upon   
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Fig. 5.12 β-glycyrrhetinic acid limits proliferation of K562 cells grown 
in culture. K562 cells were seeded at 80,000 cells per well. Control wells 
were left untreated and cell counts obtained on days 3, 4 and 5. Β-Gly was 
added at 10 µM and beginning on day 3 began to show a decrease in 
proliferation which became magnified on days 4 and 5. The results 
represented are from 5 experiments, taking the standard error of the mean 
from triplicate samples.  
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Fig. 5.13 β-Gly limits the proliferation of K562 erythroleukaemia cells in 
a dose-dependent manner. K562 cells in culture were treated with 
increasing doses of β-Gly (1, 5 and 10 µM) and cell numbers monitored over 
5 days. By day 3 the highest dose (10 µM) of β-Gly already showed a 
reduction of cell numbers and that this was a dose-dependent effect was 
very apparent by day 5 where 1 µM had decreased the cell count by 40% 
compared to control, 5 µM by 55% and 10 µM by 70%. The error bars 
represent standard error of the mean, S.E.M. from 3 experiments in triplicate. 
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treating with beta-glycyrretinic acid, it was apparent from assessing the 
viability of the K562 cells (which remained high throughout the experiments, 
data not shown) that the observed reductions in cell number may have arisen 
because of an effect on limiting cell proliferation, rather than of inducing 
apoptosis.  
 
5.3.4 β-Gly increase the doubling time of K562 cells but does not 
induce apoptosis 
To give a cursory assessment of the observations made, K562 cell doubling 
time was firstly determined in the presence of 1, 5 and 10 µM β-Gly and then 
levels of apoptosis determined. As shown in Figure 5.14, with increasing 
doses of β-Gly, the doubling time of K562 cells increased, from 25 h in the 
absence of β-Gly to 28 h with 1 µM, 31 h with 5 µM and 33 h with 10 µM. 
The experiments to determine whether in this system, β-glycyrretinic acid 
was potentially limiting cell numbers by inducing apoptosis were similarly set 
up, with 1, 5 and 10 µM β-Gly. After 5 days, apoptosis was measured, by 
determining the percentage of cells stained with annexin V, as a measure of 
phosphatidylserine exposition (to indicate cells in early apoptosis) and also 
additionally permeable to the nuclear dye, 7-actinomycin D, 7-AAD, (as a 
measure of late apoptosis.  These experiments showed that all K562 cells, 
even after 5 days in culture whether treated with 10 µM beta-glycyrretinic 
acid or not, were largely viable, the levels of early apoptotic cells typically 
varying between 5-10%; no late apoptotic (AnV+ 7-AAD+ cells were 
detected (Figure 5.15).  
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Fig. 5.14 K562 cells treated with beta-glycyrretinic acid have an 
increased doubling time. Cells (80,000/well) were treated with 1, 5 or 10 
µM beta-glycyrretinic acid over 5 days and the average doubling time 
calculated.  
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Fig. 5.15 K562 cells treated with increasing concentrations of β-Gly do 
not undergo apoptosis. K562 cells were treated with 1, and 10 µM β-Gly 
over the course of a 5-day experiment. They were then recovered and the 
degree of apoptosis assessed using a Guava Nexin assay on a Guava 
Easycyte flow cytometer. Cells in the bottom left quadrant are viable, not 
staining with annexin V (as a measure of phosphatidylserine exposition. 
Cells in the bottom right quadrant (of which there are barely any) have 
stained positive for AnV, indicating PS exposition and early apoptosis. Cells 
which have stained for AnV and the membrane permeant dye, 7-AAD are 
considered late apoptotic (top right quadrant) and any cells in the top right 
quadrant are considered dead.   
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Having shown β-Gly to reduce cell numbers of K562 cells in culture, the aim 
was to see if β-Gly-loaded MVs could induce a similar effect on K562 cells. 
As mentioned above, this lab had previously demonstrated methotrexate 
(MTX) directly in MVs released from cells treated with the drug by both 
monitoring the presence of fluorescent MTX and by directly measuring it and 
determining its concentration by HPLC (Jorfi et al., 2015). In that case it was 
in fact found that the drug was present at a 10-fold lower concentration than 
given to the parent cell. Although it was not possible to measure β-Gly 
directly in MVs, an experiment was devised to see the effect on K562 cells 
of THP-1 MVs isolated from THP-1 cells given 100 µM β-Gly. By carefully 
designing an experiment that included drug-free MVs isolated from healthy 
donor cells, the intention was to imply that any reduction in cell numbers on 
delivery to K562 cells was due to the drug within the MVs. As shown in Figure 
5.16, by day 4 and 5 there was a significant reduction in cell numbers 
following treatment with β-Gly (10 µM) as before but now also with MVs 
isolated from THP-1 cells pre-treated with a high dose of β-Gly (100 µM). 
100-fold lower concentrations of β-Gly could be used with equal efficacy 
when MV release was inhibited, in this case by treating the K562 cells with 
Y27632. By way of controls, resveratrol was found as expected to decrease 
cell numbers and jacalin to be mitogenic, significantly increasing K562 cell 
numbers. Whilst there was some inhibition of proliferation when K562 cells 
were treated with MVs isolated from healthy, untreated THP-1 cells, the 
reductions were not significant. Looking at the levels of apoptosis (Figure 
5.17) and associated light micrographs (Figures 5.18 and 5.19) it was clear 
that neither β-Gly alone nor β-Gly-loaded MVs induced significant apoptosis 
of K562 cells. Jacalin which was mitogenic also induced no apoptosis 
whereas resveratrol did. Interestingly MVs per se from healthy cells do not 
induce apoptosis but those isolated from heat-treated THP-1 cells did, 
probably due to the transfer of caspase(s) as suggested by the reduced 
induction of apoptosis in the presence of the pan-caspase inhibitor, Z-VAD-
FMK.    
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Fig. 5.16 β-Gly-loaded MVs limit proliferation of K562 cells and this is 
enhanced by inhibiting MV release. By the 4th day in culture, K562 
numbers, compared to control, untreated cells began to be reduced in 
the presence of β-Gly (10 µM) and resveratrol (40 µM). By contrast, MVs 
alone also reduced cell numbers by day 4 and 5, but not significantly. 
Jacalin, a lectin which is mitogenic for K562 cells increased cell 
numbers by days 4 and 5. 
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Fig. 5.17 β-Gly-loaded MVs whilst limiting proliferation of K562 cells do not 
induce their apoptosis. Neither β-Gly nor β-Gly-loaded MVs induces any 
significant apoptosis even after 5 days of treatment. Jacalin which is 
mitogenic for K562 also induced no apoptosis, in contrast to 
resveratrol which induced 45% apoptosis by day 5. Z-VAD-FMK, the 
cell permeable pan-caspase inhibitor did inhibit MV-mediated 
apoptosis. Z-VAD-FMK, the cell permeable pan-caspase inhibitor did 
inhibit MV-mediated apoptosis. 
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Fig. 5.18 Cell morphology (K562) after 72 h in culture following treatment 
with β-Gly. Cell images were acquired using an inverted microscope 
from Nikon, Japan (TS100). Control, untreated cells are shown in (A) as 
rounded, uniform-sized cells with a smooth plasma membrane in (B) 
cells have been treated with 15 μM jacalin, a lectin mitogenic for K562 
cells. K562 cells were treated with the liquorice-derived Β-Gly at 10 μM 
(C) and with the apoptosis-inducing Resveratrol (40 μM), (D). Arrows 
indicate apoptotic cells. These results are representative of 3 
independent pools. Bar is 20 µm. 
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Fig. 5.19 Cell morphology (K562) after 72 h in culture following 
treatment with β-Gly-loaded MVs. Cell images were acquired using an 
inverted microscope from Nikon, Japan (TS100). Control, untreated cells are 
shown in (A) as rounded, uniform-sized cells with a smooth plasma 
membrane in (B) cells have been treated with 15 μM jacalin, a lectin 
mitogenic for K562 cells. K562 cells were treated with the MVs loaded with 
liquorice-derived Β-Gly at 10 μM (C) and with the apoptosis-inducing 
Resveratrol (40 μM), (D). Arrows indicate apoptotic cells. These results are 
representative of 5 independent experiments. Bar is 20 µm. 
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5.3.5 β-Gly caused K562 cells to exit the cell cycle at G0/G1 and initiates 
erythroid differentiation 
As apoptosis did not appear to have been induced by β-Gly, whether given 
directly or via MVs, it was supposed that some effect on the cell cycle may 
be observed. To that end cell cycle analysis was carried out using the 
Guava® Cell Cycle Assay for the Guava EasyCyte. Using this assay, it was 
possible to measure G0/G1, S, and G2/M phase distributions for treated and 
control K562 cells. This established that indeed Β-Gly, whether given alone 
or via MVs, increased the % cells in G0/G1 from 33 to 43% and 35 to 44% 
respectively and reduced the % cells in G2/M from 20 to 9% and 19 to 9% 
respectively (Figure 5.20). As this exit from the life cycle was likely to mean 
that the cells were entering a state of differentiation this was briefly 
investigated. K562 cells are able to differentiate along an erythroid 
megakaryocytic pathway. As could be seen from Figures 5.18 and 5.19, 
under no conditions could an enlarged cell morphology be seen, so it was 
decided to focus a possible differentiation along the erythroid lineage. The 
assay chosen to assess such differentiation was that for measuring 
increases in fetal haemoglobin (HbF) using benzidine staining. Figure 5.21 
shows that after 48 h of treatment of K562 cells with βGA or βGA-MVs, there 
is a distinct and clear increase in the number of cells staining positive with 
TMB (tetramethylbenzidine) when treated with 10 µM βGA (18%) compared 
to untreated control (7.7%) and positive control, 10 µM hemin-treated cells. 
βGA-MV-treated cells (with 15% positive TMB staining cells) compared to 
cells treated with MVs alone (10% staining) also therefore showed a 
significant increase.  
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Fig. 5.20 Cell cycle analysis shows that β-Gly induces cell cycle arrest 
of K562 cells in G0/G1 even when delivered in MVs. K562 cells were 
treated with 10 µM β-Gly and with 30 µg of MVs from THP-1 cells loaded 
with 100 µM beta-glycyrrhetinic acid. After 72 h in culture DNA analysis was 
carried out using a cell cycle analysis assay (Guava® Cell Cycle Assay). It 
was found that both β-Gly (A) and MVs loaded with β-Gly (B) increased the 
percentage of K562 cells in G0/G1 phases whilst there was a concomitant 
decrease in the percentage of cells in G2/M.  
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Fig. 5.21 Benzidine staining (% TMB-positive cells) as a measure or 
erythroid differentiation of K562 cells. K562 cells were treated with Hemin 
as a positive control or βGA or βGA-MVs and as a negative control with MVs 
alone or untreated. βGA significantly increased the number of TMB-positive 
cells after 48 h in culture, as did βGA-MVs compared to MVs alone. 
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5.4 Discussion 
β-Gly derived from liquorice is widely used in Traditional Chinese Medicine 
as a drug described as possessing anti-inflammatory activity, inducing 
various cytokines and in having anti-viral activity. Colleagues at the Cellular 
and Molecular Immunology Research Centre first became interested in Β-
Gly from the point of view of its described ability to inhibit the classical 
pathway of complement at the level of complement C2 (Kores et al., 1997). 
Although the mechanism was not elucidated it was suggested that this 
specific inhibition might be due the ability of Β-Gly to bind C2. It was during 
these studies that the group observed inhibitory effects on cellular 
proliferation in that particular work using the acute monocytic leukaemia cell 
line (representing AML M5) THP-1.   In the meantime, many groups have 
shown the inhibitory effects on cell growth of cancer cells, and much 
research has been carried and to improve activity by structural modification 
and understanding the biological and pharmacological activities of Β-Gly 
(Kang et al., 2014); several derivatives of β-Gly have been synthesized with 
improved anti-cancer activities (Chadalapaka et al., 2008 and Gao et al., 
2012). The aim of this study was to see the effect of Β-Gly on the chronic 
myelogenous leukaemia (CML) cell line, K562. As noted and in surveying 
the recent literature, it is clear that β-Gly has an effect on cellular proliferation 
of cancer cells. There are conflicts in the literature however regarding the 
mechanism(s) of such inhibition, to some extent depending on the cancer 
cells studied. Essentially the limiting of proliferation has been described as 
being due to an induction of apoptosis or to cell cycle arrest. In this chapter, 
proliferation, apoptosis, cell morphology, and cell cycle analysis were 
performed. In addition, the prospect of using MVs as drug delivery vehicles 
for chemotherapeutic drugs, in this case β-Gly was investigated. Lipid mixing 
assays were employed to estimate if there was any degree of membrane 
fusion between MVs and target cell membranes. This showed that 
octadecylrhodamine-labelled THP-1 monocyte-derived MVs underwent lipid 
mixing, indicating a degree of fusion or hemifusion with target K562 cells, 
within 120s of mixing target cells and MVs. Having indicated a likely fusion, 
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this of course does not exclude the possibility that MVs are perhaps taken 
up by a form of endocytosis, such as macropinocytosis, which could also 
potentially allow for delivery of drugs into cells. However, endocytosis was 
not investigated as part of this thesis, but is planned for future studies.  
Looking at the growth curves of K562 cells with β-Gly versus controls it could 
be seen that over the course of the experiments, up to 5 days, any decline 
in numbers was not due to depletion of nutrients or build-up of waste 
products or overcrowding of cells, as in the control, untreated wells, the cell 
numbers increased up to 5 days. Treated and untreated cells grew at a 
similar rate up to day 3 whereupon a dose-dependent decline for β-Gly 
treated cells was observed, leading to a 2/3 reduction in cell numbers by day 
5 and an increase in doubling time from 25 h to 33 h. The inhibition of cell 
proliferation was enhanced in the presence of Y27632 which was shown to 
inhibit MV release and therefore as shown (Jorfi et al., 2015) to limit drug 
efflux by MV release. The exact mechanism for this reduction in cellular 
proliferation is still unclear but this study has certainly begun to reveal a likely 
mechanism of action. β-Gly was not found to induce any significant increase 
in apoptosis even after 5 days but did cause the K562 cells to exit the cell 
cycle at G0/G1.  K562 is a highly undifferentiated human erythroleukaemic 
cell line which can be differentiated into cells with an erythroid, myeloid, or 
megakaryocyte phenotype by a range of stimuli including Ara-C and hemin 
inducing a change along the erythroid lineage and the phorbol ester PMA 
along the megakaryocytic lineage (Leary et al., 1987; Sutherland et al., 
1986). Although the cellular morphology after treating with βGA and βGA-
MVs did not suggest differentiation to the larger megakaryocytic cell type, 
and the fetal haemoglobin assay suggested a differentiation to an erythroid 
lineage, this is far from conclusive as no markers representing differentiation 
to either lineage was looked at.  
In other work by Liu and co-workers it was interestingly found that β-Gly had 
a dose-dependent anti-proliferative effect of the human acute monocytic 
leukaemia cells, HL-60 (AML-M2 cells). They also found that β-
Glycyrrhetinic induced apoptosis but only at comparatively much higher 
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doses of at least 80 µM (Liu,D et al, 2007). In other work β-Gly was also 
found to induce apoptosis of human ovarian and breast cancer cells, but 
once more only at high concentrations. (Haghshenas, V et al, 2014; Sharma 
et al, 2012). 
Although the described experiments suggest that differentiation of K562 
cells is likely to be due to β-Gly, it should be noted that there is a small if 
insignificant degree of fetal haemoglobin (HbF) production (indicated as 
TMB-stained cells) when THP-1 MVs alone are given to K562 cells, 
suggesting that one cannot exclude that MVs themselves may be inducing 
a degree of differentiation. Indeed, in previous studies at CMIRC, it was 
found that surface proteins on THP-1 monocytic MVs carry TGF-β1 (in a 
latent complex) and that differentiation of THP-1 cells themselves was 
attributed to this although it was also speculated that microRNAs also carried 
within the MVs may also be playing a role in the cells’ terminal differentiation 
(Ansa-Addo, E. et al., 2010) and as was also shown later (Ismail et al., 2013). 
In yet another study looking at the differentiation of K562 cells this time 
towards megakaryocytes, it was found that hedgehog morphogens found in 
MVs from stimulated T cells induced such differentiation (Martinez et al., 
2006). An interesting avenue of future research would be to establish 
whether Β-Gly itself can stimulate MV release from cells, especially if MVs 
are shown to have any role in the differentiation of K562 or other cells. 
Certainly, in cells where Β-Gly induces apoptosis, it might be expected to 
see a degree of MV release as early apoptosis is associated with 
microvesiculation (Inal et al., 2012). Preliminary work in the Inal lab 
(unpublished data, personal communication) suggests that β-Gly does 
induce MV release from K562 cells at the concentrations used in this study 
(10 µM). 
Amongst the limitation of this part of the study, there are several. Firstly, the 
process of getting drug into the MV has relied upon getting it first into the cell 
from which the MV is derived and therefore on using very high 
concentrations. It was not possible in the case of β-Gly to be sure that it was 
in the resulting MV and there was some reliance on previous work with 
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methotrexate (MTX) which was shown to be in the MVs, by having used 
Alexa Fluor-labelled MTX. It therefore could not be confirmed that it had 
been delivered to the recipient cells. However, it was possible to see rather 
than an induction of apoptosis that the β-Gly MVs induced a differentiation 
of erythroleukaemia cells, K562.  
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6. General Discussion  
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6.1 The lack of standardised isolation methodology of MVs and 
exosomes and the need for improved technology 
Microvesicles are shed from all cells in the body. There are fewer MVs shed 
from skeletal muscle cells however and MV release is increased in tumour 
cells. MVs are constitutively released but in increased numbers upon 
stimulation for example in early apoptosis, necrosis or in infection and 
resulting increases in intracellular calcium. Microvesicles (MVs) also termed 
ectosomes or microparticles and exosomes make up EMVs (exosomes and 
MVs) released from most human cells. Today MV and exosome release is 
not thought of as a mere process to remove surface proteins (such as 
deposited complement proteins), and the process has gained immense 
interest with regard various immune responses and in intercellular 
communication. MVs are released directly from the plasma membrane whilst 
membrane blebs and pseudopodia are formed in a process called 
ectocytosis; exosomes however are released as a result of an endocytic 
process and are released by exocytosis in which a multivesicular body 
(MVB) releases its cargo of exosomes.  
The problems involved in isolating microvesicles (MVs) and exosomes are 
numerous which is why the elucidation of a procedure to isolate these 
populations at high yield and with a high degree of purity has proved elusive 
for some time. The desired improvements over the standard methodologies 
involving differential centrifugation should ideally provide a better degree of 
purity of samples, and increased yield even from small cellular samples. 
Importantly any improved methods should provide samples that are less 
affected by the shear forces involved in high speed centrifugation. The 
procedures should also require a minimum of steps and be quick to perform 
and cost effective.  
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Fig. 6.1 Transmission Electron Microscopy of exosomes. The exosomes 
show evidence of clumping (Heijnen et al., 1999). (Bar = 100nm). 
The purification and analysis of exosomes and MVs is particularly important 
in studies of their biological properties and as intercellular communicative 
vectors in their varying effects on target cells, especially when considering 
them as therapeutic vehicles carrying and delivering miRNA, siRNA or 
proteins to target cells.  In the introduction to this thesis the biogenesis of 
MVs was described in detail including their release from the plasma 
membrane forming blebs initially, especially in cells undergoing early 
apoptosis. These stressed cells also form pseudopodia and the release of 
MVs takes about 20 min (Cestari et al., 2012; Stratton et al., 2015b). This is 
in contrast to exosome release which can take up to 3 h and is initiated from 
an endocytic event.  Whilst exosomes range in size from 30 to 100 nm, MVs 
have a wider size range, from 100 nm to 1 µm in diameter, although it is 
believed that MVs below 100 nm in diameter also exist (Harrison, personal 
communication; ISEV meeting, April 2012, Gothenburg). There is thus no 
clean size distinction between MVs and exosomes and to compound any 
separation according to size there is the added problem of exosomes 
forming clumps and other clusters as shown in Fig. 6.1, and thus overlapping 
in size with the larger MVs.   
6.2 Development of a reverse filtration method for isolating MVs and 
exosomes 
With these problems of no clear size differential between exosomes and 
MVs, it was felt that it would not really be possible to optimise differential 
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centrifugation to yield pure populations and that cross contamination would 
remain very likely of both MVs and exosomes. This was indeed shown to be 
the case when looking at an MV sample prepared by differential 
centrifugation. This sample after filtering through a Millipore filter of 0.22 µm 
pore size revealed, upon analysis by transmission electron microscopy, that 
the sample which should not have had any exosomes because at 0.1 µm in 
diameter they would have passed into the filtrate was in fact found in the MV 
sample on the filter as shown in Fig. 6.2, indicating a clumping of the 
exosomes within the original sample. The other major concern with 
differential centrifugation for isolation of both exosomes and MVs is that the 
large centrifugal forces 1.5 to 2 h for MVs and 18 h for exosomes (at 100,000 
g) are likely to be damaging potentially altering vesicle composition, 
especially at the surface and therefore potentially modifying their capacity to 
interact with recipient cells.  
 
 
Fig. 6.2. Negative staining of differentially centrifuged MVs after 
filtering through a 0.22 µm filter. The distinct cup-shaped morphology of 
exosomes (whilst an artefactual effect of the preparation of the sample for 
electron microscopy does indicate exosomes) and therefore points to 
exosomal contamination of a MV preparation. Bar = 250nm. 
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6.3 Advantages of MV isolation using sucrose gradient or filtration 
versus differential centrifugation 
MVs and exosomes have a similar composition that depends on the cell they 
come from. In THP1 cell derived MVs and exosomes we observed that 
exosomes are enriched in LAMP1 and CD63 (LAMP3) while MVs are 
enriched in annexin V and CD11b. Vesicles recovered from the filter binds 
to annexinV better that differentially centrifuged MVs. FSC Vs. SSC of SGP 
and filter recovered MVs resembles that described for MVs in different 
studies. There are many proteins as we observed that are not common to 
MVs and exosomes and hence identifying the protein by mass spectrometry 
may provide a marker that can be used to distinguish THP-1 cell derived 
MVs from exosomes (some of them already given). The filter recovery 
protocol at the time may not give absolute purification, however given the 
time it can be optimized to give better purification and separation of different 
sized MVs. A proteomic profile of both MVs and exosomes is highly 
recommended that will give us an insight into their composition and 
functions. It may also help us to answer whether MVs and exosomes share 
any biological function? 
All the results cumulatively indicate that a better purification of MVs can be 
obtained using simple methods like filter recovery and/or sucrose gradient 
centrifugation. These methods can further be modified to isolate different 
sized MVs. One can optimize the speed, time or concentration of the 
gradient to have fractions of different sized MVs. Different sized MVs may 
also be obtained using different pore sized filters. For example, sets of MVs 
differing by 100 nm in size can be obtained using 1 µm, 0.9 µm, 0.8 and so 
on to 0.1 µm Millipore filters. The optimal method, which will require 
considerable development would be to isolate 100% pure MV or exosomes 
preparations and would involve using inhibitors and preferably by silencing 
the genes involved in the various secretion pathways. 
By virtue of the simultaneous isolation of MVs and exosomes using these 
methods it became interesting to compare the two populations. This was 
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carried out simply by cytokine microarrays and even with the limited number 
of proteins analysed, it was possible to see that many proteins were not 
present in both MVs and exosomes and that it would definitely be worth 
carrying out a global comparison of protein between the two vesicle types 
with a view to finding distinguishing markers, especially for MVs.  
Part of the work presented has compared the MVs and exosomes isolated 
by differential centrifugation with the MVs isolated by ‘reverse filtration’ and 
from sucrose density centrifugation, which is much less ‘harsh,’ in terms of 
shearing forces. In addition to exosomal contamination of MV isolates (as 
shown in this thesis and by others), other potential contaminants, which are 
of major concern, and more than likely to co-purify especially during 
ultracentrifugation, and include cell debris such as nucleic acid fragments 
(as was demonstrated in Chapter 1) but also fragments of the lipid bilayer 
from the plasma membrane and polymerised proteins. This becomes a 
major concern as the Extracellular Community is now rapidly moving into the 
area of using exosomes and MVs as therapeutic vesicles even in 
personalised therapies for example using exosomes and MVs derived from 
stem cells (Rani et al., 2015). This was particularly noticeable in the vesicle 
sample compared by agarose gel electrophoresis for contaminating nuclei 
acid where two very high molecular weight bands were detected in the 
differentially centrifuged MV sample; neither of these bands was observed 
in the MVs isolated by sucrose gradient (SGP) nor in the exosome isolate. 
This observation, of contaminating genomic DNA in MV samples, is of 
paramount importance because differential centrifugation is still the most 
common isolation method for MVs and to reiterate must be of major concern 
as we move into an era of using MVs and exosomes in therapy and other 
clinical applications.  
When SDS-PAGE was used to analyse the protein profile of the various 
samples it was found that the number of proteins in the MV preparation 
isolated by differential centrifugation was greater than in the samples 
isolated by filtration. The most likely reason for this is that, following on from 
the observations of contaminating DNA that other cell debris including 
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possible exosomes were also isolated. The less likely possibility is that upon 
filtration of supernatants from prior low speed centrifugation (to remove 
larger cellular material and cell debris) through the 0.22 µm pore size filter, 
that MVs smaller than 0.2 µm diameter had been lost in the filtrate and that 
it was mostly these MVs that carried the missing proteins. However, 
considering the size range of MVs from 0.1 µm to 1 µm, the likelihood that 
the majority of the proteins concerned are carried by MVs smaller than 0.2 
µm is very unlikely.  Furthermore, several proteins which are not that 
abundant in differentially centrifuged MVs are in fact absent from exosome 
preparations and MVs recovered by filtration. Since the majority of cell debris 
is likely to have been removed by two centrifugations at 4,000 g for 30 min 
each, any debris small enough to be still in the supernatant will then definitely 
get carried over into either the MV or exosome isolates.  Some of this debris 
which may be smaller than MVs or even exosomes may polymerise or 
otherwise aggregate into larger pieces that may indeed contaminate MVs 
and/or exosome isolates. The data presented in this thesis, including the 
analysis of filter recovery after sonication, by SDS-PAGE and agarose gel 
electrophoresis as well as ELISA for a surface-bound cytokine, TGF-β1, 
supports the concept that light sonication of the supernatant (SN) after low 
speed (2 x 4, 000 g centrifugations for 30 min each) breaks up such 
contaminating matter or clumped exosomes, to yield higher purity samples.   
 
6.4 Analysis of plasma membrane-bound TGF-β1 on MVs and 
exosomes 
This study also looked at the expression of TGF-β1 on MVs isolated by 
differential centrifugation compared with that on MVs isolated by sucrose 
density gradient centrifugation. This pleiotropic cytokine has numerous, 
sometimes opposing functions for example promoting cellular proliferation 
or inhibiting it, depending on the cell type. TGF-β1 is involved in tissue repair 
and healing during inflammation and by controlling T cell division is also 
involved in regulating inflammation. Work at CMIRC has implicated TGF-β1 
on MVs in the terminal differentiation of monocytes (Ansa-Addo, et al., 
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2010), in enhancing the invasion of cells by the intracellular protozoan 
parasite, Trypanosoma cruzi (Cestari et al., 2012) and in inducing Epithelial 
Mesenchymal Transition of prostate cancer cells (Haidery, A. PhD thesis, 
2014). Although there were higher levels of TGF-β1 detected by ELISA in 
centrifuged MVs, this could not be related to the harshness of the isolation 
procedure as it was realised that the centrifugation process could have 
merely concentrated cellular TGF-β1 and that the level detected in filtered 
MVs could represent the true level of the cytokine on MVs. Another 
possibility which was tested was a comparison of the exosome and 
microvesicular levels of TGF-β1. This would be an important analysis as 
there was a chance of much reduced levels detected in exosomes because 
unlike MVs which bud directly off from the surface plasma membrane where 
TGF-β1 is tethered to the ECM in a latent complex, exosomes might be 
expected to carry lower levels as the exosomes are derived from intraluminal 
budding from an early endosome, following an endocytic event and released 
upon MVB fusion with the plasma membrane. The acquisition of lysosomal 
markers such as LAMP-1 by exosomes suggests further possibilities for loss 
of membrane-bound TGF-β1 and indeed unlike other cytokines such as 
FGF-1 and galectin-3 (which are found in the intravesicular space because 
detectable levels were greatly enhanced upon lysis of MVs) and which are 
present at similar levels in MVs and exosomes, TGF-β1 was found at four-
fold higher concentrations on MVs (1 ng/ml) compared to 0.25 ng/ml on 
exosomes.  
It has been proposed that MVs may carry certain cytokines that lack a signal 
peptide by a process termed ‘non-conventional protein export’ after a series 
of publications eloquently summarised in a review by Nickel (Nickel, 2005). 
One such candidate cytokine was detected in the cytokine array presented 
in Chapter 3, namely macrophage migration inhibitory factor (MIF) but others 
were shown in the lab and include galectin-3, and fibroblast growth factor-1 
(FGF-1) (Inal, personal communication and Ansa-Addo, 2010). IL-1α is 
another cytokine, like TGF-β1 with pleiotropic effects and like TGF-β1 is 
bound to the cell surface (Orjalo et al., 2009) and unlike IL-1β, is rarely 
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secreted and can function either as an uncleaved precursor protein (pIL-1α) 
(Apte et al., 2006) or upon proteolytic cleavage, as a processed protein, 
which is released as a result of cellular injury and which can induce 
apoptosis. IL-1α is also involved in other immune reactions including in 
inflammation and haematopoiesis.  
 
6.4 Use of the triterpenoid liquorice derivative, β-Gly to limit 
proliferation of erythroleukaemia, K562 cells: potential new 
‘differentiation therapy’  
The use of β-Gly, a derivative from liquorice, as an inhibitory drug in various 
cancers and leukaemia’s has come to the fore in recent years (Ali et al., 
2016). As part of the work presented in chapter 5 of this thesis the activity of 
β-Gly was tested against the erythroleukaemia cell line, K562. The reason 
β-Gly was chosen for this study in itself was unexpected and relates to 
another published function of β-Gly, namely that of its capacity to inhibit 
complement C2 (Kroes et al., 1997), presumed to be due to its binding to C2 
(Kroes et al., 1997) thus rendering it unable to bind to C4b to make the C3 
convertase complex. In unpublished work, colleagues at CMIRC had been 
testing a previously reported hypothesis that the complement protein Factor 
B (specifically the Bb fragment) which is closely related to complement C2 
(39% identity at the amino acid level), may function as a growth factor for B 
cells (Ambrus et al., 1991 and Petera et al., 1988).  To see if complement 
C2 as the related Factor B share a similar ‘growth factor-like’ property, but 
this time on monocytic cell lines and K562, which release complement C2 
after 4 days in culture, β-Gly was incorporated to abrogate any growth factor-
like properties of complement C2. This work showed that β-Gly was 
drastically diminishing proliferation of THP-1 (acute monocytic leukaemia 
cells) and of K562 (erythroleukaemia cells). Initially it was not apparent if this 
effect was due to alteration of the cell cycle or induction of apoptosis and 
from the literature nothing could be gleaned as the proposed mechanisms 
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leading to inhibition of proliferation seemed to vary between different tumour 
cell types and researchers.  
Experiments were carried out over the course of 5 to 6 days in culture and 
whereas during this period K562 cell numbers increased 23 to 25-fold, in the 
presence of 10 µM of β-Gly, increase in cell numbers was at least halved 
with only a 10-fold increase. A dose-dependent effect was also noted. The 
inhibition of proliferation began to be apparent from the third day after 
addition of β-Gly and became significant, compared to control, 48 h later, on 
day 5. The inhibitory effect observed could be explained by induction of 
apoptosis, stimulation of cellular differentiation or if cell division had been 
slowed down. There certainly was an increase in doubling time, a dose-
dependent effect, based on an increasing concentration of β-Gly. If the 
interphase part of the cell cycle is prolonged, as might be expected, there 
would be a reduced frequency of division. This would result in some enlarged 
cells (Prescott, 1976), which was not observed, suggesting a reduction of 
growth rate for the β-Gly treated cells. In addition, it was found that β-Gly did 
not induce apoptosis even by the end of the experiment. This was in contrast 
to the initial findings of Gao et al also with K562 cells (Gao et al, 2012) but 
later confirmed (Gao et al, 2013). Furthermore, β-Gly had induced an exit 
from the cell cycle at G0/G1 with an associated increase in fetal haemoglobin 
suggesting differentiation towards an erythroid lineage. 
In previous work using the leukemic acute monocytic THP-1 cell line (AML-
M5) it was shown that THP-1-derived MVs began to limit the increase in cell 
numbers from 3 days post addition of MVs (30 µg protein equivalent) 
compared to untreated control, resulting in significant reductions in cell 
numbers by day 5. It was suggested at the time (Ansa-Addo et al, 2010) that 
this was due to TGF-β1 on the MVs themselves and that they were inducing 
terminal monocyte-to-macrophage differentiation with increases in the 
markers CD11b and CD14. These effects could be reversed by using a 
blocking anti-TGF-β1 antibody or by using the antagonist of TGF-β1 
signalling, SB431542. These studies bring about the question as to whether 
any of the effects noted on K562 brought about by β-Gly, including increased 
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doubling time due to a prolonged cell cycle/reduced frequency of division, 
and likely cell cycle exit and differentiation could in fact be due to a β-Gly-
mediated stimulation of MV release. To that effect, it has been shown that 
β-Gly does in fact increase MV release from K562 cells (Inal, J., personal 
communication), although at the doses used there was no dose-dependent 
effect noted. If β-Gly does indeed promote MV biogenesis in K562 cells, 
there are several pharmacological inhibitors of microvesiculation, such as 
calpeptin (Jorfi et al., 2015) which could be added together with β-Gly to 
confirm any effect of MVs released. Any such stimulation of MV release 
could be quantified and then any inhibition of MV release and associated 
effects potentially reversed by restoring the equivalent of externally sourced 
K562 MVs.  It would be particularly interesting to establish whether 
prolonged, stimulation of MV release by K562 cells can initiate 
differentiation, whilst inducing cell cycle arrest, and therefore act as a 
possible differentiation therapy as is used for monocytic leukaemia (all trans 
retinoic acid, ATRA) (Manzotti et al., 2015). There is a precedent in the 
literature for this approach as already in 2009 using the same cell line, K562, 
it was described that induction of differentiation of these cells using miR-34a 
resulted in an induction of apoptosis by the mitochondrial pathway which 
resulted in a reduction of cellular proliferation (Navarro et al, 2009). By 
limiting MV release in this case with Y276342 it was possible to achieve an 
equal limitation of K562 proliferation, now with a 100-fold lower concentration 
of β-Gly (0.1 µM). 
 
6.5 Preliminary testing of MV-based delivery of β-Gly  
To test the possibility of MV-delivered β-Gly, MVs were collected from 
monocytes that had been loaded with β-Gly. The reason chosen for using 
monocyte MVs is that monocytes themselves are attracted by chemotaxis to 
tumours. At this stage THP-1 MVs were used but for transferral to the clinic, 
peripheral blood monocyte-derived MVs could equally well be used. The use 
of MVs as opposed to exosomes was also preferred because of their larger 
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size. It was also shown that the MVs undergo a degree of lipid mixing, 
whether fusion of hemifusion, suggesting delivery of microvesicular 
contents. Cells were loaded with β-Gly, which as a lipophilic drug, enters 
cells by passive diffusion (Goldman, 2002).  It was not possible to prove that 
the β-Gly was actually within the MVs as had been shown by CMIRC 
researchers for the chemotherapeutic drug, methotrexate (Jorfi et al., 2015), 
but it was encouraging that β-Gly-loaded MVs were almost as effective in 
reducing cell numbers as β-Gly alone and that MVs on their own only limited 
proliferation to a non-significant level. 
The phagocytosis assays of MVs and exosomes were carried out as a 
follow-up to previous work carried out at CMIRC in which it was found that 
MVs could inhibit the phagocytosis of apoptotic bodies (Antwi-Baffour, 
2010). In this case however exosomes (which have a lower exposition of PS 
on the outer leaflet of the lipid bilayer) were tested. As expected this showed 
that exosomes were not as effective as MVs in inhibiting macrophage-
mediated phagocytosis of apoptotic bodies.  
 
6.6 Future work: MV-based health assessment as early biomarker of 
disease, health, and development of MVs as personalised therapeutic 
vehicles 
Having performed much developmental research on MV and exosome 
isolation, a filtration protocol was used to evaluate plasma levels of MVs in 
the general population. Although a small sample was used, it was found that 
age did not affect plasma MV levels. It was also implied that smokers may 
have reduced levels of plasma MV levels, which was backed by inhibition of 
MV release in cell culture by nicotine (which is anti-apoptotic). It was also 
found that fasting increased plasma MV levels. There are many described 
health benefits of fasting reported in the scientific literature and whether this 
could be connected to increased plasma MV levels is open to speculation. 
Rather than concentrations of MVs, it may be their specific cargo that may 
have health benefits of otherwise. As intercellular communicative vectors 
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MVs may deliver membrane proteins, or cytokines lacking signal peptides 
(such as galectins and fibroblast growth factors), carried within the vesicle 
as well as other surface bound cytokines in inactive pro-forms such as TGF-
β1 and IL-1α, MVs may also deliver microRNAs (miRNAs) and long non-
coding RNAs (lnRNAs) thereby affecting gene expression in target cells (Inal 
et al., 2012; 2013). In terms of a MV-based monitoring of well-being, it would 
also be important to assess the effect of increased levels of stress hormones 
cortisol and adrenaline on MV biogenesis. In other work, leptin the ‘satiety 
hormone’ which by inhibiting hunger can regulate energy balance is of 
interest as it can also be found in MVs, in fact adipocyte MVs (Aoki et al, 
2010). In view of the current obesity epidemic and association of leptin 
resistance (with obesity) (Lee et al. 2001), and if leptin represents a ‘hidden 
reservoir’ of the hormone, it might be wise to make such MV-based 
measurements of this hormone. 
A likely promising avenue of future research may therefore involve the 
analysis of not only MVs from fasting individuals, but also from those doing 
high intensity physical activity for whom there are well documented health 
benefits. This work is already being carried out by colleagues at CMIRC with 
external collaborators with the view to see whether there are any beneficial 
effects of applying such MVs from donors after intense exercise (Frühbeis 
et al., 2015) to a range of disease situations.  
Overall as part of a programme of therapeutic lifestyle changes (TLC) with 
the aim of reducing disease and of inhibiting the activation of cancer 
epigenomes, monitoring of MVs may become a significant tool in the years 
to come. 
MVs could also be used as vehicles carrying a very specific ‘loaded’ cargo 
and that where necessary such MVs could be manipulated with particular 
targeting features to deliver them to a specific cellular target. Such targeting 
was first performed in seminal work by Matthew Wood and his team in 
Oxford where mouse dendritic cell MVs were engineered with a specific 
peptide that targeted the MVs carrying the ability to silence a gene involved 
in Alzheimer’s to the glial cells in the mouse brain. This work is ongoing. In 
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other work, liposomes have been targeted to liver hepatocytes by having a 
surface bound β-Gly (Li et al., 2012; Cong et al., 2016; Gumpricht et al., 
2005), the same drug that was used in this thesis to inhibit erythroleukaemic 
K562 cell proliferation. In this case liposomes carrying a chemotherapeutic 
are targeted to the hepatocytes as they express receptors that can mediate 
the specific uptake of the β-Gly expressing liposomes (Ishida et al, 1993). A 
similar adaptation could be envisaged for microvesicles which have a longer 
half-life in the body than liposomes.  
6.6.1 Hydration, plasma osmolality, plasma MVs and health (as part of 
Therapeutic Lifestyle Changes) 
Adequate hydration (‘water wellness’) in the Western world is a major 
concern for the health of the population as recently highlighted in a US study 
(Brooks et al, 2017) which found in over 8,000 participants inadequate 
hydration to affect just under 30% of the population. Adequate hydration in 
this study was defined by a urine osmolality  800 mOsm/kg.  An earlier study 
in the UK found 59.4% of people to drink only one serving of water per day 
and 81% to drink up to two servings per day (Jequier et al, 2010). Figures 
from the European Federation of Bottled waters show that this lags far behind 
other European countries as shown below. 
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http://www.efbw.org  
In my own small survey of n= 166, I found more than 50% of the population was 
dehydrated. This data mirrored the study by the National Hydration Council 
(http://www.naturalhydrationcouncil.org.uk/press/water-consumption-rises-as-
brits-more-health-aware/) 
  
 
When the medical community refers to hydration, it is referring to adequate 
hydration with water as a ‘nutrient,’ which can be obtained from food just as 
much as fluids (including water) that are drunk. In terms of a recommended 
intake this is impossible to define as it is affected by an individual’s gender, body 
mass, age, physical activity and the particular climate in which they live In 
Europe the European Food Safety Authority suggests a 2.5 L intake of water for 
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men and 2.0 L for women every day through a combination of food (accounting 
for 20-30% of the intake) and fluid (accounting for 70-80% of the intake).   
The Kantar World Panel Food and Drink Usage panel is a single source 
purchase and consumption panel comprising of 11,000 individuals recording 
their total intake of food and drink (both tap and bottled water) for four one-week 
periods every year. This data has shown a 17 % increase in consumption (from 
6 billion to 7.1 billion servings of tap water) in 2015. The intake of bottled water 
has increased by 9 % and tea and coffee remain the most popular drinks in the 
UK with the equivalent of 312 servings per person in the UK in 2015 
(https://www.kantarworldpanel.com/global). The statistics also show that in the 
20 years from 1995 decisions on drinks consumption has doubled from 11% 
that were motivated by health considerations, the top 4 choices being dairy 
drinks, fruit juices, tap and bottled water 
(https://www.kantarworldpanel.com/global). 
Dehydration occurs when as little as 1-2% of body mass is lost (for example 0.7 
kg of body weight for a 70 kg person) (Kleiner, 1999) and can lead to a host of 
diseases, including kidney stones, cancers of the colon, breast and urinary tract 
(Michaud et al, 1999). 
 
Dehydration causes an increase in plasma osmolality. In terms of plasma MVs 
measured as was performed in this study, plasma osmolality (or osmolarity) was 
not considered. This may be important in measuring MVs, which may in turn be 
isolated and screened for miRNA as early diagnostic markers of cancer, or 
simply as I propose as markers of general health and wellbeing. In terms of MVs 
being released from cells under stress, members of the Cellular and Molecular 
Immunology Research Centre (CMIRC) have previously shown MVs to package 
calcium (Stratton et al, 2015). The effect that dehydration and a decrease in 
levels of intracellular water may have on the capacity of cells to release 
microvesicles is also hitherto unknown. 
Water is a universal buffer and as recently reviewed (Brown et al, 2012), the 
kidneys play a major role in maintaining a control over body fluid and balance 
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of acid-base. This homeostasis is necessary for human health and aquaporins 
(Agre, 2006), specifically aquaporin 2 (AQP2) plays an important role in this 
process. Water is needed for every function in the body, including digestion, 
circulation, absorption of nutrients and to enable the body to flush out toxins and 
in a state of dehydration, results in a diminished immune system and a myriad 
of physical problems (Popkin et al, 2010), indeed adequate hydration reducing 
risk of bowel, breast prostate and urinary tract cancers as well as of kidney 
stones (39% reduction) and of coronary heart disease (46% in men and 59% in 
women) (www.rch.org).  
The so-called ‘Warburg effect’ describes how malignant tumours develop an 
acidic extracellular pH by the accumulation of lactic acid, a hallmark of tumour 
cells, and alkaline intracellular pH (Garber, 2004). It may be of key importance 
given the increasing role exosomes and MVs have been shown to play in 
tumour growth and spread, especially as it was recently shown that low pH can 
increase exosome release (as well as uptake (Parolini et al 2009; Federicci et 
al 2010)). This may be due to the increase of intracellular calcium (Kato et al, 
2007), which is known to increase exosome and MV release (Inal et al, 2012). 
 
Aerobic glycolysis as first described by Otto Warburg  
(Gatenby, 2004: Garber, 2004). 
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Solid tumours thus having an acidic pH because of increased fermentation 
metabolism, result in increased invasion and metastasis (Stetler-Stevenson et 
al, 1993) probably due to H+ diffusing into the neighbouring tumour 
microenvironment, causing tissue remodelling and thus allowing metastasis. 
Tumour invasion does not occur in areas with normal pH. (Estrella et al, 2013). 
Previous work has shown the importance of pH in the tumour 
microenvironment and its baring on tumour growth and metastasis. This work 
has shown that injection of alkaline buffers into the tumour microenvironment 
can shrink a tumour and inhibit metastasis (Robey et al, 2009; Silva et al., 
2009). More recently it also was found that tumour cells undergo enhanced 
proliferation and are increasingly invasive in acidic environments (Estrella et 
al., 2013). There has recently been a massive promotion of alkaline water and 
of the health benefits of an alkaline diet, with barely any research to prove this 
hypothesis either way. Last year a comprehensive review of the scientific 
literature showed no evidence in support or to refute the claimed benefits of 
alkaline water for treating cancer or of acidic diet promoting cancer (Fenton et 
al, 2016), so this should be an important aim for future clinical studies within 
the context of acid-base homeostasis.  
 
6.6.2 Aloe Vera, cannabinol and bromelain: plant products for MV 
delivery in cancer 
Aloe-emodin (AE) is the main component of the anthraquinones found in Aloe 
Vera. There are numerous studies showing AE to have apoptotic and anti-
proliferative effects on tumour cells as well as in a host of other disease 
conditions (Radha et al, 2014). In view of the finding in this thesis that Beta-
glycyrrhetinic acid, derived from liquorice, in microvesicles has anti-proliferative 
properties on erythroleukaemia cells, it is interesting to note that other plant 
products such as AE have also been used within lipid nanoparticles (Chen et 
al, 2015; Wu et al, 2017). In other work, cannabinoids have been used 
successfully against cancer cells inhibiting proliferation and angiogenesis 
(Thapa et al, 2011) but also against melanoma cells (Armstrong et al, 2015) and 
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have even been encapsulated in so-called microparticles which in fact are 
biodegradable polymeric microparticles prepared using a solvent evaporation 
technique on an oil-in-water emulsion (Hernán Pérez de la Ossa et al, 2013). 
Bromelain, from the stems and fruits of pineapple (Ananas cosmosus) is 
another potential plant product with anti-cancer properties for example being 
synergistically active in conjunction with cisplatin against MDA-MBA-231 breast 
cancer cells (Pauzi et al, 2017). This has been used in bromelain-functionalized 
multiple-wall lipid-core nanocapsules (Oliveira et al, 2017) and that could also 
be delivered potentially via microvesicles or artificially synthesized 
microparticles. It should be noted that since the work presented in this thesis it 
has become apparent that cancer drugs can be loaded directly into 
microvesicles (Saari et al, 2015) bypassing the need to collect microvesicles 
carrying a drug that has been released from parent cells themselves loaded with 
chemotherapeutic drugs. 
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